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CHAPTER I 
INTRODUCTION AND PROBLEM STATEMENT 
Indomethacin and renal junction 
Indomethacin, introduced by Shen and co-workers in 1963 (Shen et al. 
1963), has marked antipyretic, analgesic and anti-inflammatory effects 
(Winter et al. 1963). Clinically, it is chiefly used in rheumatological condi-
tions (Cooperating Clinics Committee 1967; O'Brien 1968; Smyth 1970; 
Mills 1974). Indomethacin sometimes causes side effects of a neurological 
(dizziness, headache), gastroenterological (pain, pyrosis, ulcer, haemorrhage) 
or haematological (leucocytopenia, thrombocytopenia, eosinophilia) nature. 
There is no unanimity in the literature about the question as to whether 
indomethacin has an effect on renal function. There have been incidental 
reports on decreased diuresis, decreased glomerular filtration and/or de-
creased renal plasma flow (Ballabio et al. 1963, 1965; De Sèze et al. 1965; 
Norcross et al. 1963; Thompson 1964). Norcross and co-workers (1963) 
reported increased blood urea nitrogen in 46 of 530 patients during the 
first year of indomethacin medication, in 34 of them with normalization 
during the next year. De Sèze et al. (1965) reported increased blood urea 
nitrogen in 8 of 23 patients treated with indomethacin. Rothermich (1966) 
observed no pathological changes in blood urea nitrogen in 233 of 234 
patients on long-term indomethacin medication, nor any effect on renal 
histology. Also other publications have mentioned that no untoward long-
term effects were observed in large series on any parameter of renal func-
tion (Langkilde et al. 1965; Boardman et al. 1967; Chassagne et al. 1967). 
Gribnau (unpublished) observed no changes in endogenous creatinine 
clearance during 24 hours following intravenous injection of 50 mg indo-
methacin in healthy volunteers. 
The twelve patients with a persistent increase in blood urea nitrogen in 
the Norcross series (1963) included five with previously unsuspected renal 
disease. The one patient with increased blood urea nitrogen in the Rother-
mich series (1966) was likewise found to suffer from "chronic nephritis". 
These findings suggest that, in patients with renal disease the drug might 
lead to a transient decrease in renal function. 
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Indomethacin in chronic glomerulonephritis and nephrotic syndrome 
Since 1966, experience has been gained in situations in which indome-
thacin was deliberately given to patients with glomerulonephritis, particular-
ly if associated with proteinuria. Preliminary reports came from the Michiel-
sen group in Louvain. This group decided to start using an anti-inflamma-
tory agent in the treatment of chronic glomerulonephritis. Previously there 
had been some indications that this approach might be successful. In the 
Fifties, for example, Borst in Amsterdam had done considerable, but 
unpublished, research on the effects of aminophenazone and phenylbuta-
zone in patients with a nephrotic syndrome. The Borst group had observed 
that decreased glomerular filtration was repeatedly associated with de-
creased protein excretion (De Vries et al. 1960). Likewise using phenylbu-
tazone, Fieschi et al. (1955, 1965) had obtained a decrease in protein 
excretion and an increase in plasma albumin concentration in 21 of 25 
patients with a nephrotic syndrome. At the Third International Nephrology 
Congress in Stockholm (1966), Michielsen and co-workers reported that a 
similar effect could be obtained with indomethacin. This communication 
was not published in the congress proceedings. Santopadre et al. (1966) 
described an antiproteinuric effect of indomethacin in children. 
Some detailed reports on this effect of indomethacin were published 
between 1967 and 1971, the principal publications being those of Michiel-
sen et al. and those of Conté et al. These reports were not always readily 
interpretable. They described the effects of varying doses of indomethacin 
in glomerulonephritis of varying aetiology in patients showing a varying 
symptomatology and course, with and without nephrotic syndrome, with 
more or less marked renal insufficiency, refractory or not refractory to 
other medications, during varying periods of treatment and with varying 
criteria for such parameters as remission, improvement and failure. 
It was nevertheless evident from these reports that, regardless of the un-
derlying disease, indomethacin can reduce proteinuria in a nephrotic syn-
drome and thereby ensure substantial improvement for the patient. At least 
in the treatment of proteinuria in patients with proliferative and membra-
nous glomerulonephritis, the agent was found to be superior to corticoste-
roids. 
In a comparative study of 25 periods of indomethacin medication and 
34 periods of corticosteroid medication (over a non-uniform period of 
observation of several months) in 27 patients with proliferative glomerulone-
phritis, including 23 with a nephrotic syndrome, the rate of failure was 
36% for indomethacin (50-100 mg daily) versus 62% for corticosteroid 
medication (30 mg daily); the corresponding rates of improvement were 
56% and 35%, and the rates of remission were 8% and 3 % (Michielsen 
et al. 1967). In 24 patients who failed to respond to corticosteroids and 
cytostatic drugs, including 18 with a nephrotic syndrome, 6 complete re-
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missions, 13 incomplete remissions, 2 improvements and 3 failures were seen 
over a period of several months of indomethacin medication (2-3 mg/kg 
daily). In all patients the protein excretion decreased to < 5 g daily. In 
the complete remissions all abnormalities disappeared; in the incomplete 
remissions the protein excretion decreased to < 1.5 g daily; in the impro-
vements it decreased substantially. The effect did not correlate with the 
histological diagnosis and was not accompanied by a decrease in endoge-
nous creatinine clearance (Conté et al. 1967). 
In 1969, Michielsen et al. (1969) had a follow-up of 6 months on 56, of 
12 months on 44 and of 24 months on 11 patients with various types of 
glomerulonephritis. The group averages of protein excretion gradually fell 
from 4.73 to 1.43 g daily. For the endogenous creatinine clearance the 
group averages before treatment and during successive 6-month periods of 
medication were 90, 87, 90, 92 and 97 ml/min. The effect proved to occur 
in all histological groups except that of "lobular glomerulonephritis". In 
some 25% of patients the effect on proteinuria was virtually immediate; in 
50% it occurred more gradually. It was casually mentioned that the abrupt 
decreases in protein excretion were repeatedly associated with a transient 
decrease in endogenous creatinine clearance. Discontinuation of indometha-
cin treatment led to increased protein excretion and increased creatinine 
clearance (Michielsen et al. 1969). 
In the abovementioned article, and in a paper read in 1969, published 
in 1970 (Michielsen et al. 1970), the authors reported in addition that in 6 
of 7 patients with proliferative glomerulonephritis the histological features 
were improved after two years of indomethacin medication; in three of 
these patients the light-microscopic changes had in fact virtually disappeared. 
In 1970, Conté et al. reported on the results of indomethacin medication 
(2-3 mg/kg daily) in 115 patients suffering from chronic glomerulonephri-
tis of all known histological types, including 61 with a nephrotic syndrome, 
over periods ranging from 1 to 24 months ( > 12 months in 56 cases). The 
results were measured in the same way as in their publication of 1967. 
Complete remission was observed in 35%, incomplete remission in 22%, 
improvement in 15% and failure in 28% of patients. As assessed by the 
effect on proteinuria, the highest success rate (complete remission 43%, 
incomplete remission 26%) was seen in patients with a nephrotic syndrome 
without renal insufficiency and without erythrocyturia. As assessed by the 
histological features, the results were best in the so-called "minimal 
lesions": complete remission 50%, incomplete remission 17%. In a group 
of 6 patients with lupus nephritis, 3 showed a complete and 3 an incomplete 
remission. The authors did not discuss the question whether differences of 
this sort between groups were statistically significant. These patients like-
wise showed sometimes abrupt, sometimes gradual decreases in protein 
excretion, which disappeared after discontinuation of the drug. The endoge-
nous creatinine clearance did not decrease; in fact it increased in patients 
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with acute glomerulonephritis and patients with lupus nephritis. Indometha-
cin was believed to increase the selectivity of the proteinuria. It had no 
effect on serum complement activity. Unlike Michielsen et al.. Conté et al. 
failed to observe an improvement in histological features. 
The short-term effects of indomethacin (150 mg daily) on proteinuria 
and endogenous creatinine clearance in patients with proliferative and 
(extra)membranous glomerulonephritis were studied in detail by Wijdeveld 
(1971), who observed an immediate decrease in protein excretion in all 
cases. In most cases this decrease continued for days to weeks. It was not 
always associated with a decrease in endogenous creatinine clearance. In 
addition to a decrease in protein excretion and endogenous creatinine 
clearance, one patient showed a decrease in the excretion of water, sodium, 
urea, creatinine, uric acid and phosphate, with a corresponding weight gain 
and increase in the plasma concentrations. The effect of indomethacin on 
protein excretion was found to be dose-dependent. A short-term effect 
equal to that of indomethacin (150 mg daily) was observed in response to 
phenylbutazone (800 mg daily) and oxyphenylbutazone (800 mg daily). In 
spite of continued indomethacin medication, terminal renal failure occurred 
after a period of years, both in one patient with proliferative and in one 
with extramembranous glomerulonephritis. On the contrary, one female 
patient with lupus nephritis and a nephrotic syndrome, refractory to cor-
ticosteroids and azathioprine, was treated with indomethacin and 20 mg 
prednisone daily for four years and gradually showed a virtually complete 
remission, with slight proteinuria as the sole residual symptom. No histolo-
gical improvement was observed over a 2-year period either in prolifera-
tive or in extramembranous or in lupus nephritis. 
The results so far described were largely corroborated by a number of 
other investigators (Renner et al. 1971; Pierron et al. 1971; Lagrue et al. 
1971; Clarkson et al. 1972; Vihert et al. 1973). 
In 1973, three studies were published on the effect of indomethacin in 
various types of glomerulonephritis with a circumscribed histology. 
Lagrue et al. (1973) studied the effect of indomethacin as compared 
with that of chlorambucil and azathioprine in 28 patients with hypocom-
plementary "parietoproliferative" (membranoproliferative) glomerulonephri-
tis. The periods of medication were not clearly specified. Indomethacin 
proved to be far superior to the two cytostatic agents. Azathioprine was 
always ineffective; chlorambucil failed in 18 out of 22 periods of medica-
tion, and gave 4 incomplete remissions. Indomethacin failed only in 3 out 
of 20 periods of medication. It produced 4 complete, 7 transient and 6 
imcomplete remissions. The serum complement concentration was not 
influenced. Contrary to previous impressions, indomethacin was equally 
effective in a casually mentioned group of patients with normocomplemen-
tary membranoproliferative glomerulonephritis. No histological improve-
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ment was observed, although mention was made of a "certaine stabilité des 
lésions glomérulaires". 
Likewise in 1973, Michielsen et al. (1973) published their results in 11 
patients with membranoproliferative and 5 with lobular glomerulonephritis. 
These were young patients: the mean age in the first group was 18.5 (range 
3-28) years; that in the second group was 23 (17-54) years. Serum comple-
ment levels were only determined occasionally, and showed incidentally 
decreased values in only three patients. The daily indomethacin dose was 
75-150 mg and the follow-up period ranged from 6 months to 6!4 years. 
All patients had (had) a nephrotic syndrome, but the pretherapeutic levels of 
proteinuria and serum albumin concentration were not given. At the start of 
the medication 7 of the 16 patients had a protein excretion of 5 g daily or 
more; in the other 9 the protein excretion was between 0.53 and 3.98 g 
daily. Likewise shortly after starting medication, 12 patients had an endoge-
nous creatinine clearance of < 100 ml/min, with values ranging from 25 to 
90 ml/min. 
At the end of the therapeutic period the endogenous creatinine clearance 
had decreased in 13 of the 16 patients; it was unchanged or slightly in-
creased in 2 patients, and in 1 patient it had doubled from 60.5 to 122 
ml/min. In nearly all cases the protein excretion decreased gradually, but, 
even after years, discontinuation of therapy was found to lead to an in-
crease in protein excretion. Several kidney biopsies were performed in three 
cases, at intervals of 2.5 to 4 years. There were signs of favourable changes 
in the histological substrate: fewer granulocytes, less proliferation and less 
deposition of argyrophilic material. 
The principal result in this series seemed to be the decrease in protein 
excretion. The progression of renal insufficiency seemed slower than that in 
the series of Mandalenakis et al. (1971), which was used for comparison. 
They studied 22 patients with a comparable histology and age distribution, 
over a slightly shorter follow-up period and with a slightly lower average 
baseline value of glomerular filtration. In the Mandalenakis group, 14 of 
the 22 patients had died or were on intermittent haemodialysis; in the 
Michielsen group this applied to 4 out of 16 patients. The question, of 
course, is whether the difference between these small series was significant 
and, if so, to which extent it is based on suppression of the nephrotic syn-
drome as such with indomethacin or on some effect on the natural history 
of the disease. 
At the Sixth International Congress of Nephrology in Florence in 1975 
Michielsen reported a 10-year survival of 50% in 34 indomethacin-treated 
patients with membranoproliferative or lobular glomerulonephritis, versus 
one of 10% in actuarial survival curves in the literature. 
Conté et al. (1973) observed very impressive effects of indomethacin in 
20 patients suffering from diffuse glomerulonephritis associated with lupus 
erythematosus disseminatus, including 17 with a nephrotic syndrome. Ele-
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ven therapeutic periods of 9 months or longer were compared with thirteen 
therapeutic periods of comparable duration with a large dose of prednisone. 
The indomethacin was combined with chloroquine or chloroquine gentisate 
(300-400 mg daily) or with hydroxychloroquine (600-800 mg daily). In the 
prednisone group, 6 patients died and 5 developed serious extrarenal com-
plications and/or increased renal insufficiency with hypertension. The in-
domethacin-chloroquine combination, on the other hand, led to 6 complete 
remissions, 2 incomplete remissions and 3 improvements. These results were 
attributable to indomethacin as far as the proteinuria was concerned: the 
decrease in proteinuria disappeared after discontinuation of indomethacin. 
Serial histological examination was reported to have demonstrated a de-
crease of subendothelial and mesangial deposits and diminished cellular 
proliferation. A table with semiquantitative data on these parameters does 
not seem to give this conclusion very strong support. Without essential new 
data or findings, the same group (Conte et al. 1975) recently reiterated 
this conclusion with regard to the effect on histological features. 
The above described clinical studies would seem to warrant the tentative 
conclusion that indomethacin and related antiphlogistic agents often reduce 
the proteinuria in glomerulonephritis, and that this "antiproteinuric effect" 
can be utilized in the treatment of patients with a nephrotic syndrome. In 
addition, the agent can at least transiently reduce glomerular filtration, 
and sometimes it produces a decrease in the excretion of water, sodium 
and other solutes. Whether and to which extent indomethacin can exert a 
favourable influence on the course and the histological features of glome-
rulonephritis in the long run deserves further investigation. 
Pharmacological properties of non-steroid anti-inflammatory drugs 
After presenting clinical information on the antiproteinuric effect of 
indomethacin, it is interesting to consider this effect in the light of what is 
now known about this substance as a non-steroid antipyretic, analgesic, anti-
inflammatory drug. 
In speculations on the relation between the structure and the antipro-
teinuric effect of indomethacin, it seems logical to start from the fact that 
this agent shares its antiproteinuric effect with several other antipyretic, 
analgesic, anti-inflammatory drugs. This applies to phenylbutazone (Fieschi 
et al. 1955, 1965; De Vries et al. 1960; Wijdeveld 1971), p-hydroxyphenyl-
butazone (Wijdeveld 1971), indoprofen (K 4277; previous generic name is-
indone) (Tiggeler et al., unpublished), and bucloxic acid (Lagrue et al. 
1974). In only one patient has sodium retention been described during 
naproxen medication (Willkens et al. 1973); it seems possible that this 
drug, too, produces an antiproteinuric effect. Wijdeveld and co-workers 
observed no decrease in proteinuria after administration of acetylsalicylic 
acid or Ibuprofen (unpublished). Perhaps the absence of an antiproteinuric 
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effect of ibuprofen, which is only weakly anti-inflammatory, is dose-depen-
dent: perhaps a larger dose of this agent could have produced an antipro-
tcinuric effect. This possible explanation of the absence of the abovemen-
tioned effect with this agent merits consideration, for Wijdeveld (1971) de-
monstrated that the antiproteinuric effect of indomethacin is dose-depen-
dent. On the other hand, salicylates are regarded as strong anti-inflamma-
tory drugs, and the absence of an antiproteinuric effect of acetylsalicylic 
acid in situations in which other anti-inflammatory agents do produce this 
effect, therefore requires further explanation. 
The abovementioned anti-inflammatory drugs were developed by testing 
large series of structure-related compounds. In such series, certain confi-
gurations of the molecules tested proved to correlate with activity in the 
conventional tests for anti-inflammatory effect, e.g. carragheenan-induced 
oedema, AgNOs pleurisy, UV-induced erythema, cotton pellet granuloma. 
On the basis of the configuration of the most active compounds in a series, 
investigators formed an impression of the hypothetical receptor site with 
which these substances might interact. This approach is useful in order to 
visualize the molecular structures with which analogues with an optimal 
configuration might interact. So far, however, this approach has failed to 
establish a relation between the structure of these drugs, and concrete 
structures in the substrate of their activity (Shen et al. 1974; Gryglewski 
et al. 1974). 
Nor has it so far become clear how, in terms of their structure, these 
drugs can be brought under a common denominator. No more can be said 
than that they are all weakly acid substances with a strong tendency to bind 
with plasma proteins. The plasma protein binding rate of phenylbutazone 
is 99% (Burns et al. 1953). Recent data on pharmacotherapeutic indome-
thacin concentrations mention the same rate of protein binding (Mason et 
al. 1974). The antiproteinuric drugs do not differ markedly in molecular 
weight: 358 for indomethacin, 324 for p-hydroxyphenylbutazone, 308 for 
phenylbutazone, 294 for bucloxic acid and 281 for indoprofen. Naproxen 
and ibuprofen have lower molecular weights (230 and 206, respectively). 
The molecular weights of acetylsalicylic acid and of the salicylic acid rapidly 
formed from it in the organism, are 180 and 138, respectively; these two 
substances are considerably less protein-bound than the other anti-inflam-
matory drugs mentioned. 
The plasma concentrations of various anti-inflammatory drugs in therapy 
differ substantially: in the case of indomethacin these concentrations are 
tenths of a mg/1, eventually a few mg/1, but in the case of phenylbutazone 
concentrations of tens of mg/1 are involved. This illustrates the inequality 
of the potency of these drugs (as of course also demonstrated in preclinical 
tests of these agents). 
The human pharmacokinetics of the anti-inflammatory drugs also differ 
considerably. Phenylbutazone and oxyphenylbutazone have the longest 
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biological half-life (72 hours; Burns et al. 1968); that of naproxen is 14 
hours (Runkel et al. 1973), that of indoprofen is 5 hours (Fuccella et al. 
1973), that of indomethacin is 3.5-7.2 hours (Duggan et al. 1972; Palmer 
et al. 1974), and that of ibuprofen is the shortest: 1.5 hours (Fleuren H 
(1973) Personal communication). 
All in all, the only possible conclusion from the above is that there is 
no definite answer to the question, both in terms of anti-inflammatory ef-
fects and in terms of antiproteinuric effect, concerning the relation between 
structure and characteristics of these drugs on the one hand, and their 
action on the other. Since a number of quite disparate substances have an 
anti-inflammatory and antiproteinuric effect in common, it seems logical to 
seek an explanation of the antiproteinuric effect among the anti-inflamma-
tory effects of these agents. Of course it cannot be excluded with certainty 
that the antiproteinuric effect is an independent effect; in that case one 
would wish to obtain data on antiproteinuric but not anti-inflammatory 
structural analogues or on antagonists of the antiproteinuric effect. Data 
of this kind, however, are not available. 
Shen (1972) presented what he called a "biochemical profile" of indome-
thacin, in which a great many effects of this drug were arranged according 
to the concentrations required for these effects. For the range of concentra-
tions from 10 4 to 10 3 mole/1 he discussed effects on enzymes and on me-
diators involved in the inflammatory reaction; these include the inhibitory 
effect on proteolytic enzymes and on histidine decarboxylase, uncoupling 
of oxidative phosphorylation, inhibition of synthesis of mucopolysacchar-
ides; also, inhibition of the lymph node permeability factor and of brady-
kinine effects; within this range of concentrations, indomethacin also has a 
stabilizing effect on plasma proteins. For a ten times smaller range of con-
centrations (10 5 to 10 4 mole/1), he mentioned effects on cellular membran-
es: stabilization of erythrocytes, inhibition of platelet functions such as ag-
gregation, inhibition of several granulocyte functions such as Chemotaxis and 
participation in the Shwartzman reaction, and stabilization of lysosomes. In 
an again ten times smaller concentration (10 hmole/l), there was an inhibitory 
effect on the synthesis of prostaglandins. The lastmentioned concentration 
(0.36 mg/1) is within the range of (total, i.e. protein-bound -(- free) concen-
trations found in plasma at the pharmacotherapeutic dose. For the thera-
peutic use of indomethacin, there is no information on concentrations at the 
site of action, because the site of action has not been defined. Yet it would 
seem possible to conclude tentatively that the most plausible explanation of 
the in-vivo action of indomethacin would be that based on a mechanism of 
action which occurs at the lowest concentrations. 
None of the previously discussed clinical observations on the antiprotein-
uric effect of indomethacin led to more than speculative hypotheses on the 
underlying mechanism of action. In view of the unavoidable diversity of 
clinical material studied, moreover, it is impossible to qualify the long-term 
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effects of indomethacin as deviating from the natural history of the (in-
dividual) renal disease involved. Only the more favourable course of lupus 
nephritis reported by Wijdeveld (1971) and Conté et al. (1973, 1975) seems 
to deviate from what could be expected in this severe renal disease. Specul-
ations on the mechanism of action often postulate a dual effect: a decrease 
in the permeability of the glomerular basement membrane, and an anti-
inflammatory effect which reduces the immunological damage to the 
glomeruli. Decreases in proteinuria, particularly if abrupt, and decreases in 
glomerular filtration have been attributed to the first mechanism of action; 
an eventual improvement of the renal disease is hoped to result from the 
second mechanism. 
Interference with immunogenesis of glomerulonephritis? 
Limitation of the immunological damage to the glomeruli has been related 
to the inhibitory effect of indomethacin on various components of the im-
munologically caused inflammatory reaction. A number of conceivable sites 
of action of anti-inflammatory drugs in this chain of events can be mention-
ed. Indomethacin inhibits migration of neutrophilic cells in response to a 
chemotactic stimulus (Phelps et al. 1967; Van Arman et al. 1971). Only 
salicylate is known to inhibit adherence of granulocytes to endothelium in 
the presence of a stimulus (MacGregor et al. 1974). The in-vitro phagocy-
tosis of starch granules by neutrophilic granulocytes is inhibited by indo-
methacin (Chang et al. 1968). Indomethacin stabilizes the membrane of 
lysosomes (Ignarro 1971; Lewis et al. 1971; Perper et al. 1974) in the liver 
and in neutrophilic leucocytes. It reduces platelet aggregation (O'Brien et al. 
1970; Peterson et al. 1970; De Gaetano et al. 1971, 1974) and the prostag-
landin production in platelets (Smith et al. 1971). 
A few other observations can be related to a possible indomethacin action 
via an influence on immune processes. Brown et al. (1968) described in-
hibition of antigen-antibody reactions in vitro with non-steroid anti-inflam-
matory drags. The concentration of indomethacin required to inhibit precip-
itation of egg albumin reacting with rabbit anti-egg albumin, however, was 
a thousand times that commonly used in therapy. Ferri et al. (1974) found 
in rabbits that indomethacin (100 mg/kg i.v.) has an anticomplemental 
effect on C4, C2 and C3; aspirin has such an effect on CI, and phenyl-
butazone has this effect on the activation of C4 and C3. Speculation might 
utilize such differences in effect to explain different inhibitory power on 
experimental models of inflammation. Whaley et al. (1975) likewise found 
that phenylbutazone inhibited complement-mediated haemolysis at higher 
concentrations than attained therapeutically. Lagrue et al. (1973), however, 
established in a previously mentioned study on hypocomplementary nephri-
tis that no increase in the serum complement level occurred during 
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indomethacin medication. Van Arman et al. (1970) demonstrated inhibition 
of the local Shwartzman reaction by indomethacin, which did not prevent 
leucocytes from gathering at the site of inflammation; they interpreted 
these findings as indicative of blocked leucocyte disruption and prohibited 
release of enzymes. 
If, considering the possible effect of indomethacin on mechanisms of anti-
body production, we regard the various stages of the immune response, 
using the conventional division into an afferent, a central and an efferent 
component (Nossal 1967), then we touch upon some speculative associations 
with indomethacin effects reported in the literature. The initial clinical ob-
servations revealed absence of any influence on the serological so-called 
rheumatoid factors in serum (Ballabio et al. 1964). Suppression of the local 
inflammatory reaction during immunization in an attempt to induce an 
experimental disease, might reduce the chance that an antigen reaches the 
draining lymph node after intraperitoneal injection. In vitro, high con-
centrations of indomethacin (40 mg/1) inhibit protein synthesis by lympho-
cytes (Forbes et al. 1967). This effect is probably due in part to blocking 
of the energy supplies of these cells (Whitehouse 1964). Coppola et al. 
(1970) demonstrated a doubling of the survival time of skin allografts in 
guinea-pigs treated with indomethacin. In their opinion this should be 
explained by modification of the inflammatory reaction resulting from the 
cellular response during rejection. There is possibly a relation with the 
indomethacin effects recently observed by Bach (1974) on the percentage 
of #-antigen-bearing lymphocytes in the spleen. 
Clinical discussions about the theory of limitation of immunological 
damage have also placed considerable emphasis on the importance of 
clotting mechanisms. This followed the publication of a study by Vassalli 
and McCluskey (1965), who found that warfarin had a protective effect 
on the course of Masugi nephritis. Later, Naish and co-workers (1972) found 
that defibrination protected the glomeruli from nephrotoxic nephritis in 
rabbits. Vermylen et al. (1970) observed in 7 patients with proliferative 
glomerulonephritis, and Clarkson et al. (1972) in 14 of 20 patients with 
various types of glomerulonephritis, a decrease in the excretion of fibrin 
degradation products in response to indomethacin. In the study of Clark-
son and co-workers this effect was found to be due to the disappearance of 
the smaller molecular weight fragments. No effect was observed in the 
only two patients with minimal lesions and in one patient with Fabry's 
disease. The non-responders differed from the responders in the rate of 
progression of their renal insufficiency. Both groups of investigators as-
sumed that indomethacin inhibits platelet aggregation, and thereby the 
deposition of fibrin in the glomeruli. If it is true that, in glomerulonephritis, 
a lower excretion of fibrin degradation products indicates a better prognosis 
(Clarkson et al. 1972), one might speculate that this indomethacin effect 
would influence the prognosis favourably. De Gaetano et al. (1974) showed 
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inter-patient differences in the degree of inhibition of platelet aggregation 
produced by indomethacin; they also indicated the likelihood of a degree 
of parallelism between these differences and differences in the degree of 
reduction of the urinary excretion of fibrinogen and fibrin-related antigen 
in adults with glomerulonephritis. 
Effect on membrane permeability? 
The postulated decreased permeability of the glomerular basement mem-
brane to which one might tend to ascribe the abrupt decrease in proteinuria 
and the reduced glomerular filtration, has often been related to effects of 
indomethacin on cellular membranes. The concentration required for ef-
fects of this type generally exceeds therapeutic plasma concentrations by 
a factor 10. What exactly happens in these membrane effects is unknown; 
the data available are in fact always descriptive data. This is why for the 
time being the association with, say, the stabilizing effect of indomethacin 
on the erythrocyte membrane (Brown et al. 1967; Ingioi et al. 1968; Ca-
tanese et al. 1969; Kalbhen et al. 1970; Glenn et al. 1971), which protects 
the cell from lysis by heat or by hypotonicity of the environment, cannot 
mean much more than the observation that analogous words are used. A 
more useful association would present itself if it could be established that 
indomethacin, like phenylbutazone, had an antipermeability effect on the 
passage of colloidal pigments through capillary walls, i.e. both passage 
in the direction of normal tissues and passage from capillaries in inflamed 
tissue areas in the direction of these inflamed tissues (Domenjoz 1952). 
Domenjoz did not specify the concentration required for this effect of phe-
nylbutazone; the context in the publication in question, however, suggests 
that he used a dosage of 50-100 mg/kg (!) in rabbits. 
Interference with prostaglandin synthesis 
In view of the above discussed diversity of properties of non-steroid 
anti-inflammatory drugs, it is useful here to mention (without discussing 
details) that the role of prostaglandins as mediators in numerous inflam-
matory reactions in animal organisms has been established. Interested readers 
are referred to recent reviews by Ferreira et al. (1974), Robinson et al. 
(1974) and Velo (1974). Speaking very generally, prostaglandins possibly 
play a role in inflammatory processes by causing sensitization to other 
inflammatory mediators such as bradykinine and histamine. The non-
steroid anti-inflammatory drugs inhibit prostaglandin synthetases at con-
centrations which occur in body fluids during therapy. This observation 
would seem to warrant the conclusion that this anti-enzymatic activity may 
be an essential feature of the mechanism of action of these drugs (Ferreira 
et al. 1974) 
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Many of the separately mentioned effects of a drug such as indometha-
cin may be reducible to an effect on the abovementioned prostaglandin 
synthetases. However, the available knowledge of the inflammatory reaction 
and the role which prostaglandins play in it is far from complete on a num-
ber of essential points such as the effective level of the substrate (free ara-
chidonic acid) of the prostaglandin synthetases in the tissues (Brocklehurst 
et al. 1974). Prostaglandin synthetases in different tissues, probably as a 
series of isoenzymes, differ in sensitivity to anti-inflammatory drugs; this 
probably also explains that in many experiments the relative potency of 
indomethacin as prostaglandin synthetase inhibitor varies markedly as 
compared with the potency of aspirin. The extreme ratios given by Ferreira 
et al. (1974) in their review are 19:1 and 2140:1. At the same time this 
could explain that salicylates lack the effect of indomethacin on proteinuria, 
and specifically also an effect on renal prostaglandin synthetase activities, 
still to be discussed. 
Speculative discussions on the antiproteinuric effect of indomethacin often 
refer to what is known about the regulation and autoregulation of renal 
blood flow, and about the possible role of prostaglandins in these regula-
tions. It is precisely by utilizing inhibition of prostaglandin synthesis by a 
substance such as indomethacin that conclusions on the role of renal pros-
taglandins have been possible. In a review on the role of renal prostaglan-
dins as revealed by inhibitors of prostaglandin synthetase, McGiff et al. 
(1974) mentioned three facets of the action of renal prostaglandins. 
To begin with, PGE2 of renal origin is of importance for the maintenance 
of resting blood flow to the kidney. There is a continuous efflux of prostag-
landins from the kidneys even when no special demands are made on the 
renal circulation; this basal efflux is reduced by in-vivo inhibition of pros-
taglandin synthesis by indomethacin (Lonigro et al. 1973), which causes 
a reduction of renal blood flow. Experiments in this context pose the 
problem that the influence of anaesthesia and abdominal surgery on the 
phenomena studied, is insufficiently known (Zins 1975). Zins explained his 
observation of the absence of an effect of indomethacin on renal blood 
flow in unanaesthetized dogs by the fact that his experiments were done 
without anaesthesia. In circumstances which involve redistribution of renal 
blood flow, a second action of renal prostaglandins becomes apparent. 
They mediate an increase of inner cortical blood flow. Observations on 
isolated perfused dog kidneys showed that indomethacin nullified and 
reversed the time trend whereby additional increases in inner cortical blood 
flow would have occurred if indomethacin had not been administered 
(Itskovitz et al. 1973, 1974; McGiff et al. 1974). Thirdly, PGE2 antagonizes 
in the kidney the excessive activity of the vasoconstrictor-antinatriuretic 
antidiuretic system: the adrenergic nervous-renin-angiotensin-ADH system. 
For example, release of prostaglandins from the kidneys has been observed 
after renal ischaemia (Jaffe et al. 1972) and after infusion of angiotensin I, 
24 
angiotensin II or adrenaline (Needleman et al. 1973). Aiken and Vane 
(1973) demonstrated that inhibition of prostaglandin synthesis by indome-
thacin enhanced the renal vasoconstrictor effect of angiotensin II or adre-
naline, release of prostaglandins remaining absent. 
It was demonstrated by Lee et al. (1967) that renal prostaglandins are 
synthesized in the renal medulla; Muirhead et al. (1972) demonstrated the 
prostaglandin-synthesizing activity of papillary interstitial cells of the 
renal medulla in tissue cultures. In addition, Larsson et al. (1973) found 
synthesis of PGE also in the microsomal fraction of the renal cortex. Solez 
et al. (1974) studied the influence of indomethacin on the normal rat 
kidney in situ during anaesthesia; they found that a single intraperitoneal 
injection of 5 mg indomethacin per kg body weight significantly reduced 
the medullary plasma flow during 45 minutes, whereupon an increase in 
this flow occurred during 3-6 hours after indomethacin injection. The total 
renal blood flow decreased after indomethacin injection, but returned to 
normal within an hour. The changes in medullary plasma flow correlated 
with the concentrations of prostaglandin A and E in the circulation. Wil-
liams et al. (1974) found in stop-flow experiments on dogs that prostag-
landins synthesized in the medulla ended up in the urine in Henle's loop or 
in the distal tubule; it is therefore highly probable that they reach the 
macula densa via this route. It is on dysfunction of this route that Oken 
(1975) based a hypothesis on a self-perpetuating mechanism when, in acute 
renal failure, glomerular filtration stops completely due to overwhelming 
vasoconstriction. Homych (1974) observed a diuretic and natriuretic effect 
of PGA., in a patient with acute renal failure. 
Donker et al. (1975) studied the glomerular filtration rate (GFR) and 
effective renal plasma flow (ERPF) in 7 healthy volunteers, 4 patients with 
a single kidney, and 2 patients with disturbed renal function without pro-
teinuria; they determined the effect of indomethacin while these subjects 
were on a normal, and while they were on a saltless diet. In the experi-
mental situation they had created, they found that indomethacin admini-
stration caused few changes in the normal subjects; but unmistakable 
decreases in GFR and ERPF were observed in the patients with one kidney 
and in those with disturbed renal function. The authors suggested that 
indomethacin, acting via inhibition of renal prostaglandin synthesis, reduces 
the GFR particularly if renal function is limited and/or the renin-angiotcn-
sin-prostaglandin system stimulated. A corresponding finding was reported 
by Arisz et al. (1975), who observed that the effect of indomethacin on the 
GFR, and also on proteinuria, was much more pronounced during salt 
restriction, alone or supported by thiazide diuretics, than during normal 
salt intake. Observations reported by Ryan et al. (1975) and Hulme et al. 
(1975) showed that renal blood flow changes produced by ligation of the 
renal artery or infusion of renin and angiotensin II, altered the glomerular 
permeability to macromolecules. This is why an explanation of an antipro-
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teinuric effect and of an increased selectivity of proteinuria need not be 
sought in redistribution of the blood flow to entirely different (juxtamedul-
lary) glomeruli, alleged to be qualitatively and quantitatively less permeable 
to proteins. 
Indomethacin in experimental glomerulonephritis* 
A few studies have been published on the effect of indomethacin in 
experimental glomerulonephritis; in addition there is one publication on 
the effect of bucloxic acid in experimental nephritis. 
Lagrue et al. (unpublished; personal communication 1974) studied 
Masugi nephritis in rats. They observed that indomethacin, administered 
before induction of the experimental nephritis and during its course, re-
duced protein excretion without affecting serum complement levels or 
histological features. 
Vindel et al. (1974) studied the effect of bucloxic acid in rabbits with 
Masugi nephritis. The agent was administered in a daily dose of 25 mg/kg 
during 4 weeks, beginning the day after 3 consecutive days on which heter-
ologous antiserum was administered. For comparison we may consider the 
mean effective daily dose of 820 mg which Lagrue et al. (1974) used in the 
treatment of various forms of human chronic glomerulonephritis. On the 
10th day of the experiment, 6 untreated and 6 treated rabbits showed 
pathological proteinuria; in 2 untreated animals this still existed on day 60, 
in 4 untreated animals it was no longer present at that time. In 4 of the 
animals in the group treated with bucloxic acid, the proteinuria had already 
disappeared on day 20; in 2 animals this was found on day 50. In all un-
treated animals the serum complement levels were markedly decreased 
during the first 30 days of the experiment; this was the case in only 2 of the 
treated animals. In contrast to the untreated animals histological examination 
of the kidneys of the treated animals showed less leucocytic infiltration and 
less proliferation, and there existed no glomerulosclerosis. 
Vihert et al. (1973) described the effect of indomethacin (5 mg/kg daily) 
on experimental "proliferative membranous" glomerulonephritis induced in 
rats by a method resembling that used to induce Heymann-type nephritis. 
Indomethacin was given at the time of immunization in one group, and 
starting a month after immunization in another group. Controls with and 
without glomerulonephritis and both indomethacin-treated groups were 
followed up over a period of 8-12 weeks. Parameters studied were 
protein excretion (g/1), blood pressure, plasma albumin, and histological 
features. The results were striking: the group treated early showed hardly 
* The terminology of experimental glomerulonephritis used in this section, is discus-
sed in chapter II. 
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any abnormalities; the group treated late was exactly intermediate between 
the group treated early and the untreated control group, for all parameters. 
The group treated early developed only minor histological lesions. In 
the group treated late, substantially less cellular proliferation was found, 
and there was much less deposition of immunoglobulins in the kidneys 
than in the natural history of the disease. It cannot be deduced from the 
material presented whether immune complex nephritis was involved, or 
rather nephrotoxic nephritis with autologous antibodies. 
These results were not supported by two recent Dutch studies: one by 
Daha (1973) on Masugi nephritis, and one by Fecnstra (1974) on heterolo-
gous immune complex nephritis ("passive" Heymann-type nephritis). 
Daha (1973) induced nephrotoxic nephritis by intravenous injection of 
rabbit anti-rat glomerular basement membrane IgG. Only when a small 
dose of antiserum was given, a subcutaneous injection of 4 mg indomethacin 
per kg body weight daily caused a decrease by 40-60% of protein excretion 
during a follow-up over a period up to 40 days. The endogenous creatinine 
clearance was not influenced, and no effect was observed on the selectivity 
of proteinuria. Semiquantitative assessment showed no immunohistochemical 
differences, but indomethacin administration seemed to reduce the cellular 
proliferation in the autologous phase of the experimental nephritis. Daha 
focused in particular on the synthesis of glomerular basement membrane 
material, studied by incorporation of radioactive hydroxyproline. He found 
that, in the heterologous and early in the autologous phase, indomethacin 
caused the already increased synthesis to increase further by 30% and 15%, 
respectively. 
Feenstra et al. (1974, 1975) induced experimental immune complex 
nephritis by intraperitoneal administration of rabbit anti-rat tubular brush 
border (FxlA) IgG. This experimental glomerulonephritis was not accom-
panied by pathological proteinuria, and he studied the effect of indome-
thacin (4 mg/kg daily) on the histological, immunohistochemical and elec-
tron-microscopic changes. When indomethacin was administered before 
or during induction of the nephritis, immunofluorescence showed less de-
position of rabbit IgG (heterologous phase), but as much deposition of rat 
IgG and complement (autologous phase). The immune complex aggregates 
in the glomeruli, detected by electron microscopy, seemed to be smaller and 
less far penetrated through the GBM in the indomethacin-treated animals. 
Where complexes were localized in the lamina rara interna, interposition of 
mesangium between endothelium and basement membrane was observed. 
Moreover, the indomethacin-treated animals showed more pronounced 
formation of "spikes", GBM substance interposed between subepithelially 
localized immune complex aggregates. Feenstra excluded the possibility of 
influence of medication on absorption of antibody from the peritoneal cavity 
during immunization. To explain the indomethacin effects, he speculated 
about such factors as decreased permeability of the GBM, increased synthe-
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sis of GBM material and inhibition of the phagocytic activity ascribed to the 
mesangium. 
The findings reported show that, in Masugi nephritis, the response of 
the histological features to a non-steroid anti-inflammatory drug was 
sometimes absent (Lagrue), sometimes slight (Daha) and sometimes mark-
ed (Vindel), and that an influence on protein excretion was always present. 
In a possibly likewise nephrotoxic nephritis (Vihert) with autologous anti-
bodies, both protein excretion and morphology also responded favourably to 
indomethacin. In the only immune complex nephritis in which indomethacin 
was tested in an experimental disease, an unmistakable modification of the 
morphological features was observed (Feenstra). 
Sessa et al. (1975) reported an effect of indomethacin (4 mg/kg daily) 
on the clinical course of puromycin aminonuclcoside nephropathy in rats: 
hypoproteinaemia, hypercholesterolaemia, uraemia and protein excretion 
in the indomethacin-treated rats were substantially less marked than those 
in the untreated rats. They started indomethacin medication at a time in 
the course of the disease (day 7) when protein excretion was already sig-
nificant. They ascribed the indomethacin effect to a phenomenon they had 
described earlier (Sessa et al. 1973) as increased activity of epithelial cells, 
giving rise to increased synthesis of GBM material. 
Summary and problem statement 
From the presented data two effects of indomethacin can be distinguished 
and seem to deserve further exploration. 
The first may be called the short-term effect and is represented by an 
influence on protein excretion and other parts of renal excretory function 
such as glomerular filtration rate and excretion of water, sodium and other 
solutes. This effect seems to have been found so far only in situations with 
a previously damaged kidney. It seems attractive to ascribe this effect to 
mechanisms of action presenting themselves at indomethacin concentrations 
in the order of therapeutic plasma concentrations. From that point of view 
an effect via inhibition of prostaglandin synthetases seems the most plausib-
le. There are no data in the literature about this short-term effect in experi-
mental nephritis. 
The second effect may be called the long-term effect and is represented 
by an influence of indomethacin on the course of glomerulonephritis. Data 
from the literature on the question as to whether the drug has a beneficial 
effect on the ultimate prognosis of glomerulonephritis are highly controver-
sial, both in clinical and in experimental nephritis. Confirmation of such a 
beneficial effect would be of particular importance since it would imply the 
possibility to delay or even to reverse the so far irrevocable course of 
chronic glomerulonephritis. 
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Experiments in animals seem indispensable to obtain a better insight 
into the abovementioned phenomena and problems. For both effects it is 
virtually impossible to obtain from human pathology a large enough num-
ber of reproducible situations, on the one hand because we have a still only 
fragmentary knowledge of the aetiology of human glomerulonephritis, and 
on the other hand because patients present themselves for treatment in 
widely diverse stages of the disease. The particular problem of the existence 
of a long-term effect could only be solved by means of prospective studies 
on a random basis. Apart from the impossibility to obtain uniform groups, 
the random basis would have the consequence that a proportion of patients 
suffering from a nephrotic syndrome would have to be deprived from a 
drug which often has a beneficial effect on proteinuria, whereas on the 
other hand a proportion of patients without nephrotic syndrome would 
have to be submitted to long-term treatment with indomethacin, which is 
not without side-effects. 
We, therefore, decided to study the two effects of indomethacin in ani-
mals with experimental glomerular diseases with a well determined type 
and onset. We selected two types of glomerulopathy: autologous (Heymann-
type) immune complex glomerulopathy and puromycin aminonucleoside 
nephropathy. Both diseases can be induced in rats in a way that they are 
associated with severe proteinuria. The specific questions we tried to answer 
were: 
1. Has indomethacin a short-term effect on experimental proteinuria and, 
if so, under which conditions? 
2. Does indomethacin influence the natural course of the two types of 
glomerular disease? 
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CHAPTER II 
EXPERIMENTAL GLOMERULAR DISEASE 
A complete review of the extensive literature on experimental glomerular 
disease would exceed the scope of this study and duplicate excellent reviews 
published abroad (Rother 1965; McCluskey et al. 1969; Lannigan et al. 
1969; Wilson et al. 1974) and in The Netherlands (Van Es 1971; Felt-
kamp-Vroom 1973; Feenstra 1974). 
Roughly, two types of experimental glomerulopathy produced via immune 
mechanisms can be distinguished: those caused by circulating antibodies 
against the glomerular basement membrane (anti-GBM nephritis) and those 
caused by deposition of circulating antigen-antibody complexes (immune 
complex nephritis). These two groups can be differentiated with immuno-
fluorescence methods using fluorescein-labelled antibodies against immuno-
globulins. In anti-GBM nephritis this method reveals a linear fluorescence 
along the glomerular basement membrane, whereas in immune complex 
nephritis a granular immunofluorescence pattern is obtained. 
The earliest model of experimental anti-GBM nephritis is the "nephroto-
xic glomerulonephritis" which Masugi (1933) produced in rats after admi-
nistration of heterologous antiserum produced in rabbits against homoge-
nate of rat kidneys. A more recent model of anti-GBM nephritis is the 
"experimental allergic nephritis" which Steblay (1962) induced by immuni-
zing sheep with GBM homogenate from monkey, man, rabbit, dog or rat 
in complete Freund's adjuvant. An essential difference between these two 
models is that "Masugi nephritis" begins with passive administration of he-
tero-antibody and continues by production of auto-antibodies, whereas in 
"Steblay nephritis" there is only production of auto-antibodies. The severity 
and chronicity of the lesions in Masugi nephritis depend on the animal 
species and the antibody dosage. Spontaneous recovery is possible after a 
single low-dosage antibody injection. In the most severe form the animals 
can die within 24 hours showing extensive intravascular coagulation in the 
kidneys, as they did in Feenstra's experiments (1974). The severe forms 
with a more protracted course provide a model of human anti-GBM glome-
rulonephritis as observed in Goodpasture's disease. The sheep suffering 
from Steblay nephritis died within a few months of fulminating extracapil-
lary glomerulonephritis. 
30 
Experimental immune complex nephritis has been induced with a variety 
of antigens. A wellknown example is acute serum sickness, often studied in 
rabbits after administration of bovine serum albumin. After a single intrave-
nous injection of a large dose of the antigen, deposition of immune complex 
aggregates is found along the GBM of these animals for several weeks (Fish 
1966). Prolonged exposure to the antigen by repeated daily injections of 
small amounts can lead to chronic immune complex nephritis (Dixon et al. 
1961; Germuth et al. 1953, 1973). Lesions of this type can be induced also 
by administration of soluble antigen-antibody complexes (McCluskey et al. 
1962). 
A model of immune complex nephritis commonly used as a model of 
human epimembranous nephritis, is the experimental condition which 
Heymann and co-workers described as "autoimmune nephrosis" in 1959. 
Watson and Dixon (1966) re-named it "kidney-in-adjuvant nephritis", and 
Edgington et al. (1967a) referred to it as "autologous immune complex 
nephritis". Since this model is one of the two types of nephropathy used 
in our study, it deserves a more detailed discussion. 
In 1959 Heymann and co-workers described glomerular changes which 
occurred in rats after repeated intraperitoneal injection of a mixture of 
complete Freund's adjuvant and low-speed supemate of a blood-free rat 
kidney suspension in saline. The disease developed after three or more 
injections given at two-week intervals, and closely resembled the nephrotic 
syndrome in human pathology: massive proteinuria, hypoproteinaemia and 
hyperlipaemia occurred. After the second or third injection the animals 
showed ascites for a number of days: the presence of oedema was not 
clearly specified either by Heymann et al. or by subsequent authors, with the 
exception of Allison et al. (1974). The latter studied many aspects of the 
pathophysiology of experimental glomerulonephritis in rats; they reported 
that none of their animals with Heymann-type nephritis was oedematous. 
They also made mention of the absence of hypoproteinaemia even in ani-
mals with a final degree of proteinuria of 400 mg per animal per 24 hours 
or more. 
The disease described by Heymann et al. persisted after discontinuation 
of antigen administration. Homogenate of homologous as well as of auto-
logous (own kidney after unilateral nephrectomy) rat kidney proved to be 
capable of inducing the disease. In 1962 the same investigators reported a 
higher incidence of the disease after immunizing with kidney cortex 
homogenate than by immunizing with renal medulla homogenate. In addition 
it was found that the use of complete Freund's adjuvant containing Myco-
bacterium tuberculosis was essential: the disease did not develop when 
Mycobacterium tuberculosis was replaced by Mycobacterium butyricum. 
This contradicts the effect of this Mycobacterium in our study and in that of 
Allison et al. (1974). Attempts made by Heymann et al. (1962) to induce the 
disease in animals other than rats failed. Moreover, the role of Freund's 
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adjuvant proved to be another one than that of a means to induce sterile 
peritonitis. Injections of antigen mixed with likewise peritoneum-irritating 
talcum suspensions did not cause the disease. The aetiology and the patho­
genesis of the disease being in fact unclear, Watson and Dixon (1966) pre­
ferred the designation "kidney-in-adjuvant nephritis" for the time being. In 
their publication they reported that it was possible to induce a more severe 
disease by coupling the supernatant of the low-speed (90 min, 1600 χ g at 
4 0 C) centrifuged kidney homogenate to diazonium derivatives of arsanilic 
and sulphanilic acids. 
The granular immunofluorescence pattern which is found in this type of 
glomerulopathy, had been demonstrated as early as 1963 by Heymann 
and his group. In 1966 and 1967 it was demonstrated by Glassock et al. 
(1966), Edgington et al. (1967a, 1967b) and Grupe et al. (1967) that the 
antigen of the Heymann-type glomerulopathy was of tubular rather than 
of glomerular origin. It could be located in the brush border of the 
epithelium of the proximal convoluted tubule. Edgington et al. (1967b, 
1968) achieved a high degree of purification of this antigen, which they 
called RTE-as t o distinguish it from earlier described renal tubular epithe­
lial (RTE) antigens. They started from a renal tubular epithelial fraction 
(Fxl) of fractionated rat kidneys from which they obtained a saline-insolu­
ble ultracentrifugally sedimentable fraction A (FxlA). From this fraction 
FxlA they obtained RTE-as by sodium desoxycholate solubilization, frac­
tional ammonium sulphate precipitation, preparative block electrophoresis 
and a series of column-chromatographic procedures. The pathogenetic me­
chanism of this immune complex nephritis proved to be more complicated 
than that of serum sickness (Edgington et al. 1967b; Glassock et al. 1968): 
once a process of antibody production is started by administration of 
RTE-a,-,, immune complexes are formed in which the animal's own circu­
lating RTE-as is included. The abovementioned authors demonstrated the 
presence of small amounts of this antigen in the circulation in healthy rats; 
they also demonstrated that the antigen in the immune complex aggregates 
in the GBM in the diseased animals consisted mainly of the animal's own 
RTE-as- F o r this reason the disease has been called "autologous immune 
complex nephritis". 
A possible counterpart of this disease in human pathology is suggested 
by clinical observations reported by Naruse et al. (1974), indicating that 
constant supply of autologous antigen prevents "membranous glomerulo­
nephritis with autologous renal tubular antigen in the immune complex 
aggregates" from entering a remission. 
Edgington et al. (1969) transplanted kidneys of isologous healthy donors 
to recipients in whom active Heymann-type nephritis had been induced by 
injection of autologous antigen; they observed an immune complex nephri­
tis developing in the healthy kidneys, and thus demonstrated that the pro-
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auction of autologous antigen-antibody complexes continues, at least for 
some considerable time after induction of the disease. 
Attempts have been made to find possibilities of inducing a so-called 
"passive" Heymann-type nephritis which, unlike the "active" form so far 
discussed, would result from antibody rather than antigen administration. 
Hoedemaeker (1972) observed that a number of nephrotoxic sera caused 
not only a linear but also a granular deposition of IgG along the GBM; 
the immune complexes proved to be composed of the antibody injected 
and RTE antigen: in the production of anti-GBM antibodies, antibodies 
against the tubular antigen had apparently also been produced. Sugisaki et 
al. (1973) injected only the antibody against tubular antigen, and observed 
that an immune complex nephritis resulted from deposition of immune 
complexes, consisting of homologous antibody and the autologous circulating 
brush border antigen. Feenstra (1974, 1975) induced a "passive" Heymann-
type nephritis by giving rats heterologous anti-rat FxlA antibodies produced 
in rabbits. 
In histological terms, Heymann-type immune complex nephritis is an 
epimembranous glomerulonephritis. Microscopically it is characterized by 
appositions to the epithelial side of the GBM — "spikes" — and absence 
or near-absence of inflammatory infiltrates or cellular proliferation. 
Electron-microscopically it is characterised by thickening of the GBM, spike 
formation, and by the presence of subepithelial electron-dense deposits 
(Heymann et al. 1959; Feldman et al. 1963, 1964; Alousi 1969). 
A few other details of this type of experimental glomerulonephritis 
deserve further discussion. To begin with, different rat strains show differ­
ent sensitivity (Watson et al. 1966), and every study must therefore com­
mence with pilot experiments on the rat strain available. Secondly, the 
immunization schedule can be established only empirically, for pertinent 
data from the literature provide little guidance in this respect. There have 
been descriptions (Watson et al. 1966; Alousi et al. 1969; Lannigan et al. 
1969) of schemes of immunization with single, bimonthly or weekly 
injections; the onset of proteinuria can be 6-12 weeks after the first 
antigen injection, and a stable level of proteinuria is attained after 
14-20 weeks. The range of variation of proteinuria in isologous animals 
cannot be predicted either, for many reports give only mean values for 
groups of animals. Thirdly, little is known about the mechanism of the 
contribution of Freund's adjuvant to the development of immune complex 
nephritis. To the relevant data already presented (Heymann et al. 1962; 
Allison et al. 1974) it can be added that Watson et al. (1966) observed no 
development of nephritis when nephritogenic streptococci were used instead 
of Mycobacteria. In addition they found an influence of the emulsifier on 
the degree of proteinuria attained. Sugisaki et al. (1973) added В. pertussis 
to the adjuvant, which caused increased severity of the disease. Finally, 
hardly anything is known about the contribution of the diazotation to the 
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induction of the nephritis; we used the diazotation procedure following 
Watson et al. (1966) and Lannigan et al. (1969). The former authors 
reported that the disease produced by chemically altered kidney showed no 
qualitative morphological difference from that obtained by native kidney. 
The use of azoproteins as antigens was introduced by Landsteiner (1918), 
who in this way coupled many compounds as haptene to protein, whereupon 
the specificity and cross-reactivity of immune sera to azoproteins were 
investigated. Applying Singer's general statement on haptenes and antigenic 
determinants (1965) to the antigenic material used to induce an immune 
complex nephritis, it can only be said that what is involved is an undoubted-
ly heterogeneous mixture of many conjugates. Particularly studies on hap-
tenes conjugated with synthetic polypeptides have shown that introduction 
of a haptene can greatly enhance the immunogenic activity of the resulting 
conjugate; the latter can be used to induce formation of antibodies against 
the carrier protein, against the site of conjugation of carrier and haptene, 
or against the haptene. For a pertinent review the reader is referred to Gill 
(1972). 
A glomerulopathy of an entirely different type can be induced with the 
aminonucleoside of puromycin. The nephrotic syndrome thus produced was 
first described by Frenk et al. in rats (1955). After administration of 15 
mg puromycin aminonucleoside per kg body weight daily during 10-12 
days, they observed in their immature rats a syndrome which encompassed: 
massive oedema, ascites, proteinuria, hypoproteinaemia, hyperlipaemia and 
azotaemia. 
Puromycin aminonucleoside nephropathy presents a model of human 
'lipoid nephrosis", both on the basis of the abovementioned electron-
microscopic features in the acute phase, and in view of the selective pro-
teinuria observed in the experimental disease by Lannigan et al. (1969), 
which has also been reported in the human syndrome (White et al. 1970). 
The course, severity and possible lethality of the disease are dependent 
on the dose and the mode of administration. For example, the disease is 
most rapidly induced by intravenous injection (Lannigan et al. 1962), 
whereas serial subcutaneous injections induce later and less marked pro-
teinuria, sometimes followed by progressive renal failure (Borowsky et al. 
1961). Administration of the aminonucleoside during a few days only is 
followed by a transient period of proteinuria. In such experiments the onset 
of proteinuria may be expected on day 6-8 of the experiment; maximum 
protein loss in urine occurs after 2-3 weeks, and the acute, very marked 
proteinuria disappears within a few weeks, sometimes with some slight 
residual increase in proteinuria in relation to the baseline value. A propor-
tion of the animals studied by Lannigan et al. (1969) showed another 
spontaneous increase in proteinuria 6 months after the acute illness; this 
was accompanied by glomerulosclerosis and renal insufficiency. In this 
respect it is to be noted that these authors denied the importance of the rat 
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species used in these experiments. Actually (although they give control 
values about healthy animals), they did not discuss the question as to 
whether their animals might develop in the course of their natural history a 
nephropathy of increasing age (cfr Elema et al. 1971). 
Microscopic examination of the kidney in puromycin aminonucleoside 
nephropathy has revealed PAS-positive droplets, present even before onset 
of proteinuria, in the glomerular epithelial cells and the proximal convolu-
ted tubule cells (Hoch-Ligeti 1960; Lannigan et al. 1962). Electron-
microscopic examination sometimes shows slight broadening of the GBM 
(Kurtz et al. 1962), which in other cases is entirely normal (Lannigan et al. 
1969), with only fusion of epithelial foot processes (Lannigan et al. 1969). 
The aminonucleoside dosages reported vary from 100 mg/kg intra-
venously in one dose (Lannigan et al. 1962, 1969) to 15 mg/kg subcutane-
ously every day for 5-8 days (Kurtz et al. 1962) or longer (Borowsky et al. 
1961). 
For curiosity's sake we mention the only published cases of aminonucleo-
side nephritis observed in human subjects by Nussenzveig et al. (1963): they 
were five patients treated with this agent for trypanosomiasis. The pro-
teinuria persisted for a maximum of 7 weeks, and the hypalbuminaemia and 
hypercholesterolaemia disappeared shortly after. There were no residual 
symptoms. 
The pathogenic mechanism of puromycin aminonucleoside nephropathy 
is obscure. It is taken for a disease involving no immune mechanisms, the 
most essential argument being that the proteinuria occurs within 24 hours 
of intravenous injection of the substance (Lannigan et al. 1969; Wilson et 
al. 1958). Hoyer et al. (1972) demonstrated that perfusion of the kidney 
with puromycin aminonucleoside was able to produce proteinuria in a rat 
not treated with aminonucleoside which received the kidney as a transplant. 
Venkatachalam et al. (1970) demonstrated that changes in the GBM are 
responsible for the proteinuria in this disease. Using the enzyme beef liver 
catalase which, as cytochemically demonstrated, does not pass the healthy 
GBM as a tracer, they found it in nephrotic animals in the urinary space 
within 3 minutes of intravenous injection. 
Michael et al. (1970) described the disappearance of the glomerular po-
lyanion, a sialoprotein lining the epithelial cell adjacent to the GBM, during 
the initial phase of the proteinuria caused by aminonucleoside; they did 
not discuss the question whether this was cause or effect of the proteinuria. 
The same group (Blau et al. 1972) described increased synthesis of GBM 
sialoprotein in rats with aminonucleoside nephropathy, based on the fin-
ding of increased incorporation of i4C-labelled glucosamine in sialic acid 
when this precursor was given two days after aminonucleoside administra-
tion. In 1973 this observation was confirmed by Daha. He reported stimul-
ated GBM synthesis in vitro 4 days after initiation of aminonucleoside 
treatment, i.e. at a time when no proteinuria existed in his animals. 
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Mcintosh et al. (1972) isolated and purified a glycoprotein from the 
urine of rats with aminonucleoside nephropathy, which proved to differ in 
hexose content from the analogue (non-collagenous GBM glycoprotein) in 
the urine of healthy animals. They interpreted this finding as indicative of 
damage to the basement membrane in response to the aminonucleoside or 
due to the passage of large amounts of protein. 
36 
CHAPTER III 
MATERIAL AND METHODS 
Test animals 
The test animals used in this study were rats of three different strains: 
a) Female Wistar rats (random bred Albino Glaxo) aged 2 - 2.5 months, 
weighing 200 - 250 g. 
b) Male A X С 9935 (ACI) rats aged 3 months, weighing about 195 g. 
c) Male PVG/C rats. This inbred strain has been bred since 1947 by Glaxo 
Laboratories, Glaxo Research Farm, Harefield, Middlesex, Great Britain; 
in 1962 it was introduced in the Central Animal Laboratory of the 
Medical Faculty, Nijmegen, via the Institute of Psychiatry, Bethlem Royal 
Hospital, Monks Orchard, Beckenham, Kent, Great Britain. 
The nephritis was always induced in adult males which at the start of the 
experiment were 12-19 weeks old. The Wistar rat was used as source of the 
antigenic material for the Heymann-type nephritis. The PVG/C rat, inbred 
in 1975 in generation 71 since 1962, had been continued in the usual manner 
with brother-sister combinations as basic colony for breeding. 
It seems of importance to consider a number of data on the course of life 
of the normal PVG/C rat, particularly because these data are not available 
in the literature. In the course of life of the rat (Farris et al. 1949; Van der 
Gulden et al. 1972), the age of sexual maturity is 50 - 70 days; the life-span 
under protected conditions is about 40 months - a period which corresponds 
with a human life-span of 100 years. A survey of the data we collected is 
presented in fig. 3.1. During growth to maturity the creatinine production 
increases until a balance is struck after about 150 days. During this period 
the endogenous creatinine clearance, expressed per kg body weight, shows a 
slight decrease; the plasma creatinine concentration increases from 30 - 40 
to about 50 ¿¿mole/I. The total serum protein value is about 60 g/1 throughout 
life. The findings concerning serum protein values correspond with those in 
the literature (Scheving et al. 1968, 1973). It is to be noted that blood 
sampling for protein determination must be standardized in view of circadian 
fluctuations (Scheving et al. 1968). The values presented in fig. 3.1 were 
determined between 11.00 h and 14.00 h, when total protein and albumin 
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3.1 Data on healthy male PVG/C rats during life-span of 50-540 days. 
values are lowest. Scheving et al. (1968, 1973) found protein levels of 61 - 66 
g/1, with electrophoretically determined albumin levels of about 30 g/1. Our 
test animals showed a slight so-called physiological proteinuria (about 15 - 20 
mg/day from day 100), which did not increase further during the period of 
life studied. This physiological proteinuria has long been known (Sellers et 
al. 1950; Perry 1965; Van Es 1971), particularly in male rats. The protein 
excreted partly consists of an «o-globulin synthesized in the liver (Roy et al. 
1966, 1967) and of pre-albumin (Riimke et al. 1970). 
Some rat strains (especially male Wistar rats) (Perry 1965; Van Es 1971) 
show an increase in proteinuria after the age of 6 months. This is associated 
with thickening of the GBM (Van Es 1971; Elema et al. 1971), and at a 
more advanced age - 10 months and later - with focal glomerulosclerosis 
(Elema et al. 1971). Elema observed this glomerulosclerosis already at an 
age of 6 months in rats which underwent unilateral nephrectomy when they 
were 3 months old. The PVG/C strain we used did not show this proteinuria 
of age, and examination of the kidneys up to age 18 months revealed no 
signs of glomerulosclerosis. The normal electron-microscopic features of a 
glomerulus of the male PVG/C rat at age 21 weeks are shown in photo 16; 
at age 50 weeks (photo 17) the GBM is slightly thicker, and at age 75 weeks 
(photo 18) the thickening is slightly more pronounced. 
Biotechnical data 
The test animals were accommodated in metal cages with a wire-mesh 
floor, in groups of 4 - 6 animals per cage. The cages stood in a quiet room, 
not exposed to direct daylight. In view of the possible influence of a decrease 
in ambient temperature to 5 - 10oC on effects of a non-steroid anti-inflam-
matory drug other than indomethacin (phenylbutazone; Green et al. 1971), 
it can be mentioned that the temperature never fell below 20oC; on hot 
summer days it was sometimes as high as 30oC. There were no facilities for 
air humidification. 
The animals were given tap water ad libitum, which they took from a 
nippled bottle placed on the cage. The feed given was RMH-B (Hope Farms, 
Woerden, The Netherlands); the formula indicated by the manufacturer 
mentions a sodium content of 191 /i.Eq/g. In experiments with a low-sodium 
diet the animals received a special feed from the same source, which 
according to the manufacturer contained 5.13 /¿Eq/g sodium. Oral admi-
nistration of drugs was effected by intubation with a blunt metal needle on 
a syringe. Subcutaneous injections were given into the scruff of the neck. 
For blood sampling the animals were anaesthetized in a closed box with 
ether-soaked cottonwool on the floor. Immediately after the excitation stage 
of anaesthesia the animals were taken from the box; they were then flaccid 
and motionless, their respiration being slow, regular and deep. Blood samples 
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Fig. 3.2 Data from observation in metabolic cage in a healthy male A χ С rat, continuously living in the cage. 
were obtained by orbital puncture; when the animal was sacrificed, blood 
was obtained by puncture of the abdominal aorta. We followed the manage-
ment guidelines of the biotechnical manual of Van der Gulden et al. (1972). 
For collection of 24-hour urine the animals were placed in metabolic 
cages. We used cylindrical glass cages in a wooden cage-holder. In a cage of 
this type the animals can eat from a grid in a glass gangway; spillage can be 
collected. Water spilled from the drinking-nipple is also caught and collected 
outside the cage. Stools are collected on a sieve beneath the wire-mesh floor; 
the urine passes this sieve and is funnelled into a collecting-bottle. This 
makes it possible to measure the intake of water and food, and the produc-
tion of faeces and urine. The animals must become accustomed to life in 
such cages. Placed for a few hours in a cage of this type, they are sometimes 
very restive and aggressive the first time. A first more protracted period in 
such a cage can cause a weight loss in the order of tens of grammes per 24 
hours. Healthy adult animals accustomed to the cages have a daily intake of 
16 - 19 ml water and 8 - 14 g of the abovementioned non-sodium-restricted 
feed. 
The degree of accuracy with which a rat permanently living in a metabolic 
cage can be studied, is shown in fig. 3.2; the stable value of creatinine excre-
tion shows that complete urine collection could be achieved. Comparison of 
this figure with figs. 4.3 and 4.4 shows that observation during one day per 
week in the metabolic cage suffices for an adequate follow-up on the devel-
opment and course of a disease which continues for months. 
The antigenic material used to induce Heymann-type nephritis* 
The antigenic material used to induce Heymann-type nephritis was pre-
pared as indicated by Lannigan et al. (1969). Rats were killed by striking the 
back of the head and neck very hard against a table. The kidneys were im-
mediately removed, collected in a beaker (placed on melting ice), stripped of 
adipose tissue and capsule, and cut as small as possible. To the finely cut 
kidneys we added 4 times their weight of 0.3 M sucrose, adjusted to pH 7.4 
with NaHCO:|. The material was then homogenized in Potter tubes. Cen-
trifugation (1000 X g during 5 minutes at 20C) gave a sediment consisting 
of cell debris and nuclei. The supernatant was used for further processing. 
To it was added half the volume of 0.3 M sucrose. The fluid was ccntrifuged 
* For preparation of (his material we made grateful use of the advice of Dr P. T. 
Henderson (Pharmacological Laboratory, Medical Faculty, Nijmegen); by measuring 
succinate dehydrogenase activity, he verified on a few occasions the ample presence of 
mitochondria in the fraction obtained from kidney homogenate. 
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during 20 minutes (7000 X g at 20C). The sediment was again taken up in 
sucrose solution and centrifuged during 20 minutes at 7000 X g. The sedi-
ment then obtained largely consisted of mitochondria, as verified by deter-
mination of succinate dehydrogenase activity and electron-microscopic 
examination (photo 1). Next, the sediment was re-suspended in sucrose 
solution; after determination of the protein concentration (Lowry's method), 
this was adjusted to 24 mg/ml. The material was stored at —20oC until fur-
ther processing. With the above described procedure, one kidney yielded 
about 10 mg protein. 
For diazotation we used 50 mg sulphanilic acid per 500 mg protein. The 
sulphanilic acid was dissolved in 10 ml 0.082 M HCl while being heated, 
whereupon the solution was placed in an ice-bath and stirred. A solution of 
sodium nitrite was added drop by drop (20 mg in 5 ml distilled water). The 
diazonium salt thus obtained was added drop by drop to the antigenic 
material (at + 0.5oC and pH = 8.2). With NaHCO.., (about 4 g per 500 mg 
protein) and 1 N NaOH the pH was constantly kept at 8.2. The coupling 
reaction was allowed to take place for 2 hours at room temperature, the 
solution assuming an orange colour. The diazotized material was dialysed 
against 5 I 0.01 M phosphate buffer pH 8.2. This dialysis was carried out 
three times during 16, 8 and 16 hours, respectively, at 40C. The protein 
concentration of the dialysate was determined according to Lowry and then 
adjusted to 11 mg/ml. The material was stored at —20oC. 
Immunization for Heymann-type nephritis 
To immunize an animal for induction of Heymann-type nephritis, 2 mg 
protein (0.18 ml) with 0.17 ml complete Freund's adjuvant was intraperitone-
ally injected. The mixture, an unstable suspension, was freshly prepared for 
the injections and re-mixed on a whirlmixer before administration to each 
subsequent animal. The Freund's adjuvant used was Difco Bacto no. 0638-60 
which, per ampoule of 10 ml, contains 1.5 ml Arlacel A (mannidc mono-
oleate), 8.5 ml Bayol F (paraffin oil) and 5 mg killed, dried Mycobacterium 
butyricum. 
Induction of puromycin aminonucleoside nephropathy 
In a first experiment, 15 mg puromycin aminonucleoside (Sigma Chemical 
Cy) per kg body weight was given by intraperitoneal injection daily on 7 
days; in subsequent experiments, 15 mg/kg was subcutaneously injected daily 
on 5 days. Fresh solutions of puromycin aminonucleoside were prepared for 
each use, the substance being dissolved in saline. Between uses, the substance 
was stored in an exsiccator at 40C. 
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Fin. 3.3 Single-dose experiments on pharmacokinetics of indomethacin after oral 
administration in non-fasting rats: young and adult healthy animals, and animals with 
Heymann-typc nephritis. 
Indomethacin 
Indomethacin was made available as pure substance by Merck, Sharp & 
Dohme B.V., Haarlem, The Netherlands. For administration the in­
domethacin was dissolved in 0.01 M phosphate buffer pH 8.0. The con­
centration was so chosen that all animals received 2 X 2 ml daily. The daily 
dosages per animal were 2 X 0.15, 2 X 0.30 and 2 X 0.60 mg. In pilot 
experiments on A X С and PVG/C rats, a fair mortality was observed at a 
daily indomethacin dosage of 2 X 0.30 mg. This was why a daily indo­
methacin dosage of 2 X 0.15 mg was used for the majority of the long-term 
experiments. The apparently not inconsiderable toxicity of indomethacin 
prompted us to investigate the rate of disappearance of indomethacin in a 
preliminary experiment after single-dose oral administration of 5 mg/kg in 
young and mature older rats, and in animals with Heymann-type nephritis 
with a protein excretion of 200 - 490 mg/day. Fig. 3.3 shows that in each of 
the three groups the half-life of indomethacin was the same: 4.0 - 4.5 hours. 
This value is in accordance with that reported in the literature by Hucker et 
al. (1966), who in rats also found indomethacin metabolites which Duggan 
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et al. (1972) demonstrated in human subjects. In our study no indomethacin 
metabolites in rats were investigated. 
Biochemical methods* 
Creatinine was determined by an alkaline picrate technique adapted to 
automatic analysis (Jansen et al. 1970); urinary sodium was determined by 
flame photometry against an internal lithium standard; plasma cholesterol 
was determined according to Richterich (1971). Urinary protein was deter­
mined by the biuret method after precipitation with trichloroacetic acid; the 
serum total protein value was determined according to Lowry (1951); plasma 
indomethacin was measured by fluorometric analysis (Gribnau et al. 1973). 
Monospecific antisera (rabbit anti-rat albumin; rabbit anti-rat IgG) were 
obtained from Nordic, Tilburg, The Netherlands; with these antisera, 
albumin and IgG concentrations in serum and urine were determined by 
single radio-immunodiffusion according to Mancini, as modified by Van 
Munster et al. (1965). The albumin and IgG concentrations were recorded 
as pei cents of the concentrations in the reference serum: pooled normal 
serum obtained from 20 rats aged 19 weeks. The selectivity of proteinuria 
was calculated according to Cameron and Blandford (1966), by expressing 
IgG clearance as a proportion of albumin clearance. 
Histochemical methods** 
For microscopic examination, small pieces of renal cortex were fixed in a 
Tellyesniczky solution during 3 hours at room temperature. The tissues were 
dehydrated and embedded in Paraplast (Amstelstad, Amsterdam, The 
Netherlands). The sections (2 μ thick) were routinely stained with haema-
toxylin-eosin, periodic acid Schiff (PAS) and silver methenamine according 
to Jones (1957). 
For immunofluorescence the direct method was employed, using rabbit 
anti-rat IgG (RaR) and rabbit anti-rat C3 complement (RaC) antisera. These 
* The biochemical studies mentioned in the fust paragraph were earned out in the 
Laboratory (head- Dr A Ρ Jansen) of the University Department of Medicine, 
St Radboud Ziekenhuis, Nijmegen, with the exception of the indomethacin determina­
tions, which were made in the Pharmacological Institute of the Medical Faculty and 
Faculty of Sciences, University of Nijmegen. Radial immunodiffusion studies were 
done in the Laboratory (head Dr Ρ J J van Munster) of the University Department 
of Pediatucs, St Radboud Ziekenhuis, Nijmegen. 
** The histological investigations were carried out in the Department of Pathology of 
the University of Groningen (head Prof Dr Ph J Hoedemaeker) 
The electron microscopic studies were carried out in the Department of Flectron 
Microscopy of the University of Groningen (head Dr I Molenaar) 
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sera were conjugated to fluorescein isothiocyanate according to Thé (1970). 
Small pieces of renal cortex were snapfrozen in pre-cooled Freon (—100oC). 
Cryostat sections (2 μ) were incubated with the antisera during 30 minutes 
at room temperature. After rinsing in phosphate-buffered saline (pH 7.2) 
during 30 minutes at room temperature, the sections were mounted in 
buffered glycerine (pH 8.4). The preparations were examined in a Leitz 
fluorescence microscope with epi-illumination. 
For electron-microscopic examination, small pieces of renal cortex (1 cu 
mm) were fixed in a formaldehyde-glutaraldehyde mixture (Hoedemaeker 
et al. 1970) during 1 hour at room temperature after rinsing in tris-buffer 
(pH 7.3). They were post-fixed in 2% phosphate-buffered OSO4 (pH 7.35) 
during 2 hours at 4 0 C. After dehydration the material was embedded in 
Epon 812. Ultra-thin sections were cut on an LKB ultratome and contrasted 
with 5% uranyl acetate (45 minutes at room temperature) and lead citrate 
(2 minutes at room temperature). The sections were studied in a Philips 
EM 300. 
Grouping, selection of animals for morphological study, block diagrams, 
tables with numbers of animals in the course of experiments 
When animals were assigned to various groups in week 0 or on day 0 of 
an experiment, the place of each animal in a group was based on random 
assignment. In subsequent re-grouping, efforts were made to form compar­
able groups. For division of a group into two new groups, the animals were 
ranked according to degree of proteinuria: the animal with the highest 
protein excretion was assigned to the first new group, the next two animals 
to the second new group, the next two to the first new group, etc. In this 
way it was ensured that the two new groups had approximately the same 
mean proteinuria. 
Animals were selected for morphological study by comparing the indivi­
dual protein excretion with the mean of the group: animals selected had a 
protein excretion approximating the mean as closely as possible. Whenever 
in either of two groups to be compared an animal died, we took from the 
comparative group an animal whose protein excretion differed least from 
that of the deceased animal in the first group. 
The various experiments on Heymann-type nephritis were marked A, B, 
C, etc.; the experiments on puromycin aminonucleoside nephropathy were 
marked PA, PB, PC, etc. A subdivision into groups of animals given dif­
ferent treatments within the same experiment, was marked by an additional 
capital letter, thus: A for natural history of disease, В for indomethacin 
medication started prior to induction of nephritis, and С for indomethacin 
medication started later. In animals with Heymann-type nephritis the addi­
tional capitals В and С were sometimes subdivided into B, and B.>, and Q 
45 
and C2, respectively: B
:
 and C, indicating that indomethacin medication, 
once started, was continued throughout the experiment, and B2 and C, 
indicating that indomethacin medication was discontinued during the period 
of observation. To elucidate: group PC-B indicates a group of animals 
treated with indomethacin from before the disease was induced, in the 
context of experiment PC on puromycin aminonucleoside nephropathy. 
Two block diagrams indicate at which time in the course of the two 
diseases studied, and during which type of treatment, morphological studies 
were made. The duration of illness is marked at the bottom of these dia­
grams; the capital letters mark the experimental group to which the animal 
in question belongs; numbers to the right of the columns refer to the photo­
graphs from the electron-microscopic study of the relevant phase of the dis­
ease during the relevant treatment, in the illustrations section. The designa­
tions week 1 or day 1 of illness always refer to the week during which (day 
on which) the first injection of antigen or the first injection of puromycin 
aminonucleoside was given. 
Two appendices to this thesis present tables which, with reference to 
various figures, indicate how many animals were compared in given 
experiments; this makes it possible to evaluate the ranges of variation 
indicated in the figures, and the conclusions concerning significance of 
differences based on these indications. Of course in both groups of experi­
ments the number of animals diminished with increasing time as a result of 
incidental spontaneous deaths, removal of animals from the group for 
morphological study, and division of experimental groups into new groups. 
Statistical analysis 
For statistical analysis we made use of guidelines given in the manual of 
Natrella (1963). In studying the significance of a difference between two 
groups, a pseudo-normal distribution of the values in the populations studied 
was postulated. Significance was assessed by one-sided t-testing. The effective 
number of degrees of freedom was calculated from the variances of the two 
means and the number of animals per population. 
Most figures on groups of animals indicate means with standard error of 
the mean; in a few general survey figures, this range of variation is not 
indicated for the sake of clarity, but is given in the comparison of the various 
groups included in the figure with groups of animals given medication. 
In a few instances in which a correlation between two variables was 
assumed to exist, this was assumed to be linear; the significance of the 
correlation coefficient of the regression line was assessed by t-testing, in 
r V N - 2 
which Student's t = (degrees of freedom = N - 2). The values of the 
V I - г 2 
percentiles of the t-distribution were used as in a two-sided t-test. 
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CHAPTER IV 
HEYMANN-TYPE NEPHRITIS 
Induction of the disease 
In preliminary experiments we attempted to induce Heymann-type nephritis 
in different combinations (antigen from Wistar rats to A X С and to PVG/C 
rats; antigen from PVG/C rats to PVG/C rats), with differently processed 
antigen mixtures (with and without Freund's adjuvant, with and without 
diazotation) and using different immunization protocols (varying: antigen 
dose per injection, frequency and number of injections). 
With diazotized Wistar antigen in complete Freund's adjuvant and with 
at least 10 immunizations (1 injection per week during 10 weeks) consider­
able protein excretion was induced in A X С rats. The degree of proteinuria 
seemed to be dependent on the number of injections. Fig. 4.1 shows the 
difference in protein excretion between two groups of 10 A X С rats each, 
U protein-V (mg/day) 
200 
55 60 65 70 75 80 85 90 day 
Fig. 4.1 Influence of frequency and number of antigen injections (10 weeks once 
vs twice weekly) on protein excretion in Heymann-type nephritis, studied in 3 groups 
of 10 male A χ С rats. Control animals demonstrate "physiological" proteinuria. 
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immunized by 19 and 10 intraperitoneal injections, respectively, of Wistar 
antigen in 10 weeks. The animals given 19 injections attained a mean protein 
excretion of about 140 mg/day; those with 10 injections significantly 
exceeded the physiological proteinuria present in non-immunized controls. 
Fig. 4.2 shows protein excretions at week 14 in PVG/C rats immunized by 
12, 14, 16 and 18 injections, respectively; the figure also encompasses the 
A X С rats of fig. 4.1 (both groups). As fig. 4.2 shows, the PVG/C rats 
developed a significantly higher protein excretion. In addition, these pre­
liminary data show that injections given twice weekly for a period longer 
than 6 weeks produced no further increase in protein excretion in the 
PVG/C rats. Representative individual observations on the development of 
pathological proteinuria in an A X С rat and in a PVG/C rat are presented 
in fig. 4.3 and fig. 4.4, respectively. As already pointed out with the discus­
sion of fig. 3.2, observation in the metabolic cage once a week is sufficient 
to study the development and course of the pathological proteinuria. 
The effect of reducing the antigen dose to 10% is shown in fig. 4.5: the 
protein excretion was reduced by 50%. Comparison of this observation with 
the effect of halving the number of injections with an unchanged dose per 
injection, reveals the relatively great importance of the number of injections. 
In addition the figure shows that no pathological proteinuria occurred when 
Freund's adjuvant was not added. Fig. 4.6 shows that a considerable degree 
U p r o t e m - V ( m g / d a y ) in week 14 -
1000 
1 0 0 
PVG/C rats 
AxC rats 
19 4 f- 16 1Θ 
antigen injections 
Fig. 4.2 Protein excretion in week 14 of experiments on Heymann-type nephritis in 
two groups (n = 10) of A χ С rats, injected once resp. twice weekly with antigen, and 
in four groups (n = 5) of PVG/C rats, injected twice weekly with antigen for resp. 
6, 7, 8 and 9 weeks. 
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Fig. 4.3 Неутапп-type nephritis in an Α χ С rat (Rat A 6). 
Fig. 4.4 Heymann-type nephritis in a PVG/C rat (Rat В 6). 
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Fig. 4.5 Influence of dose of antigen and of Freund's adjuvant on protein excretion 
in Heymann-type nephritis, studied in 3 groups of PVG/C rats: ЕЛ (n = 6) = normal 
dose of antigen; EA' (n = 10) = 0.1 normal dose; EA" (n = 10) = normal dose of 
antigen, no Freund's adjuvant; all groups injected twice weekly for 6 weeks. 
of protein excretion can also be induced in PVG/C rats with isologous 
(PVG/C) antigen; this figure likewise shows that use of undiazotized 
antigen causes failure of Wistar antigen as well as of PVG/C antigen to 
produce pathological proteinuria. Finally, it is shown that administration of 
only Freund's adjuvant during 6 weeks (an injection twice weekly) also fails 
to cause pathological proteinuria; microscopic examination of the kidneys of 
these animals 25 weeks after the first injection of Freund's revealed no ab­
normality. 
In view of the significantly more marked protein excretion in the PVG/C 
rat and because the A X С rat is less manageable and often has congenital 
kidney anomalies, it was decided to induce the disease in PVG/C rats for 
further study. Wistar antigen (12 injections of 2 mg protein diazotized as 
indicated in chapter III, with 0.17 ml complete Freund's adjuvant) was used 
for immunization. 
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Fig. 4.6 Protein excretion in 5 groups of 6 male PVG/C rats: 4 groups injected twice 
weekly for 6 weeks with: diazotized PVG/C antigen, antigens without diazotation, or 
Freund's adjuvant alone, and a control group. 
The nephrotic syndrome 
In the course of the experiments, with the homologous (Wistar) antigen 
active Heymann-type nephritis was induced in several series of rats. Fig. 4.7 
presents a survey of the mean protein excretion values in these series; ranges 
of variation are not included to avoid cluttering; they will be shown in 
chapter V in the comparison of these animals with groups of indomethacin-
treated animals. We see that pathological proteinuria appears about week 7, 
gradually increases and attains after week 12 - 14 a plateau value of which 
the means in the various series range from 430 to 900 mg/day. 
Fig. 4.8 shows the data on plasma cholesterol and creatinine concentra­
tions collected from the experimental series, with reference also to creatinine 
excretion and endogenous creatinine clearance. The plasma creatinine con­
centrations and clearance values were not different from the values given for 
normal controls of comparable age in chapter III; renal failure, therefore, 
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F/g. 4.7 Protein excretion in Heymann-type nephritis (only mean values are given; 
SB values are mentioned in chapter VI). 
did not seem to occur during periods of observation up to 60 weeks. Plasma 
cholesterol values, however, were markedly increased: at least twice and 
often several more times the normal mean value. 
We collected a number of data on serum protein levels in the animals at 
weeks 24 and 29. As table 4.1 shows, the total serum protein value was 
slightly decreased, the albumin and IgG levels showing a substantial decrease. 
Table 4.1. Data on serum protein concentrations (means ± SE) in rats with 
Heymann-type nephritis in two experiments at week 24 (F) and week 29 (G), 
respectively. 
Group 
healthy controls 5 
F 13 
G 10 
total serum 
protein (g/1) 
61.0 ± 1.0 
54.0 ± 2.3 
53.2 ± 1.7 
albumin 
(% standard) 
100 
26.1 ± 3.6 
IgG 
(% standard) 
100 
31.8 ± 2.0 
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F/g. 4.8 Collection of data concerning individual animals with Heymann-type 
nephritis. 
Fig. 4.9 plots the total serum protein values of these 23 animals against 
protein excretion; the figure shows that in this range of proteinuria (400 to 
1000 mg/day) there was no negative correlation between serum protein con­
centration and protein excretion. Nor was it possible to demonstrate a 
negative correlation between serum albumin level and protein excretion as 
fig. 4.10 demonstrates. There was a correlation between albumin concentra­
tion and total serum protein value: hypalbuminaemia was significantly more 
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Fig. 4.9 Plot of individual values of serum protein concentration vs protein excretion 
for the animals mentioned in table 4.1. 
Fig. 4.10 Plot of individual values of serum albumin vs protein excretion, and of 
values of serum albumin vs total serum protein in 13 rats with Heymann-type nephritis 
in week 24 of disease. For serum albumin vs total serum protein: г = 0.749; ρ < 0.01. 
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marked with a greater decrease in total serum protein (r = 0.749; ρ < 0.01). 
In the animals of experimental group F mentioned in table 4.1, the selectivity 
of proteinuria was measured by the ratio 24-hour ClgG: Calbumin at week 
23, week 24 and week 25. The mean value of the individual means was 
0.41 ± 0.047 (mean ± SE), range 0.13-0.68. Fig. 4.11 shows that with 
increasing protein excretion proteinuria was less selective. 
A surprising finding was that none of the animals ever showed oedema in 
spite of the non-salt-restrictcd diet. Fig. 4.12 shows the body weights of the 
animals in the experimental group with the greatest protein excretion (group 
I of fig. 4.7) in relation to the weights of normal controls of comparable age. 
This comparison, too, gives no indication of oedema formation. 
In two groups of 8 animals each the effect was studied of dietary sodium 
restriction, alone or in combination with administration of the diuretic 
furosemide. A group of 8 animals given normal feed served as control. The 
findings obtained in this experiment are presented in fig. 4.13. First of all it 
is apparent that the nephrotic animals were very well capable of sodium 
retention; in the salt-restricted animals the sodium excretion showed a 
substantial decrease within a few days, and after one week of sodium 
restriction the sodium excretion was virtually nil. Administration of furose-
10 
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Uprotem 'Vdng/day) 
Fig. 4.11 Plot of 13 individual values for selectivity of proteinuria (mean of three 
values, in weeks 23, 24 and 25 of experiment) versus protein excretion (mean of three 
values in these weeks): r = 0.767; ρ < 0.01. 
55 
Body weight ( g ) 
400-
3 5 0 
3 0 0 
2 5 0 
200-
•—· healthy controls 
o ^ o Heymann-type nephritis 
"Τ 1 Γ-
15 25 
100 200 300 
age(days) 
Fig. 4.12 Body weights of healthy male PVG/C rats (n = 40; cfr. Chapter III) and 
of PVG/C rats (n = 8) of the same age with Heymann-type nephritis. No difference 
exists between the two groups. 
mide did not seem to have caused extra sodium excretion. One week after 
termination of a 3-\veek period of salt restriction the salt-restricted animals 
again excreted as much sodium as the control animals. 
The body weights of the two groups of salt-restricted animals showed the 
predictable decrease (partly to be ascribed to the animals' lack of familiarity 
with the new diet: they hardly touched the new feed the first few days). Fig. 
4.13 also shows a significant decrease in endogenous creatinine clearance in 
the salt-restricted animals (about 50% decrease). After returning to an un­
restricted diet for a week, the animals showed a return of endogenous 
creatinine clearance to approximately the initial value. In the salt-restricted 
animals the protein excretion during the first week on the restricted diet was 
less than that in the control group (on day 3 and day 7 of salt restriction in 
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Fig. 4.13 Results of experiment on sodium restriction of diet; two experimental groups 
(n = 2 χ 8) were observed during 3 weeks of special diet; one experimental group was 
treated for the first week with 1 daily i.p. injection of l mg furosemide (Δ Δ). 
Values of this and the other ( • •) experimental group are to be compared with 
the control group (O O). 
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the group given the diet with furosemide (p < 0.05) and on day 3 in the 
group without furosemide (p < 0.05)). Afterwards this difference dis­
appeared. 
Morphological findings in Heymann-type nephritis 
Microscopic examination of the kidneys of rats with Heymann-type 
nephritis revealed hardly any changes in H and E stained sections. There 
was no proliferation of endothelial-, mesangial- or epithelial cells. The 
glomeruli contained no granulocytes; nor were fibrin deposits observed. 
Blood vessels and interstitium were likewise normal throughout the period 
studied, but slight thickening of the capillary walls was found. The silver 
methenamine stain showed in all test animals, from week 18 on, "spikes", 
i.e. ridge-like argyrophilic projections on the epithelial side of the GBM. 
Characteristic examples of sections stained with haematoxylin-eosin and 
silver methenamine are presented in photo 2 and photo 3. This glomerular 
disease, therefore, should be interpreted as epimembranous non-proliferative 
glomerulopathy. 
Immunohistochemical studies with fluorescein-labelled rabbit anti-rat IgG 
(RaR) and with rabbit anti-rat complement (RaC) revealed from disease 
week 4 on a fine granular deposition of rat IgG in the glomeruli (photo 4). 
The preparations treated with RaC were negative at that time. At disease 
week 6'Λ, the rat IgG deposits had increased in size and number (photo 5, 
photo 6). At that time a weak but unmistakable fluorescence with RaC was 
first seen (photo 12). From this time on, animals with pathological 
proteinuria showed also binding of rat IgG to the brush border of the tubules 
(cfr. photo 7 and photo 8). At subsequent disease weeks (photographs 9 - 1 1 , 
13-15) there was always coarse granular fluorescence upon using RaR and 
RaC. 
In view of the absence of distinct light-microscopic changes, electron-
microscopic examination seemed the method of choice to study the de­
velopment and course of Heymann-type nephritis. For comparison with the 
features obtained in the diseased animals, photographs 16, 17 and 18 show 
electron micrographs of kidneys of normal PVG/C rats at different ages. 
At d i s e a s e w e e k 4 (photo 20), i.e. after 7 injections of homologous 
antigen, electron-microscopy showed hardly any abnormality. GBM thick­
ness and structure were normal. Epithelial and endothelial cells presented a 
normal appearance. After a careful search, a few electron-dense deposits 
were found in the lamina rara externa of the GBM in the slit-pore between 
the epithelial foot processes (photo 20.1). 
At d i s e a s e w e e k 6V2 (fig. 4.14; photo 21), when some animals al­
ready showed pathological proteinuria, the number of electron-dense deposits 
(photo 8). 
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Fig. 4.14 Course of disease of animals shown in photos 5, 6, 12, 21. 
in the lamina rara externa had increased, and they were slightly larger than 
at week 4. Moreover, some fusion of epithelial foot processes was seen at a 
few sites in the glomerulus. 
At d i s e a s e w e e k 11 (photo 22) the GBM was slightly thickened. A 
fair number of smaller and sometimes larger subepithelial electron-dense 
deposits was found at scattered sites. The fusion of epithelial foot processes 
had increased. 
At d i s e a s e w e e k 18 (photo 23), i.e. when the proteinuria had 
attained its high plateau value, the GBM showed irregular thickening with 
large, irregular, subepithelial electron-dense deposits. GBM substance had 
formed between the deposits and also between deposits and epithelium. The 
cytoplasm of the epithelial cells over the deposits often showed increased 
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Fig. 4.15 Course of disease of animal shown in photos 2, 3, 25. 
density. Distinct epithelial foot processes were not longer visible. 
At d i s e a s e w e e k 22 (photo 24) all changes had further increased 
in comparison with week 18. The GBM thickness had doubled. The electron-
dense deposits had further increased in size, as had the amount of newly 
formed GBM substance. There was still complete fusion of epithelial foot 
processes. 
At d i s e a s e w e e k 33 (fig. 4.15; photo 25) epithelial foot processes 
were seen at many sites in the GBM; they were entirely enclosed in newly 
formed GBM substance. Contrary to what was observed at weeks 18 and 22, 
foot processes were visible again at some sites. For the first time, moreover, 
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Fig. 4.16 Course of disease of animal shown in photos 14, 26. 
frequent conspicuous electron-microscopically empty spaces were seen 
around immune complex aggregates. 
At d i s e a s e w e e k 59 (fig. 4.16; photo 26) the halos around immune 
complex aggregates proved to have increased. At some sites the GBM in fact 
showed "holes" without electron-dense substance. Intact epithelial foot 
processes were again visible at several sites. The features of week 33 (with 
irregular projections from the GBM) had been replaced by those of a 
markedly thickened GBM in which the earlier projections appeared to have 
been taken up. The thickening sometimes amounted to five times the original 
thickness. 
At d i s e a s e w e e k 75 (photo 27) the markedly thickened GBM was 
entirely devoid of external projections. Remnants of immune complex 
aggregates surrounded by halos were visible in the GBM, and the remainder 
consisted almost entirely of newly formed GBM substance. 
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Discussion 
The granular fluorescence found along the GBM with anti-rat IgG and 
anti-rat complement antibodies, indicates deposition of immune complexes 
as pathogenic mechanism of the glomerulopathy studied. Although in induc-
tion of this glomerulopathy no use was made of a purified antigen as 
described by Edgington et al. (1968), it is nevertheless to be concluded that 
the antigen involved in this experimental glomerulopathy is related to 
RTE-a,-, or at least that it is present at the same site: in the brush border of 
the proximal tubule. 
This was demonstrated by the fact that, in animals with pathological 
proteinuria at week 6V2, fluorescence of this brush border was observed with 
RaR. Evidently the rat antibodies against this antigen partly pass through the 
GBM as a result of the proteinuria, and bind themselves to the antigen 
involved in the disease. Fleuren (Fleuren GJ, 1975; personal communication) 
demonstrated that diseased animals indeed have circulating antibodies 
directed against brush border antigens. 
As photo 1 indicates, the mitochondrial kidney fraction used as antigenic 
material also contains a fair number of dense bodies. These so-called 
cytosomes are lysosomal structures characterized by their having a single 
surrounding membrane; they originate from invaginations between the bases 
of the microvilli of the brush border of the cells of the proximal tubule, 
pinched off from their contact with the surface membrane. It is a plausible 
assumption that these cytosomes, in terms of antigenic properties, are closely 
related to brush border antigens. The degree to which the excessively present 
mitochondria are antigenic, and their possible relatedness in antigenic 
properties to those of the brush border and the cytosomes, are unknown. 
The name-giving of this experimental glomerulopathy can be based on its 
morphology and on the pathogenetic mechanism. Morphologically, it is an 
epimembranous non-proliferative glomerulopathy; the pathogenetic designa-
tion should be autologous experimental immune complex glomerulopathy. In 
order to avoid these more or less clumsy designations, and in accordance 
with common parlance in the literature, we decided to use the term 
Heymann-type nephritis. 
The clinical term "nephrotic syndrome" denotes a combination of symp-
toms: proteinuria, hypoproteinaemia, oedema, and hyperlipaemia. Our 
animals differ in so far from this clinical syndrome, that they did not have 
any oedema. In his original publication Hey mann (1959) mentioned that in 
his animals it was difficult to establish the presence of oedema and ascites; 
after this observation he really confined his discussion to the subject 
"ascites", mentioning that this frequently occurred quite independent of 
renal disease upon intraperitoneal administration of an adjuvant. The publi-
cation of Watson and Dixon (1966) made no mention of oedema. Our 
negative findings concerning oedema are in agreement with a report by 
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Allison et al. (1974), who found no oedema in rats with autologous immune 
complex nephritis showing protein excretion of 400 mg/day or more. These 
authors also failed to find hypoproteinaemia in their test animals: the total 
serum protein concentration was 5.66 ± 0.56 g/100 ml (mean ± SD; 
η = 15), versus 5.77 ± 0.35 g/100 ml (n = 12) in healthy control animals. 
Our animals, too, showed no or only a slight decrease in total serum protein 
value, in spite of considerable proteinuria. Table 4.1 showed that severe 
hypalbuminaemia was present in these animals. Data on the colloid-osmotic 
pressure of these sera are not available. It can be safely assumed, however, 
that the effects of decreased albumin and IgG concentrations on the total 
protein value are compensated by an increase in the analogue of the a^-
globulin fraction, as known from human pathology. Since this fraction 
contains large molecules it is virtually certain that the colloid-osmotic 
pressure of the serum was decreased in our animals with nephritis. The 
sodium intake in the animals without dietary restriction was very ample; 
moreover, the experiments with a sodium-restricted diet showed that the 
diseased animals were capable of retaining sodium. Taking all this into 
account we can only speculate that the level of hypalbuminaemia at which 
oedema occurs seems to be lower in rats than in humans. 
The data on albumin concentrations presented in table 4.1 show that 
certainly marked hypalbuminaemia was present, and that absence of 
oedema can therefore not be explained by a very high rate of albumin 
synthesis. The scanty data from the literature on the rate of albumin 
synthesis indicate that, in the case of severe renal protein loss, albumin 
synthesis in the rat liver is at best doubled (Katz et al. 1967; Marsh et al. 
1960). The results of in-vivo determinations differ significantly from in-vitro 
results measured in the perfused liver: Katz et al. (1963, 1967) found an 
in-vivo albumin turnover of 3.5 mg/hour per 100 g body weight in healthy 
rats, versus an albumin synthesis in the normal perfused rat liver of 10 
mg/ hour per 100 g body weight. 
The marked urinary IgG loss indicates that the proteinuria in our animals 
was aselective. This finding is in agreement with the findings obtained by 
Lannigan et al. (1969) in Heymann-type nephritis: Sephadex G-200 filtration 
of serum and urine showed a hardly diminished ratio between urinary con­
centration and plasma concentration over the range of molecular radius from 
35 A to 70 A. 
Observations in the salt-restricted animals showed that the rats with 
Heymann-type nephritis can quite well retain sodium. It was also found that 
these diseased animals showed no sign of increased sodium retention. 
Apparently, in this situation, the animals are insusceptible to the dose of 
furosemide given. Although we measured neither blood pressure nor serum 
sodium concentration, it seems logical to ascribe the significant decrease in 
creatinine clearance to a prerenal cause, viz. a contraction of extracellular 
volume and blood volume. 
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It was found that, at least after 3 weeks' salt restriction, the decrease in 
endogenous creatinine clearance was reversible when salt was restored to the 
diet for a week. A striking finding was the decrease in proteinuria during the 
first week of the three-week period of salt restriction. 
The morphological course of the glomerulopathy cannot be directly 
compared with the diseases described in the literature. Part of the available 
data concerned the morphology only indirectly (Heymann et al. 1959; 
Watson and Dixon 1966; Edgington et al. 1968; Glassock et al. 1968). 
Alousi et al. (1969) described the morphological changes in "active" 
Heymann-type nephritis induced by giving an antigen injection every two 
weeks until a proteinuria level of 50 mg/24 hours was attained. Feenstra 
(1974) and Feenstra et al. (1975) carried out morphological studies on 
"passive" Heymann-type nephritis induced by a single injection of hetero-
logous antibody against brush border antigens. Nevertheless it may be useful 
to draw a number of comparisons. 
To begin with, signs of an inflammation in the glomeruli were absent in 
our animals. There was no proliferation, no exudation in the form of fibrin 
deposits or polymorphonuclear leucocytes, and the changes were found 
exclusively in the GBM. Immunohistochemical techniques disclosed immune 
deposits along the GBM, but never in the mesangium; Alousi et al. did 
describe fluorescence in the mesangium. Particularly in the initial stage of 
the disease, deposits are much more readily demonstrated by immuno-
fluorescence than by electron microscopy. This was also observed by 
Feenstra (1974, 1975), who found fluorescence within 48 hours of antibody 
administration in heterologous immune complex nephritis, and by Couser 
(1975) in incipient autologous immune complex nephritis. As pointed out, 
immunofluorescence with RaR was positive in our material already after 
7 antigen injections; only when pathological proteinuria had developed was 
fluorescence of the brush border of the tubules observed. The deposits were 
found to the same extent in all glomeruli. 
Like Alousi and Feenstra, we also found only a few electron-dense 
deposits at a time when pathological proteinuria had not yet developed; these 
deposits were found in the lamina rara externa. The increase in the size and 
number of immune complexes in our animals can be compared with the 
course described by Alousi; another similarity is the fusion of the epithelial 
foot processes from the time of occurrence of proteinuria, and the ultimate 
formation of projections outside the GBM in the later stage of the disease. 
Alousi's observations ended 24 weeks after onset of pathological proteinuria; 
Feenstra terminated his study of heterologous immune complex nephritis 90 
days after induction of the disease. Probably as a result of the limited period 
of observation, these investigators did not reach a point in the course of the 
disease at which resolution of the electron-dense deposits in the GBM 
commenced. These very late changes have not been previously described in 
experimental glomerulopathy. 
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As already mentioned, the proteinuria remained unchanged in spite of the 
changes in morphological features, both at the time of onset of GBM defects 
and afterwards, when the gaps seem to be filled with newly formed GBM 
substance. Development of GBM defects with a subsequent stage in which 
these defects seem to be refilled with normal GBM, was reported by Lewis 
et al. (1974); they observed persistance of proteinuria in rats with autologous 
immune complex nephritis after transplantation of the diseased kidney to a 
histocompatible nephrectomized normal rat. They explained their findings by 
interruption of the immune activity responsible for immune complex 
formation, followed by resolution of glomerular deposits. In view of our 
findings it seems probable that the kidneys would have developed the same 
morphological features if no cxplantation had been carried out. 
Conclusion 
By means of the procedure described it was possible to induce an immune 
complex glomerulopathy of the type introduced by Heymann et al.. Despite 
the severe degree of proteinuria only a partial nephrotic syndrome developed: 
only slight hypoproteinaemia but severe hypalbuminaemia, no oedema. 
During dietary salt restriction the diseased animals were found to be capable 
of salt retention. The proteinuria proved to be aselective. The clinical as well 
as the morphological course of the disease was followed over a considerable 
period. Induction of the disease was found to be reproducible; it was found 
that use of undiazotized antigenic material failed to produce pathological 
proteinuria. 
Possibilities to observe individual diseased animals on the one hand, and 
the knowledge obtained concerning the course of the disease in general, 
seemed to us to be sufficient to warrant starting a series of comparative 
observations on a possible effect of indomethacin on the course of this 
disease. 
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CHAPTER V 
PUROMYCIN AMINONUCLEOSIDE NEPHROPATHY 
Induction of puromycin aminonucleoside nephropathy 
Puromycin aminonucleoside nephropathy was studied in male PVG/C 
rats; it was induced in animals which were 12 - 18 weeks old at the start of 
the experiments. Two different induction protocols were used: 15 mg/kg 
intraperitoneally for 7 days, and 15 mg/kg subcutaneously for 5 days. With 
the former, larger, intraperitoneal dose considerable protein excretion was 
attained. However, when this dose was given to a group of 20 animals aged 
18 weeks at the start of the experiment, the animals became severely ill: 
after 15 days they were apathie and took little feed, and at the end of the 
third week of the experiment 18 of the 20 animals died. The animals in this 
preliminary experiment were constantly kept in metabolic cages. The course 
of the disease during the first 7 weeks in one of the two survivors is shown in 
fig. 5.1. 
In view of the high mortality in this experiment we decided to use the 
second protocol mentioned before. Moreover, the animals were no longer 
constantly kept in metabolic cages. In this way considerable protein excre-
tion could be attained without any mortality. 
The nephrotic syndrome 
Puromycin aminonucleoside nephropathy was induced in several series of 
rats. The mean protein excretion values in these series are presented in fig. 
5.2. Pathological proteinuria developed after about 1 week, was maximal at 
about 21/2 weeks, and then diminished. The higher the age of the animals at 
the start of the experiment, the higher the maximum of protein excretion 
was. After about 7 weeks protein excretion had diminished to its pre-
induction value. Only the two survivors of the group given 15 mg/kg 
intraperitoneally for 7 days continued to show a higher protein excretion at 
a level of about twice the pre-induction value. The animals marked PB and 
PC in fig. 5.2 were followed up during 16 and 12 months, respectively. No 
pathological proteinuria developed during the follow-up period. Nor did a 
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Fig. 5.1 Puromycin aminonucleoside nephropathy in a PVG/C rat, induced with 1 
daily injection of 15 mg/kg i.p. for 7 days. 
further increase in protein excretion occur in the animal shown in fig. 5.1, 
as fig. 5.3 indicates. 
The body weight changes which occurred in the various series are shown 
in fig. 5.4, which indicates that the body weight rose during the first 10-12 
days of the experiment. The increase was greater as the animals had a 
greater protein excretion. After a maximum, the body weight decreased 
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Fig. 5.2 Protein excrclion in puromyein aminonucleoside nephropathy (only mean 
values are given; SE values are mentioned in chapter VII). 
Fig. 5.3 Puromycin aminonucleoside nephropathy and further life of animal shown 
in fig. 5.1. Note: protein excretion exceeds pre-existent "physiological" proteinuria, and 
is stable during V/i year after the acute disease. 
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Fig. 5.4 Body weight fluctuations (means ± SE) during acute disease stage of puro-
mycin aminonucleoside nephropathy. 
within a week to a minimum, the degree of weight fluctuation again showing 
a positive correlation with the severity of the disease. The decrease some­
times involved several tens of grammes; in experiment PE (fig. 5.2) the 
difference between maximum and minimum weight in the acute phase of 
illness averaged 58 g. The animals never showed oedema or ascites. The 
body weight after several months did not differ from that of healthy animals 
of the same age. 
Brief transient polyuria occurred in the animals with the higher protein 
excretion values. In animals PB and PF (fig. 5.2) the mean diuresis never 
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Fig. 5.5 Pattern of diuresis values (means -ί= SE) during puromycin aminonucleosidc 
nephropathy in the experimental groups PC and PE. 
Fig. 5.6 Pattern of values of creatinine excretion (means -L SE) during puromycin 
aminonucleosidc nephropathy in the experimental groups PC and PE. 
exceeded 10 ml/day. In the animals of experiment PE the mean of the 
individual maximum diuresis values was 20.4 ± 1.8 ml (n = 8; range 
14.2 - 30.3 ml/day). Fig. 5.5 shows the variations in diuresis value in animals 
PC and PE (mentioned in fig. 5.2); the weight loss fell within the brief 
period with increased diuresis. 
In a large number of animals the creatinine excretion showed a brief 
transient decrease from day 5 - 15. Fig. 5.6 shows the variations in the group 
data for experiments PC and PE; the phenomenon is most clearly read from 
70 
Table 5.1. Experiments on natural history of puromycin aminonucleoside nephropathy, arranged in order of age of 
the animals. Mean group values ± SE for body weight, maximum protein excretion, and maximum diuresis. The 
dose is given in absolute amount, administered to the animals; using the data in fig. 3.1 the dose per g kidney was 
estimated. 
Experimental Age at day 0 Dose Dose per g kidney Body weight (g) Maximum Up,oi.V Maximum diuresis 
group η (weeks) (mg) (mg) day 0 fluctuation (mg/day) (ml/day) 
245 not > 10 
310 not > 10 
370 11.1 
505 15.0 
520 20.4 
Correlation coefficients of linear regression: 
maximum protein excretion and dose: г = 0.99; ρ < 0.005 
maximum protein excretion and dose per g kidney: r = 0.947; ρ < 0.05 
PB 
PF 
PD 
PE 
PC 
41 
8 
10 
8 
10 
12 
12 
14 
17 
18 
16.5 
18.3 
18.8 
20.9 
21.9 
10.9 
10.9 
11.2 
12.8 
13.4 
223 
243 
249 
277 
282 
no fluctuation 
6 
19 
54 
39 
maxiTium proteinj '- ia tmg /day) 
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o 
0 
o 
o 
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dose (mg) 
12 13 14 
dose per gr к dney (mg) 
Fig. 5.7 Relation between maximum protein excretion and absolute dose (r = 0.99; 
ρ < 0.005), and between maximum protein excretion and dose per g kidney (r = 0.947; 
ρ < 0.05) in puromycin aminonucleoside nephropathy in 5 experimental series of rats, 
of different ages, as mentioned in table 5.1. 
the values of experiment PC. Data on endogenous creatinine clearance at 
several moments in the course of the disease were not collected for groups 
of animals. 
Table 5.1 presents numerical values for several of the findings discussed. 
The animals are arranged in the order of their age at the start of the 
experiment. The puromycin aminonucleoside dose used in the various groups 
is given in this table, not in amount per kg body weight (this was always 
5 Х І 5 mg/kg) but in absolute amounts. By estimating the kidney weight in 
animals of the age concerned (from data presented in fig. 3.1) it was possible 
to calculate the dose of puromycin aminonucleoside given per gramme kidney 
in the various groups. These dosages are also listed in the table. A significant 
correlation was found between maximum protein excretion and actual dose 
and dose per gramme kidney, respectively; this is illustrated in fig. 5.7. 
On the basis of individual values in the animals in experiments PC and 
PE, in which experiments protein excretion was most severe (fig. 5.2), the 
correlation was studied between individual maximum protein excretion value 
on the one hand, and on the other hand the body weight on disease day 3, 
the maximum diuresis in the acute phase, and the difference between 
maximum and minimum weight during the acute phase of illness. It was 
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Fig. 5.8a Relation between the individual values of maximum protein excretion during 
puromycin aminonucleoside nephropathy and body weight at day 3 (no correlation), 
maximum diuresis (r = 0.957; p < 0 0 1 ) in the acute stage of the disease, and body 
weight fluctuation (r = 0.751; ρ < 0.01) dunng the acute disease in the experimental 
group PC. 
found that the animals with the greatest protein excretion also developed the 
highest degree of polyuria and the greatest weight fluctuation; in experiment 
PE it was found that the animals with the highest weights developed the 
highest protein excretion values. These data are illustrated by fig. 5.8a and 
5.8b. 
Fig. 5.9 shows the data on plasma cholesterol, plasma creatinine and 
serum protein concentrations, and endogenous creatinine clearance, collected 
from the experimental series. Comparison with the values given in chapter 
III for normal controls of comparable age shows that in the acute disease 
hypercholesterolaemia nearly always occurred; no hypercholesterolaemia was 
observed after several months. Neither during the acute phase nor later a 
distinct increase in plasma creatinine concentration, a decreased creatinine 
clearance or a conspicuous hypoproteinaemia was found. We collected a 
number of data on serum protein concentrations on disease day 20. As 
shown in table 5.2, there was a slight decrease in total serum protein, a 
moderate decrease in serum albumin and a marked decrease in serum IgG. 
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Fig. 5 8b Relation between the individual values of maximum protein excretion 
during puromycin aminonucleoside nephropathy and body weight at day 3 (r = 0 832, 
p<001) , maximum diuresis (r = 0 806, ρ < 0025) in the acute stage of the disease, 
and body weight fluctuation (r = 0 908, ρ = 001) during the acute disease, in the 
experimental group PE 
Table 5.2. Data on serum protein concentrations on day 20 of puromycin 
aminonucleoside nephropathy with a protein excretion at this day of 
204 ± 49 mg/day (mean d- SE). 
Experimental Total serum Serum Albumin Serum IgG 
group η protein (g/1) (% standard) (% standard) 
Healthy controls: 
mean dz SE 
Nephropathy: 
mean ± SE 
range 
10 
61.0 ± 1.0 
57.6 ± 2.3 
43.8 — 69.1 
100 100 
72 ± 5.7 23 ± 2 
41 — 102 12 — 3' 
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Fig. 5.9 Collection of data concerning individual animals with puromycin amino-
nucleoside nephropathy. 
Fig. 5.10 plots individual maximum protein excretion values against total 
serum protein and serum albumin and IgG concentrations. Only a negative 
correlation was demonstrable between protein excretion values and serum 
albumin concentrations. The selectivity index of proteinuria on day 20 in 
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Fig. 5.10 Plot of individual values of maximum protein excretion during puromycin 
aminonucleoside nephropathy in 10 rats, versus values on day 20 for total serum 
protein concentration (no significant correlation), serum albumin concentration (r = 
0.836; ρ < 0.01), and serum IgG concentration (no significant correlation). 
Fig. 5.11 Plot of individual values of selectivity of proteinuria at day 20 of puromycin 
aminonucleoside nephropathy, versus protein excretion at day 20 and maximum of 
protein excretion during disease, respectively; no significant correlation was found. 
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Fig. 5.12 Plot of individual values of total serum protein concentration at day 20 of 
puromycin aminonucleoside nephropathy versus serum albumin concentration and 
serum IgG concentration on this day; no significant correlation was found. 
these animals was 0.33 ± 0.076 (mean ± SE); range 0.10-0.95. Fig. 5.11 
illustrates that, in this type of nephrotic syndrome in this phase of the 
disease, there was no demonstrable correlation between selectivity and 
degree of proteinuria. Also no correlation was found between total serum 
protein and serum albumin and IgG concentrations (fig. 5.12). 
Re-induction of the disease 
In the animals of experiment PB, a new disease period was induced 16 
months after the first induction; this was done in 5 animals by administration 
on two consecutive days of 15 mg puromycin aminonucleoside per kg 
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subcutaneously. These animals developed a period of pathological proteinuria 
with a maximum of 220 mg/24 hours on day 13; no polyuria occurred, and 
the body weight showed only slight fluctuations. After this second acute 
phase of illness a pathological proteinuria remained at a level, which was 
twice as high as before the second induction (cf. fig. 7.7). 
Morphological findings in puromycin aminonucleoside nephropathy 
The light microscopy of the kidneys of animals with puromycin amino-
nucleoside nephropathy was normal in all stages of the disease. Immuno-
histochemical examination did not demonstrate deposits of IgG and comple-
ment in the glomeruli. Our discussion of morphological findings is therefore 
confined to the electron-microscopic features observed on days 8, 16, 23, 
110, 240 and 460. 
At d a y 8 (photo 48) the GBM was of normal thickness. No endothelial 
changes were visible. The epithelial foot processes showed fusion at many 
sites. An increased density was seen in the cytoplasm of the epithelium where 
this was directly adjacent to the GBM. Numerous vacuoles were found in the 
epithelial cells, and especially in the foot processes. 
At d a y 16 (photo 49) the GBM showed slight thickening. Fusion of 
epithelial foot processes was virtually complete. The number of vacuoles in 
the epithelial cells was smaller than on day 8. 
At d a y 2 3 (photo 50) the GBM showed a normal thickness. Normal 
epithelial foot processes were again distinguishable at some sites. The 
cytoplasm of the epithelial cells no longer contained vacuoles. 
At d a y s 1 1 0 (photo 51), 2 4 0 (photo 52) a n d 4 6 0 the epithelial 
cells were normal. At all these days mentioned the GBM showed normal 
stratification but was thickened, an estimated 25% versus the GBM in 
healthy animals of the same age. 
At d a y 4 9 0 (photo 53) after acute illness microscopic examination was 
made in animal PA 18 which, as mentioned, had been exposed for 7 days to 
puromycin aminonucleoside administration (fig. 5.3). Comparison of photo 
53 with photo 18 (of a healthy animal of about the same age) shows 
that the GBM in the animal with the severe puromycin aminonucleoside 
nephropathy was 1.5-2 times as thick. 
In none of the preparations from animals with puromycin aminonucleoside 
nephropathy subendothelial or subepithelial electron-dense deposits were 
observed. 
Discussion 
The absence of positive immunofluorescence in immunohistochemical 
studies, and the absence of electron-dense deposits in the GBM, indicate that 
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an immune complex pathogenesis of puromycin aminonucleoside nephro-
pathy is unlikely — a situation analogous to that in human "genuine lipoid 
nephrosis". The tendency of the GBM to thicken suggests a toxic influence 
of aminonucleoside on the GBM, making it temporarily permeable to plasma 
proteins. In long-term aminonucleoside administration, moreover, proteases 
of extrarenal origin (specifically from neutrophilic granulocytes) could inflict 
damage on the GBM (Gang et al. 1972). 
A striking negative finding in our animals was the absence of visible 
evidence of oedema; yet the weight fluctuations suggest a degree of fluid 
retention. Frenk et al. (1955) did mention oedema and ascites in puromycin 
aminonucleoside nephropathy; they studied rats weighing about 140 g, versus 
a weight of about 100 g in controls. Borowsky et al. (1961) and Lannigan 
et al. (1969) likewise described oedema and ascites in their animals with 
puromycin aminonucleoside nephropathy. The fact that these three groups of 
authors gave larger doses of puromycin aminonucleoside is probably of im-
portance in explaining the difference between their findings and ours: Frenk 
et al. gave 15 mg/kg/day for 12 days; Borowsky et al. gave this dose for 2 
weeks; Lannigan et al. gave a single dose of 100 mg/kg intravenously or 
intraperitoneally. Both Borowsky et al. and Lannigan et al. reported severe 
hypalbuminaemia after some 2 weeks in their animals. The former authors 
mentioned a serum albumin level of about 8.5 g/1, versus 31 g/1 in healthy 
controls. Lannigan et al. indicated that at the height of the pathological pro-
teinuria, only traces of albumin were detectable in the serum. 
The characteristic course of the disease, with marked protein excretion 
during a number of weeks, gradually increasing to a maximum and sub-
sequently showing gradual diminution, has also been described in the 
literature. The animals of Borowsky et al. (1961) attained a maximum 
protein excretion after 6 weeks; about 50% of the animals attained a plateau 
value at about week 12, which was about twice the previous physiological 
proteinuria; in the other 50% of the animals protein excretion persisted at 
about 240 mg/day, which in some of them showed a gradual further increase 
in the course of several weeks (total period of observation: 30 weeks); a 
small number of animals died. The animals used in this study were Sprague-
Dawley rats weighing 80 - 100 g. Lannigan et al. (1969) maintained that the 
rat species used is not important, and used several varieties, weighing 
110 - 200 g. These animals attained a maximum protein excretion after about 
2 weeks (up to 1000 mg/day); a few died between day 10 and day 20. In 
most animals protein excretion rapidly diminished although in many a slight 
increase versus the initial value persisted. A spontaneous increase was seen 
again after 20 - 30 weeks (up to about 200 mg/day). 
Our animals showed no persistence of increased protein excretion in com-
parison with the physiological value after the acute phase of illness. However, 
this could have happened if a more severe degree of disease had been in-
duced. Apart from this, an explanation of the absence of a late reaction in 
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our animals might be sought in the fact that our rat strain did not tend to 
develop increased proteinuria with increasing age. In this respect there are 
no data available on the animals used by Borowsky et al. and Lannigan et 
al.. As pointed out, we did see a slight persistent increase in protein excretion 
after re-induction of the disease. During the months following this re-
induction, however, the protein excretion showed no further increase in these 
animals. 
The literature provides no exact data on the renal function in the course of 
puromycin aminonucleoside nephropathy. Our findings, too, are in fact in-
adequate on this point. Partly because of this it is difficult to explain the 
body weight fluctuations in these animals. It is evident that our animals did 
not show an initial weight gain of up to about 40% versus controls, as 
reported by Frenk et al. (1955). The weight fluctuations in our animals are 
due mostly to the marked weight loss which occurred after the initial gain. 
The polyuria observed in our animals always presented itself after 12-15 
days; as fig. 5.4 shows, the minimum weight value was always found some-
what later. 
An interesting observation was that of the correlation between the degree 
of protein excretion and the puromycin dose given, expressed as absolute 
quantity chosen on the basis of a dosage per kg body weight; it seems logical 
to seek an explanation of this correlation in the gradual decrease during life 
of the kidney weight as percentage of body weight. Accordingly, a correla-
tion also existed between the dose given per g kidney weight and the protein 
excretion attained. The dosage per kg body weight and the fact that the 
target organ weight in animals of varying age was ignored, involved the 
impossibility to achieve the same level of proteinuria in all groups. Of course 
it cannot be excluded with certainty that susceptibility to puromycin 
aminonucleoside damage varies with age. 
The marked decrease in IgG concentration observed at day 20 should 
perhaps be explained by the loss of large amounts of this protein in this 
aselective proteinuria; the capacity of the organism for increased albumin 
production to compensate losses may exceed that for increased IgG produc-
tion. Further serial investigations in the course of the disease could probably 
elucidate this point. The aselectivity of proteinuria in our experiments 
differed from the selective proteinuria reported by Lannigan et al. (1969). 
These authors found a urine : plasma protein ratio of 1 : 1 for proteins with 
a molecular radius of about 35 A, and of about 1 : 20 for proteins with a 
molecular radius of about 60 A. Again, only serial investigations in the 
course of the disease could complete the description of the selectivity of 
proteinuria and could also reveal whether the selectivity of proteinuria varies 
in the course of the disease. 
The absence of hypercholesterolaemia long after acute illness can merely 
be mentioned. This finding makes no contribution to an explanation of the 
occurrence of hyperlipaemia in the human nephrotic syndrome. 
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The mortality in the experiment with the higher puromycin amino-
nucleoside dosage may in part have been related to the constant stay in 
metabolic cages during this experiment. It is not inconceivable that our 
animals too could survive the more severe disease, if they spended more time 
in the normal group cages. 
The morphological course of the disease in our animals can be readily 
compared with the syndrome described by Lannigan et al. (1969). Their 
animals developed a disease of comparable severity with that in our animals, 
after a single injection of puromycin aminonucleoside; fusion of the epithelial 
foot processes was already complete in these animals at day 8. The authors 
also observed transient vacuolisation of epithelial cells and only a slight 
thickening of the GBM. Likewise, they observed reappearance of the foot 
processes as the protein excretion diminished to a low or physiological level. 
Conclusion 
In male PVG/C rats a brief transient period of marked pathological 
proteinuria was induced with puromycin aminonucleoside. The dose per 
amount of renal tissue proved to determine the severity of protein excretion. 
Oedema and ascites were not observed. The proteinuria proved to be 
aselective. The natural history of the disease was followed for a long time 
both clinically and morphologically; the disease seemed suitable for com-
parative studies of the possible effect of indomethacin. Puromycin amino-
nucleoside nephropathy could be used as a model of "minimal change" 
nephropathy; the low selectivity of the proteinuria in our animals contrasts 
with the high selectivity in human "genuine lipoid nephrosis" (White et al. 
1970). 
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CHAPTER VI 
EXPERIMENTS ON EFFECTS OF INDOMETHACIN IN 
HEYMANN-TYPE NEPHRITIS 
Introduction 
With the natural history of Heymann-type nephritis (described in chapter 
IV) in mind, we studied effects of indomethacin in this experimental renal 
disease. In accordance with the aims of the study as presented in chapter I, 
this study focused both on the effects of long-term medication (doses 
2 X 0.15 mg and 2 X 0.30 mg daily) and on effects of short-term medica-
tion (doses 2 X 0.15 mg, 2 X 0.30 mg and 2 X 0.60 mg daily). 
In experiments on long-term effects, indomethacin was given in several 
stages of the disease: from prior to induction throughout the animal's course 
of life; from prior to induction to the end of immunization or to a more 
advanced stage of the disease; from immediately after the immunization 
period; and from a later stage with fully developed proteinuria. The intention 
was to imitate the various situations which can be encountered when patients 
present themselves for treatment of their chronic glomerulonephritis. Appen-
dix I presents data on the numbers of animals in the long-term experiments. 
In short-term experiments, indomethacin was sometimes given in one of 
the larger doses to animals which had previously received 2 X 0.15 mg daily 
for a longer period; sometimes the animals were given one or more of the 
abovementioned three doses while they had never received indomethacin 
before. In one short-term experiment a comparison was made between 
indomethacin effects without and with dietary salt restriction. 
A morphological study was made of 36 animals in different stages of the 
disease and of 4 healthy animals. Block diagram no. 1 presents a survey of 
the times at which morphological examinations were made and of the 
numbers of animals involved. 
The effect of indomethacin on the nephrotic syndrome 
The effect of indomethacin medication started prior to the immunization 
period and continued throughout the experiment, was studied in a group of 
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Fig. 6.1 Effect of indomethacin treatment (2 d.d. 0 15 mg p.o. from week 0; CB) on 
protein excretion in Heymann-type nephritis. Statistical significance of difference CB 
vs CA (one-sided t-test): 
ρ < 0.025 weeks: 10, 14, 16, 23, 24, 27, 28, 30, 31, 32, 33, 35, 37, 40, 55; 
ρ < 0.05 weeks: 11, 17, 22, 25, 29, 34. 
Fig. 6.2 Individual values of protein excretion in weeks 16, 18 and 23 in experiment 
shown in fig. 6.1; comparison of indomethacin-treated animals (CBi) with untreated 
animals (CA). 
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25 animals (later divided into two groups), which were compared with 39 
(later 18) untreated animals. The effect of this medication is shown in fig. 
6.1. The figure shows that even in the first weeks of pathological proteinuria, 
the protein excretion in the treated group was less than that in the untreated 
animals; from week 14 on the protein excretion in the treated group was 
about 100 mg/day less than that in the untreated animals. The difference 
between treated and untreated groups, as assessed in separate paired values 
from week to week, was statistically significant in all but the 18th, 19th and 
20th week of the experiment. Fig. 6.2 presents the individual protein 
excretion values in weeks 16, 18 and 23 in the groups compared; this figure 
gives an impression of the wide range of protein excretion within the group, 
and of the intra-individual fluctuations. The groups never differed in diuresis, 
body weight and creatinine excretion. 
Fig. 6.3 presents an analogue of fig. 6.1 for the first 17 weeks of an 
experiment in which untreated animals were compared with rats given 
2 X 0.15 mg indomethacin daily only during the period of immunization. 
From week 18 on there was no longer a significant difference in protein 
excretion between the two groups. At no time the groups showed differences 
in diuresis, body weight or creatinine excretion. These results proved to be 
Uprotem-V (mg/day) [ 
О 4 θ 12 16 20 24 " 28 week" 
Fig. 6.3 Effect of indomethacin treatment (2 d.d. 0.15 mg p.о. week 0-7; DB) on 
protein excretion in Heymann-type nephritis. 
Statistical significance of difference DB vs DA: 
ρ < 0.025 weeks: 8, 9, 10, 11, 12; 
ρ < 0.05 weeks: 7, 17. 
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Fig. 6.4 Effect of indomethacin treatment (2 d.d. 0.15 mg p.o. week 0-7; FBa) on 
protein excretion in Heymann-type nephritis. 
Statistical significance of difference FBa vs FA: 
ρ <0.01 weeks: 9, 13, 27, 28; 
ρ < 0.025 weeks: 11, 14. 
F/g. 6.5 Effect of indomethacin treatment (2 d.d. 0.15 mg p.o. from week 0, GBr, 2 
d.d. 0.15 mg week 0-7, GBa) on protein excretion in Heymann-type nephritis. 
Statistical significance of difference GBi vs GA: 
ρ < 0.025 weeks: 10, 14; 
ρ < 0.05 weeks: 17, 21, 23. 
Statistical significance of difference GB2 vs GA: 
ρ < 0.025 week: 14; 
ρ < 0.05 weeks: 10, 17, 23. 
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Fig. 6.6 Effect of indomethacin treatment (2 d.d. 0.30 mg p.o. from week 0, IBi; 2 
d.d. 0.30 mg week 0-7, IB2) on protein excretion in Heymann-type nephritis. 
Statistical significance of difference IBi vs IA: 
ρ < 0.005, excepted ρ < 0.025 weeks 16, 20, 24. 
Statistical significance of difference IB2 vs ΙΑ: ρ < 0.01, excepted ρ < 0.05 weeks 16 
through 24. 
reproducible in a second experiment, as shown in fig. 6.4: a significant 
difference in protein excretion existed between the two groups during many 
weeks, the difference being minimal or absent in weeks 16-21. 
Fig. 6.5 shows the results of an experiment comparing untreated animals, 
animals constantly treated with indomethacin (2 X 0.15 mg daily), and 
animals treated only during immunization. There was no significant 
difference between these groups in disease weeks 21 and 22; in week 10, 
week 14 and week 17, the indomethacin-treated groups showed a significantly 
lower but not intervaried protein excretion as compared with the control 
group. Fig. 6.6 presents the results of an experiment of the same design as 
that in fig. 6.5, but with an indomethacin dose of 2 X 0.30 mg daily. The 
protein excretion in the treated groups was about 45% less than that in the 
untreated group; at no time was the difference between treated and un-
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Fig. 6.7 Lack of effect of 
indomethacin treatment 
(2 d.d. 015 mg p.o. from 
week 7; EC) 
on protein excretion in 
Heymann-type nephritis. 
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Fig. 6.8 Lack of effect of indomethacin treatment (2 d.d. 0.15 mg p.o. from week 7; 
FC) on protein excretion in Heymann-type nephritis. 
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Fig. 6.9 Lack of effect of indomcthacin treatment (2 d d 0.15 mg ρ о. from week 
19, with 2 dose increases; CC) on protein excretion in Heymann-type nephritis. 
treated animals absent (specifically not in weeks 18 - 22), and protein 
excretion in the treated groups persisted at the same level until week 27 (end 
of observation). In weeks 14 through 27, the protein excretion in group IB, 
(fig. 6.6) was 45.3% ± 2.3% (mean ± SE) less than that in group IA. For 
group CB (fig. 6.1) the protein excretion in weeks 14 through 55 (except 
weeks 18, 19 and 20) averaged 25.7% ± 1.4% lower than that in group 
CA; this demonstrates that reduction of the proteinuria is dose-dependent 
(p < 0.005). 
Two experiments demonstrating the lack of an effect on protein excretion 
of indomethacin medication started in week 7, i.e. after completion of the 
series of antigen injections, are shown in figs. 6.7 and 6.8. In a third experi­
ment in which a group of initially 10 animals given indomethacin from week 
7 on was compared with 20 untreated animals (group GA, fig. 6.5), there 
was likewise no demonstrable difference in protein excretion. Fig. 6.9 shows 
the lack of an effect of indomethacin medication started in disease week 19. 
In these animals, increased doses likewise failed to produce an effect. Treat­
ment was continued (with 2 X 0 15 mg daily) in 6 of these animals and 
discontinued in 6 of them; both groups maintained the same level of protein 
excretion up to and including observation week 55. 
Fig. 6.10 presents the data collected from the experimental series on 
plasma cholesterol and plasma creatinine concentration, creatinine excretion 
and endogenous creatinine clearance in animals given long-term indome­
thacin medication from week 0 on. Comparison with the values given in 
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Fig. 6.10 Collection of data concerning individual indomethacin treated animals (2 
d.d. 0.15 mg p.o., continuously given from week 0) with Hcymann-type nephritis. 
chapter III for healthy animals of comparable age, and with the values given 
in fig. 4.8 for animals in which Heymann-type nephritis was allowed to take 
its natural course, shows that no renal failure occurred in the animals given 
indomethacin from week 0 on, and that hypercholesterolaemia existed in 
these animals as well as in the untreated diseased animals. The values of the 
parameters presented in fig. 6.10 for the animals constantly treated with 
indomethacin, were of the same order in the other medication groups so far 
discussed (this refers to the 8 animals sacrificed for morphological examina­
tion). 
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In weeks 31 - 32 of disease, the selectivity of proteinuria was measured in 
the group of animals described in fig. 6.4, which were given 2 X 0.15 mg 
indomethacin daily during the period of immunization (FB^); the group 
mean of the individual means of the two observations of 2 X 24 hours, was 
0.46 ± 0.039 (mean ± SE; range 0.30 - 0.60). This value does not differ 
from the selectivity index 0.41 ± 0.047 given in chapter IV for untreated 
animals with Heymann-type nephritis (cf. table 6.1). 
Short-term studies on effects of indomethacin 
As already demonstrated in fig. 6.9, treatment with 2 X 0.15 mg indome-
thacin daily, started in disease week 19, had no effect on the protein excre-
tion in Heymann-type nephritis. Nor was the protein excretion affected by 
a subsequent two-fold or even four-fold increase of the abovementioned 
dose. A four-fold increase of the indomethacin dose from 2 X 0.15 to 
2 X 0.60 mg daily, however, did have a significant effect on the protein 
excretion during the second week of medication at this dosage in a group of 
animals given 2 X 0.15 mg daily from week 0 on. These were animals CB 
in fig. 6.1 ; this experimental group was divided into two groups of 10 animals 
each, and one of these two groups continued on a daily dose of 2 X 0.15 
mg. The significant (p < 0.05) decrease in protein excretion observed during 
the second week of medication in the high-dosage group (disease week 32) is 
shown in fig. 6.11. In this respect it should be noted that, in the week in 
question, the creatinine excretion in the high-dosage animals was significantly 
lower (p < 0.01) than that in animals which had continued on the standard 
dose of indomethacin. Calculation of group protein excretion values as 
means of the individual values per /¿mole creatinine excreted, gave values 
which did not differ significantly. In disease week 35, too, the animals whose 
Table 6.1. Data on scrum protein concentrations and selectivity of proteinuria 
(means ± SE) in rats with Heymann-type nephritis (FC: after 1 week 2 d.d. 
0.60 mg indomethacin p.o.) 
Experi- η Week of Total serum Albumin IgG Selectivity 
mental experiment protein (% standard) (% standard) index 
group (g/I) 
FA 
FB 2 
FA 
FC 
13 
8 
10 
10 
24 
31-32 
31 
32 
54.0 ± 
53.4 
56.9 
53.7 
2.3 
3.5 
1.8 
2.2 
26.1 ± 
31.0 
35.2 
34.7 
3.6 
4.2 
7.7 
6.5 
31.8 
32.7 
32.2 
33.2 
± 2 . 0 
4.0 
2.6 
3.2 
0.41 ± 
0.46 
0.50 
0.54 
. 0.047 
0.039 
0.12 
0.13 
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Fig. 6.11 Effect of indomcthacin, 2 d.d. 0.60 mg ρ ο. ¡η weeks 31-32 of Heymann-typc 
nephritis, on protein excretion in animals previously treated with 2 d.d. 0.15 mg from 
week 0. Protein excretion in week 32 in group treated with large dose is smaller than 
in controls (p < 0.05). Indomcthacin treatment was stopped in high-dosage group after 
week 32, in this group in week 35 protein excretion is still smaller ( ρ < 0.01) than in 
control group. 
When protein excretion values are expressed per μπιοίε creatinine excreted, the diffe­
rence is absent in week 32, and less significant in week 35 (p < 0.05). 
indomethacin medication had meanwhile been discontinued showed a lower 
creatinine excretion than those which had continued on the standard dose of 
indomethacin. Calculation of protein excreted as mg protein/Timole creatinine 
now gave values which differed significantly (p < 0.05); the significance, 
however, was less than that shown in fig. 6.11 (p < 0.01). In disease week 
40 both groups of animals had the same creatinine excretion. Endogenous 
creatinine clearance was not determined in these animals. 
In a further series of observations on a total of 40 animals in various 
disease weeks (week 23, weeks 25 and 26, week 33, weeks 31 to 35), the 
possible effect was studied of indomethacin in daily oral doses of 2 X 0.30 
and 2 X 0.60 mg, in animals not previously given indomethacin as well as in 
animals given 2 X 0.15 mg from week 7 on. All comparisons were made 
with a group of animals, with virtually the same degree of protein excretion, 
in which medication was not changed. These observations revealed no effect 
of the larger indomethacin doses on protein excretion, endogenous creatinine 
clearance or body weight. A selection from these experiments is presented in 
figures 6.12 through 6.15. 
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Fig. 6.12 Lack of effect, as seen in Ihe individual values, of indomethacin, 2 d.d. 0.60 
mg in week 23 of Heymann-typc nephritis, on protein excretion in previously untreated 
animals. Straight and interrupted lines indicate means ± SE, respectively. 
Fig. 6.13 Stable pattern of individual creatinine excretion values during experiment 
shown in fig. 6.12; at least at the end of the week of indomethacin treatment, medi-
cation probably has no effect on endogenous creatinine clearance in 4 animals. 
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Fig. 6.14 Lack of effect, as seen in the individual values, of indomethacin, 2 d d. 0.60 
mg in weeks 31-35 of Heymann-type nephritis, on protein excretion in animals pie-
viously treated with 2 d.d. 0.15 mg from week 7. Straight and interrupted lines indicate 
means •i SE, respectively. 
F/g. 6.15 Pattern of individual creatinine excretion values during experiment shown 
in fig. 6.14. Endogenous creatinine clearances were not measured in the beginning of 
indomethacin treatment period. 
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Fig. 6.12 shows the individual values in 9 animals given 2 X 0.60 mg 
indomethacin daily during one week; the creatinine excretion measured on 
the second day of medication was the same as the pre-treatment value (fig. 
6.13), and the endogenous creatinine clearance measured after a few days in 
4 animals showed no decrease as compared with pre-treatment values. 
Fig. 6.14 and fig. 6.15 likewise show the course of individual values, 
demonstrating the absence of any indomethacin effect in animals previously 
given 2 X 0.15 mg daily. The higher dosage had been given for some 3 
weeks, during which tolerance had been good. As fig. 6.14 indicates, this 
group included no "responders" showing a permanent decrease in protein 
excretion; the group means shown, fairly stable as such in this experiment, 
equalled those in the control group. The course of creatinine excretion as 
measured on a series of days during this experiment, was quite stable. 
Endogenous creatinine clearance, measured halfway the experiment and at 
its completion, showed no marked fluctuations. 
The possible effect of indomethacin during sodium restriction was studied 
in an experiment in which a number of animals were fed a low-sodium diet 
during 3 weeks. A proportion of the animals was given 1 mg furosemide 
daily by intraperitoneal injection during the first week of sodium restriction. 
Halfway the 3-week period of sodium restriction, 2 X 0.60 mg indomethacin 
daily was given during one week. The experiment thus encompassed six 
groups of 8 animals each: 
• animals on a normal unrestricted diet; 
• animals on an unrestricted diet, given indomethacin; 
• animals on a salt-restricted diet; 
• animals on a salt-restricted diet, given furosemide; 
• animals on a salt-restricted diet, given indomethacin; 
• animals on a salt-restricted diet, given furosemide and indo-
methacin. 
For the effects of a sodium-restricted diet as such, and the absence of an 
extra effect of furosemide, we can refer to fig. 4.13 and to the description 
given in the relevant section of chapter IV. Fig. 6.16 shows the effects of 
indomethacin in the animals on a normal unrestricted diet: no effect on 
protein excretion, nor on the other parameters, sodium excretion, body 
weight, creatinine excretion and endogenous creatinine clearance could be 
found. 
An entirely different situation was found in the animals with Heymann-
type nephritis given indomethacin while on a salt-restricted diet, as such or 
in combination with furosemide. One individual observation is shown in fig. 
6.17. In this experimental set-up indomethacin caused a marked decrease in 
protein excretion, from values of about 700 mg to values of about 300 mg 
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F/g. 6.77 Effects of indomethacin treatment in an animal with Heymann-type neph­
ritis during sodium restriction. 
per day. During the first few days creatinine excretion and diuresis decreased. 
At the end of indomethacin medication endogenous creatinine clearance was 
still decreased, but creatinine excretion had almost returned to normal. Body 
weight increased during indomethacin medication. The effects proved to be 
almost immediately reversible after discontinuation of indomethacin. This 
shows a striking similarity to the short-term effect of indomethacin which 
Wijdeveld (1971) described in human patients with a nephrotic syndrome. 
Fig. 6.18 and fig. 6.19 show these effects in terms of group means. Fig. 6.18 
reveals that treatment or non-treatment with furosemide made no difference 
in the indomethacin-treated animals on a salt-restricted diet. Fig. 6.19 shows 
that the entire group of salt-restricted animals, with or without furosemide, 
was characterized by a decrease in protein excretion during indomethacin 
medication which was immediately reversible upon discontinuation of indo­
methacin. 
A possible effect of indomethacin on selectivity of proteinuria was studied 
only in animals on a normal unrestricted diet; in 10 animals not previously 
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treated with indomethacin, the selectivity index was 0.50 ± 0.12; after one 
week of indomethacin medication (oral daily dose 2 X 0.60 mg) the index 
was 0.54 ± 0.13 (mean ± SE). Together with the previously discussed 
values for the selectivity index in other experimental groups with Heymann-
type nephritis, the data on serum protein concentrations in these animals and 
in other groups are listed in table 6.1, which shows that the groups did not 
differ significantly. 
Morphological findings 
Light-microscopic and immunohistochemical (e.g.: photos 7 and 8) 
examination of the kidneys of indomethacin-treated animals with Heymann-
type nephritis revealed no differences from untreated animals with this 
disease. The following discussion is therefore confined to electron-
microscopic findings. 
Animals constantly treated with indomethacin from week 0 
At d i s e a s e w e e k 4 (photo 28) these animals, like the untreated 
animals, showed a normal GBM, normal epithelial- and endothelial cells 
and, very sporadically, an electron-dense deposit in the lamina rara externa. 
The only difference in the indomethacin-treated animals was the presence at 
some sites of subendothelial deposits (photo 28.2). 
At d i s e a s e w e e k 6V2 (photo 29) the features in the animals con-
tinuously given 2 X 0.30 mg indomethacin from week 0 were the same as 
those in the natural history of the disease. Subendothelial electron-dense 
deposits were not seen. 
At d i s e a s e w e e k 1 1 (photo 30), comparison of treated and un-
treated animals with approximately the same degree of proteinuria showed 
a slightly thickened GBM in the treated animals; scattered small or some-
times larger subepithelial electron-dense deposits were unmistakably more 
evident in the treated animals. Subendothelial deposits were not observed at 
this time in the treated animals. 
At d i s e a s e w e e k 18 (photo 31) the features in the indomethacin-
treated animal were the same as those in the untreated animals. No subendo-
thelial deposits were observed in the treated animal. 
At d i s e a s e w e e k 2 2 (photo 32) the GBM changes in the treated 
animal showed a similarity to those in the untreated. The immune complex 
aggregates deposited in the GBM seemed to show a somewhat looser 
structure in the treated animal; around these aggregates, moreover, trans-
lucent areas seemed to develop - a phenomenon which in the natural history 
of the disease did not develop until weeks 33 - 59. No subendothelial 
electron-dense deposits were observed. 
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Fig. 6.20 Course of disease of animal shown in photo 33. 
At d i s e a s e w e e k 3 3 (fig. 6.20; photo 33) the features in the treated 
animals differed from those in the natural history of the disease. The 
thickening of the GBM was less irregular and erratic; the immune complex 
aggregates seemed to have been largely taken up into the GBM. The animal 
in which during weeks 31 and 32 a dose increase was given did not show 
subendothclial electron-dense deposits. 
At d i s e a s e w e e k 5 9 (photo 34) the GBM was as thickened in the 
treated animals as in the natural history of the disease; immune complex 
aggregates were entirely embedded in the GBM material. As at week 33, the 
treated animals often showed translucent areas around the aggregates, but 
real holes in the GBM were not observed in this stage of the disease. This 
contrasts with the frequent occurrence of such holes in the GBM in this stage 
of the natural history of the disease. 
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I n s u m m a r y , comparison of untreated animals with animals given 
indomethacin continuously from week 0 on, disclosed a number of dif-
ferences: at disease week 4 the treated animals showed subendothelial 
electron-dense deposits; at disease week 11 the GBM changes in the treated 
animals were more severe - a difference which was not clinically found; like-
wise with an unchanged severity of clinical findings, formation of translucent 
areas around immune complex aggregates was found at week 22 (earlier than 
in the natural history); at week 33 in the treated animals the GBM was 
evenly thickened without irregular projections (the latter did occur in the 
untreated animals). Finally, at week 59 the treated animals virtually showed 
no holes in the GBM, whereas in the natural history of the disease these 
were quite common in this stage. 
Animals treated with indomethacin from week 7 on 
At d i s e a s e w e e k 1 1 (photo 35) the features were the same as those 
observed in animals treated with indomethacin from week 0 on, and evidently 
more severely changed than those in the untreated animals. Subendothelial 
electron-dense deposits were not observed. 
At d i s e a s e w e e k 18 (photo 36) the changes in the GBM were ent-
irely the same as those in the untreated group at the same time; no subendo-
thelial deposits were found. 
Animals treated with indomethacin during the first 6 weeks 
At d i s e a s e w e e k 11 (photo 37) the changes in the GBM were 
similar to those seen in animals treated with indomethacin from the start or 
from week 7 on (photos 30 and 35). No subendothelial deposits were found. 
At d i s e a s e w e e k 18 (photo 38) the pathological changes in the 
GBM were more marked than in any other previously mentioned group of 
animals in this stage of the disease; there was very marked thickening of the 
GBM. Immune complex aggregates were embedded in newly formed GBM 
material; at numerous sites these electron-dense deposits were surrounded by 
translucent areas, which in all the other groups of animals were not seen 
until a later stage of the disease. 
At d i s e a s e w e e k 2 2 (photo 39) the changes were similar as those 
in the natural history of the disease, the difference being that there were un-
mistakable optically empty spaces around the aggregates. 
The above discussion of possible effects of indomethacin on the mor-
phology of the disease has already implicitly presented two observations on 
short-term indomethacin treatment: the subendothelial deposits found at 
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disease week 4 in animals given indomethacin from week 0 on, and the more 
severe changes found at week 11 in animals treated with indomethacin from 
week 7 on. The possible influence of short-term indomethacin treatment was 
also studied in a later stage of the disease, at times when a plateau value of 
the protein excretion had been attained. 
At d i s e a s e w e e k 2 2 (photo 40) the effect of 2 X 0.15 mg 
i n d o m e t h a c i n d a i l y d u r i n g o n e w e e k was studied in animals 
not previously given indomethacin. At low magnification the changes of the 
GBM proved to be identical to those in the untreated group (photo 24). At 
higher magnification, subendothelial electron-dense deposits were observed 
at several sites. 
Also a t d i s e a s e w e e k 2 2 (photo 41) the effect of 2 X 0.15 m g 
d a i l y d u r i n g 4 w e e k s was studied. Like the previous group, these 
animals showed changes in the GBM in this stage which were comparable 
with those in the natural history of the disease: again, subendothelial 
eleçtron-dense deposits were regularly observed at higher magnification. 
At d i s e a s e w e e k 2 7 (photo 42) the effect of 2 X 0.60 m g 
d a i l y d u r i n g 2 w e e k s was studied in previously untreated animals. 
The changes in the GBM generally did not differ from those described in the 
untreated group at disease week 22. As in the other groups given short-term 
indomethacin treatment, subendothelial deposits were regularly seen. 
For comparison with the abovementioned animals which received high-
dosage indomethacin medication during weeks 26 and 27, and which had 
never before received indomethacin, a dose increase to 2 X 0.60 m g 
d a i l y d u r i n g 2 w e e k s was given to animals already treated with 
indomethacin f r o m week 7 o n (photo 43). Again, the features were 
highly similar to those seen in the untreated group at week 22; unlike the 
three short-term treatment groups discussed above, the animals already on 
indomethacin for a longer period did not show subendothelial electron-dense 
deposits. 
Finally, the effect of a short-term dose increase was studied in animals 
already on indomethacin treatment since week 19; in these animals the 
d o s e i n c r e a s e t o 2 X 0.60 m g was given during w e e k s 31 a n d 
3 2 (photo 44). The pathological changes in the GBM in these animals were 
similar to those seen in the same stage during the natural history of the 
disease. At higher magnification, however, subendothelial deposits were 
often observed. 
The morphology a t w e e k 5 9 was studied in three groups of animals 
which had served as controls. In animals treated with indomethacin from 
week 19 on (fig. 6.21; photo 45), which received dose increases in weeks 27 
to 33 and then continued on 2 X 0.15 mg indomethacin daily, the GBM 
was markedly thickened at week 59, as it was in the natural history of the 
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F/g. 6.21 Course of disease of animal shown in photo 45. 
disease. There were unmistakable translucent areas around the immune 
complex aggregates, and holes were seen in the GBM at several sites. Sub-
cndothelial electron-dense deposits were likewise seen at several sites. In 
animals treated with indomethacin during the first 32 weeks of the disease 
and given the four-fold dose during the last 2 weeks of medication (fig. 6.22; 
photo 46) a markedly thickened and irregular GBM was seen at week 59, 
with beginning translucency around the immune complex aggregates and 
only sporadic holes in the GBM. These features were therefore most 
reminiscent of those observed in animals treated with indomethacin from 
week 0 on. No subendothelial electron-dense deposits were seen. 
In animals treated with indomethacin from week 19 on and given two 
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Fig. 6.22 Course of disease of animal shown in photo 46. 
dose increases in weeks 27 to 33, whereupon indomethacin was discontinued 
(photo 47), the GBM also showed marked and regular thickening at week 
59. The immune complex aggregates were entirely embedded in newly 
formed GBM material, and few translucent areas and very few holes were 
seen in the GBM. There was marked fusion of foot processes, in contrast to 
the observation in animals treated with indomethacin from week 0 on. No 
subendothelial deposits were found. 
To summarize: the most marked morphological changes of the disease 
were found in animals treated with indomethacin from week 0 on; in these 
animals the abnormalities at week 11 were more marked than those in the 
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natural history of the disease; the formation of translucent areas seemed to 
start earlier; at week 33 the irregular features of the GBM with many 
projections were absent; at week 59 there were much less holes in the GBM. 
The formation of translucent areas around immune complex aggregates at 
an earlier stage than in the natural history of the disease was likewise 
observed in the animals treated with indomethacin during weeks 0 through 6, 
at week 18, and to a less degree at week 22. It was also observed in animals 
given indomethacin from week 7 on, with a dose increase during weeks 26 
and 27. The phenomenon of holes in the GBM, seen in the very late phase in 
the natural history of the disease, was much less common in the animals 
given indomethacin from week 0; the same applied to week 59 for the 
animals treated from week 0 to week 33 and from week 19 to week 33. Not 
only in the animals continuously given indomethacin from week 0 on but 
also in the animals treated from week 0 through week 6 and those treated 
from week 7 on, the changes at week 11 were more marked than those in 
the natural history of the disease. Virtually complete fusion of epithelial foot 
processes was observed in all animals studied at weeks 18-22 ; the treated 
groups did not differ from the untreated animals in this respect. An excep-
tion was the extensive fusion of foot processes observed at week 59 after 
indomethacin treatment during weeks 19 through 33 (photo 47). 
During indomethacin treatment subendothelial electron-dense deposits 
were observed in two disease periods: in the very early phase during medica-
tion from week 0 on, at disease week 4; and in the later phase after week 18 
in animals not previously treated with indomethacin, if the drug was given 
during 1 week (photo 40), 4 weeks (photo 41), 2 weeks in large dosis (photo 
42), and after treatment during 15 (photo 44) and during 31 weeks (photo 
45), respectively. 
They were not found in an animal given indomethacin from week 0 on 
which received an increased dose of indomethacin during weeks 31 and 32, 
and which was examined at week 33; nor in animals treated from week 7 on 
and given an increased dose in weeks 26 and 27; nor in animals treated with 
indomethacin from week 19 to week 33 and examined at week 59. Treatment 
in weeks 7 to 11 also failed to lead to formation of subendothelial deposits. 
These subendothelial electron-dense deposits were never found in the natural 
history of Heymann-type nephritis. 
For comparison with these findings during indomethacin medication of 
diseased animals, an electron-microscopic examination was made of the 
kidneys of four animals aged 26 weeks after 2 weeks' medication with 
2 X 0.15 mg and 2 X 0.60 mg daily, respectively. Subendothelial electron-
dense deposits were regularly found in the GBM in these animals (photo 19); 
these did not differ from the deposits found during indomethacin treatment 
of animals with a glomerulopathy as described in this chapter and as still to 
be discussed in chapter VII in animals with puromycin aminonucleoside 
nephropathy. 
105 
Discussion and conclusions 
The experiments on long-term indomethacin medication have demonstrat-
ed that, under certain conditions, this drug has an effect on the protein 
excretion which results from experimental immune complex glomerulo-
nephritis. To produce this influence, indomethacin had to be administered 
during induction of the disease. If it was given later, i.e. after the phase of 
immunization or later, the drug had no effect on the proteinuria in the long-
term experiments, and only in animals on a salt-restricted diet in the short-
term experiments. 
The effect of indomethacin given during immunization and after, seems to 
be dose-dependent. In animals treated with 2 X 0.15 mg indomethacin daily 
the reduction of protein excretion was in the order of 26% during more than 
a year; treatment with 2 X 0.30 mg daily proved to reduce the protein 
excretion by about 45%. 
If indomethacin was given during immunization only, then the reduction 
of protein excretion at a daily dosage of 2 X 0.15 mg persisted only until 
about disease week 20. Up to week 20, there was no difference between the 
groups given indomethacin continuously and those treated only during im-
munization. If the indomethacin dose was 2 X 0.30 mg daily, then not only 
was the reduction of protein excretion more marked but, at least until week 
27, the difference between the continuously treated groups and those treated 
only during immunization, disappeared. This indicates a second dose effect: 
high-dosage indomethacin medication exclusively during immunization 
produced not only more marked but also more prolonged reduction of 
protein excretion. 
The question of the significance of the period about the 20th week arises. 
Not only is this the time at which the curves of the protein excretion values 
of the animals treated only during immunization come to coincide with those 
of the control animals (at a daily dosage of 2 X 0.15 mg), but it is also the 
time at which the animals given continued medication with 2 X 0.15 mg 
daily temporarily show the same level of protein excretion as the control 
groups. In this context it may be pointed out that the morphological features 
in treated and untreated animals (apart from translucency around immune 
complex aggregates) generally were alike at week 18, whereas at week 33 
the animals given continued medication with 2 X 0.15 mg daily showed less 
changes than the controls. The impression is that, about week 20, a new 
phase of the disease commences and that in this second phase indomethacin 
affects the proteinuria only if it is continued or if it was given in larger doses 
in the weeks of antigen injections. We are unable to explain these 
phenomena. 
In an effort to explain the long-term effect of indomethacin it must be 
taken into account that this effect was observed only if the drug was given 
at least during immunization. Bearing this fact in mind, several possible 
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explanations can be considered. For example, indomethacin might interfere 
with the ability of the intraperitoneally given antigen to start the immune 
reaction in the animal. This could involve an "anti-inflammatory" effect, by 
which indomethacin might reduce the degree of a possible intraperitoneal 
inflammatory reaction. We have no data on the peritoneal reaction to antigen 
administration during immunization, apart from the fact that no macroscopic 
differences were observed between the peritonea of indomethacin-treated 
animals and controls. On the basis of the data on indomethacin effects listed 
in chapter I, it is conceivable that indomethacin interferes at several sites 
with immunological events underlying the disease. Stabilization of lysosomal 
membranes might lead to reduced phagocytosis of antigen and, therefore, to 
a less marked reaction of the immunological apparatus. Indomethacin might 
locally modify the reactions which occur when the GBM is damaged by 
deposition of immune complexes. A weakly acid substance such as indome-
thacin is excreted in the proximal convoluted tubule, and a higher con-
centration at this site seems therefore plausible; in this way indomethacin 
might interfere with the liberation of renal tubular antigens (the question 
whether the antigen which partly causes and in any case maintains the 
disease really originates from the kidneys, is left undiscussed here). Another 
possibility to be considered is an influence of indomethacin on the synthesis 
of GBM material at the time of the arrival of immune complexes; or an 
effect on the development of intraglomerular blood coagulation in the initial 
phase of the disease. 
It was not the intention of this study to analyse these many possibilities; 
we can do no more than present suggestions. It is possible to imagine 
numerous, complicated experiments for further analysis of precisely the early 
phase of Heymann-type nephritis and the effects of indomethacin on this 
phase. The question is whether a motivation of such experiments can be 
derived from the ambition to exert a favourable influence on the course of 
human chronic glomerulonephritis with the aid of such a drug as indo-
methacin. Unfortunately, patients with glomerulonephritis usually present 
themselves more or less long after completion of the phase of induction of 
the disease. At least in our experimental model, neither the effects on pro-
tein excretion nor those on the morphological features which can be obtained 
by long-term indomethacin medication in a later phase of the disease, 
warrant the conclusion that prevention of further progression of glomerulo-
nephritis could still be accomplished at that time. This conclusion would 
seem to be of considerable importance for clinical nephrology. Until it is 
disproven, this conclusion could withhold the clinician from exposing pa-
tients with longstanding chronic glomerulonephritis to the risks of long-term 
indomethacin medication solely in order to delay terminal renal failure. 
Our observations on the influence of the dietary sodium content on short-
term indomethacin effects merit further consideration. The facts that indo-
methacin reduces protein excretion only in association with a salt-restricted 
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diet, and that the effect occurs and disappears immediately upon institution 
and discontinuation of treatment, respectively, undermine the plausibility of 
an explanation of the antiproteinuric effect on the basis of an influence on 
the immunological events underlying the disease. The absence of effect on 
the selectivity of proteinuria, studied in animals on an unrestricted diet, like-
wise indicates the improbability of an effect of indomethacin on the perme-
ability of the GBM, at least in this model. The effect in association with a 
salt-restricted diet is entirely analogous to that in a human nephrotic 
syndrome. This effect provides the clinical pharmacologist with new pos-
sibilities to study structural analogues of indomethacin, both with regard to 
qualitative effects and in terms of dose comparisons - in a manner which 
would not be feasible with human subjects. 
The impression is gained that a certain degree of circulatory insufficiency 
- hypovolaemia - is necessary to give the antiproteinuric effect of indome-
thacin its chance. The fact that the hypalbuminaemia in the nephrotic rat 
proved as such to be insufficient in this respect, is in accordance with the 
observation that our salt-unrestricted rats never developed oedema despite 
the ample sodium intake, whereas at a comparable level of hypalbuminaemia 
the human patient not given dietary restrictions would certainly be expected 
to develop oedema (Wijdeveld 1971). It seems likely that the kidney of the 
PVG/C rat needs a stronger volume-regulatory stimulus than the human 
kidney in order to achieve a block of renal sodium excretion. Our 
experiments have shown that the antiproteinuric effect of indomethacin in 
our animals occurred only as soon as the kidney was in a situation in which, 
on volume-regulatory grounds, its sodium excretion had ceased. 
Our observations also showed that the antiproteinuric effect in the rats, like 
that in many human patients (Wijdeveld 1971), was accompanied by an - at 
least partly - transient decrease in endogenous creatinine clearance. It would 
be of interest to establish whether this phenomenon also occurs in the salt-
restricted PVG/C rat without glomerulonephritis. We may be tempted, with 
Donker et al. (1975), to speculate on the possibility of a correlation between 
this indomethacin effect and the inhibition of prostaglandin synthesis which 
indomethacin causes. One would then postulate that renal prostaglandin 
reduces the effects of a stimulated renin-angiotensin system on renal function, 
and that consequently inhibited prostaglandin synthesis would give these 
effects as much more emphasis as the renin-angiotensin system is more 
stimulated by hypovolaemia. The views on the intrarenal functions of prosta-
glandin presented in chapter I can be used as a corollary to this postulate; 
but they would be valid confirmation only after being corroborated in 
focused experiments. Such experiments would have to concern the question 
how a predominant angiotensin activity can reduce proteinuria. Factors such 
as reduced filtration pressure per nephron or changed pressure gradients 
within the nephron population might play a role in this respect. 
In a more detailed account of the morphological features revealed by 
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electron-microscopic examination, it can certainly be maintained that indo-
methacin administration caused demonstrable changes. The most important 
finding was probably that indomethacin medication during the weeks of in-
duction of the disease, whether continued later or not, proved to be 
associated with an earlier occurrence of translucent areas surrounding im-
mune complex aggregates in the GBM; at least in animals continuing on 
indomethacin to week 33, this process was not followed by an apparent 
disappearance of the immune complex aggregates from the GBM and replace-
ment with newly formed GBM material (as is observed in the natural history 
of the disease). Interpretation of these findings in the sense of an influence 
on the prognosis of the syndrome seems impossible; in fact, the differences 
between untreated animals and animals continuously given indomethacin 
from week 0 on are not marked enough to warrant such an interpretation 
(fig. 6.1); and the animals treated with indomethacin during immunization 
(fig. 6.3) showed no difference from the untreated animals at the time of 
examination (photos 38 and 39). With the available data it is likewise im-
possible to determine whether these differences were based on an intrarenal 
activity of indomethacin or on an indirect influence on the disease process. 
Further evaluation in this respect would be possible with the aid of data on 
the ratio, in these animals, between antigen administered and endogenous 
antigen/antibodies/immune complexes, data obtained by quantitative im-
munohistochemical examination, and data on the activity of the mesangium 
and the degree of GBM synthesis in untreated and treated animals. In 
addition, morphological data on the natural history of the disease in animals 
at several proteinuria levels would be required. Comparable data on these 
parameters cannot be found in the literature. 
In the earliest phase of the disease (photos 20, 21, 28 and 29) we did not 
observe the mottled appearance of the lamina densa of the GBM, ascribed to 
the passage of immune complex aggregates through this part of the GBM, 
which Feenstra (1974, 1975) described in heterologous immune complex 
glomerulopathy. The increased spike formation which Feenstra found in the 
late phase in indomethacin-treated animals with this glomerulopathy, was 
not observed either in our animals. In this respect it is to be borne in mind 
that Feenstra used a larger indomethacin dose (4 mg/kg daily). In view of 
the smaller indomethacin dose we used, it seems illogical for our animals to 
suggest a relation (as Feenstra suggested for his animals) to the increased 
GBM synthesis in indomethacin-treated rats as observed by Daha (1973) in 
the course of nephrotoxic glomerulonephritis. On the basis of the morpho-
logical features, moreover, the virtual absence of defects in the GBM at week 
59 in animals continuously given indomethacin from week 0 on (photo 34) 
is more readily explained by non-disappearance of the immune complex 
aggregates than by an increased degree of replacement with newly formed 
GBM material. The explanation based on diminished resolution of immune 
complex aggregates during long-term indomethacin treatment, is supported 
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by comparison with the stage characterized by "holes" in the GBM in the 
course of the natural history of the disease (photo 26) and the later phase 
(disease week 75) in the natural history (photo 27) in which these defects 
have been filled. The appearance of the structures interpreted as residual 
immune complex aggregates in photo 34, is quite different from the evenly 
grey fields in the GBM seen in the last stage of the natural history examined. 
Questions concerning the nature of the subcndothelial electron-dense 
deposits described, and the reason for their being found at the times des-
cribed, cannot be answered. It has been suggested (Feenstra, 1974) that this 
finding indicates diminished penetration of immune complexes through the 
GBM in response to indomethacin. Our results argue strongly against this 
view. The decisive counter-argument lies in the finding that such deposits 
are present also in animals without immune complex nephritis, both in the 
case of non-immunological puromycin aminonucleoside nephropathy with 
indomethacin treatment (cf. chapter VII) and even in normal controls given 
indomethacin. The exact nature of these electron-dense deposits remains 
unknown for the time being. 
To summarize: indomethacin given at least during induction of experi-
mental immune complex nephritis was found to modify the course of the 
disease. The protein excretion remained at a lower level; the morphological 
changes in the GBM after some 7 months were less marked, and sub-
sequently the immune complexes situated in the GBM seemed slowly to 
resolve, while the number of translucent areas in the GBM was less. In later 
phases of the disease indomethacin influenced the proteinuria only if the 
degree of hypovolaemia in the animal was enhanced by dietary salt restric-
tion. 
Indomethacin medication sometimes led to the appearance of subendo-
thelial electron-dense deposits, which must not be interpreted as immune 
complexes. These subendothelial deposits were also found in some healthy 
control animals given short-term indomethacin treatment. The experiments 
have lent no support to the notion that indomethacin medication started after 
induction of the disease could delay the progression of chronic glomerulo-
nephritis. The antiproteinuric effect observed in nephrotic rats on a salt-
restricted diet affords possibilities for pharmacological investigation of anti-
inflammatory drugs. 
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CHAPTER VII 
EXPERIMENTS ON EFFECTS OF INDOMETHACIN IN PUROMYCIN 
AMINONUCLEOSIDE NEPHROPATHY 
Introduction 
The possible effect of indomethacin (in oral daily doses of 2 X 0.15 mg, 
2 X 0.30 mg and 2 X 0.60 mg) on the course of puromycin amino-
nucleoside nephropathy was studied in comparison with the natural history 
of the disease as discussed in chapter V. We considered the possible effect of 
indomethacin medication started before induction of the disease or at dif-
ferent times during the course of the disease. Both the primarily induced 
disease and a secondly induced disease period were studied. All observations 
were made in animals fed a normal unrestricted diet. Appendix II presents 
data on the numbers of animals in the experiments; block diagram no. 2 
presents a survey of the times at which morphological examinations were 
made and of the numbers of animals involved. 
Effect of indomethacin on the nephrotic syndrome 
In the set-up of the experiment described in chapter V, in which puromy-
cin aminonucleoside was given intraperitoneally during 7 days, indomethacin 
(2 X 0.15 mg) was orally given to two groups of 6 animals each, from day 
-4 and from day 10, respectively. Fig. 7.1 demonstrates that the animals 
given indomethacin from day -4 showed a modest but statistically significant 
reduction of protein excretion as compared with untreated control animals; 
medication started on day 10 had no demonstrable effect. The animals 
became seriously ill from day 15 of the experiment on, and 18 of the 20 
animals in the experiment died. The postmortem revealed no macroscopic 
evidence of abnormalities; none of the animals showed ascites or hydro-
thorax. 
In a group of 40 rats aged 18 weeks in which the disease was induced by 
daily injections of 15 mg/kg subcutaneously during 5 days, 3 treated groups 
of 10 animals each were compared with a control group of 10 animals. 
Indomethacin medication was started on day 0, on day 6 and on day 16 
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Fig. 7.1 Observations on effect of treatment with indomethacin 2 d.d. 0.15 mg on 
protein excretion in puromycin aminonucleoside nephropathy, induced in PVG/C rats 
(age 18 weeks) with 15 mg/kg i.p. injected once daily for 7 days. Protein excretion is 
significantly reduced in rats treated with indomethacin from day —4 (group PA-B; 
η = 6) in comparison with control animals (ΡΑ-A; η = 8) (ρ < 0.05 day 12, 18, 
ρ < 0 025 day 14, ρ < 0.01 day 10, 16); indomethacin treatment is without effect in 
animals treated from day 10 of disease (group ΡΑ-C; η = 6). 
(2 X 0.15 mg daily). Only the group treated from day 6 was found to show 
a statistically significant difference from the control group; fig. 7.2 presents 
the protein excretion curves. The reduction of protein excretion, occurring 
when medication was started before induction of the disease (fig. 7.1), could 
not be reproduced in the animals in this experiment; likewise the animals 
treated from day 16 did not show any effect. The importance of the observa­
tion in the group treated from day 6 is subject to question, for fig. 7.3 shows 
that this indomethacin-treated group, and the control group selected for 
equality of protein excretion, in the course of the experiment, before medica­
tion was started, showed differences in body weight, diuresis and creatinine 
excretion. These differences imply that the control group, with the higher 
body weight, received a relatively larger dose of puromycin aminonucleoside. 
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Fig. 7.2 Observations on effect of treatment with indomethacin 2 d d. 0.15 mg on 
protein excretion in puromycin aminonucleoside nephropathy, induced in PVG/C rats 
(age 18 weeks) with 15 mg/kg s.c. injected once daily for 5 days. Protein excretion is 
significantly reduced in rats treated with indomethacin from day 6 (group PC-Ci; 
η = 10) in comparison with control animals (PC-A; η = 10) (ρ < 0.05 day 13, 17, 23, 
ρ < 0.025 day 21, 25, ρ < 0.01 day 15, 19). 
No effect was seen in this experiment of treatment with indomethacin started on day 
—2, and started on day 16 
The difference in protein excretion between the two groups is therefore 
better ascribed to a difference in puromycin aminonucleoside dose than to 
an effect of indomethacin. 
The difference in protein excretion between the two groups discussed in 
the previous experiment, could not be reproduced in a group of animals aged 
14 weeks at the start of the experiment, in which the disease was induced in 
the same way; fig. 7.4 demonstrates that both groups showed an identical 
course of protein excretion. In these groups no differences were found in the 
pattern of variation of body weight, diuresis and creatinine excretion during 
the disease. 
In 32 animals aged 17 weeks the disease was induced in the usual way by 
5 consecutive injections; 8 untreated animals were compared with 3 treated 
groups of 8 animals each, which received 2 X 0.60 mg daily from day 0 on 
(PE.B), from day 6 (PE.C,) and from day 16 (PE.Ca). There were 3 deaths 
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Fig. 7.3 Pattern of variation of body weight, diuresis, and creatinine excretion during 
puromycin aminonucleoside nephropathy in the two groups PC-Α versus PC-Ci, 
shown for differences in protein excretion in fig. 7.2. 
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Fig. 7.4 Lack of effect of treatment with indomethacin 2 d.d. 0.15 mg on protein 
excretion in puromycin aminonuclcoside nephropathy, induced in animals aged 14 
weeks with 15 mg/kg s.c. injected once daily for 5 days. Untreated control group 
(PD-A; η = 10) and group treated with indomethacin from day 6 (PD-C; η = 10) do 
not show differences. 
Fig. 7.5 Lack of effect of treatment with indomethacin 2 d.d. 0.60 mg on protein 
excretion in puromycin aminonucleoside nephropathy, induced in animals aged 17 
weeks with 15 mg/kg s.c. injected once daily for 5 days. Untreated control group 
(PE-Α; η = 8) and groups (n = 3 χ 8) treated from day 0 (PE-B), from day 6 (PE-Ci), 
and from day 16 (PE-Cs) do not show differences. 
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Fig. 7.6 Lack of effect of treatment with indomethacin 2 d.d. 0.30 mg on protein 
excretion in puromycin aminonucleosidc nephropathy, induced in animals aged 12 
weeks with 15 mg/kg s с. injected once daily for 5 days. Untreated control group 
(PF-A; η = 8) and groups (n = 2 χ 8) treated from day 0 (PF-B) and from day 6 (PF-C) 
do not show differences. 
in group PE.B and 3 in group PE.CV Fig. 7.5 shows that no difference in 
the course of protein excretion was found between the three treated groups 
and the control group. Nor did the groups differ in body weight, diuresis 
and creatinine excretion. 
In view of the mortality in this experiment at a daily dosage of 2 X 0.60 
mg indomethacin, the next experiment was carried out with a daily dose of 
2 X 0.30 mg. The disease was induced in 3 groups of 8 animals each at age 
12 weeks. The results are shown in fig. 7.6: the groups did not significantly 
differ in protein excretion or in the other parameters. 
Finally, we studied the possible influence of indomethacin on protein 
excretion after a second induction of puromycin aminonucleosidc nephro­
pathy in animals who had had the disease 16 months earlier. We compared a 
control group of 5 animals with three indomethacin-treated groups, given 
2 X 0.15 mg daily from day 0 on (n = 5), 2 X 0.60 mg daily from day 0 
(n = 8) and 2 X 0.15 mg daily from day 6 (n = 5). Fig. 7.7 shows that 
occasionally the protein excretion in the groups treated from day 0, in fact 
exceeded that in the control group, most unmistakably in the group given the 
large indomethacin dose. The groups did not differ in body weight, diuresis 
and creatinine excretion. 
Fig. 7.8 shows the data on plasma cholesterol and creatinine concentra­
tions, serum protein concentration and endogenous creatinine clearance 
collected from the experimental series. The values presented do not differ 
from those in fig. 5.9. Comparison with the values given in chapter III for 
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F/'^ . 7.7 Observations on effect of treatment with ¡ndomethacin on protein excretion 
in second induction of puromycin aminonuclcosidc nephropathy 16 months after 
previous induction of disease. Puromycin aminonucleoside 15 mg/kg s.c. once daily was 
given on two subsequent days. 
Protein excretion in groups treated with indomethacin from day 0 (2 d.d. 0.15 mg p.o.: 
PBII.B, η = 5; 2 d.d. 0.60 mg p.o.: PBII.B\ η = 8) exceeded protein excretion in 
untreated group (PBII.A, η = 5) (for group PBII.B*-·. ρ < 0.025 day 13, ρ < 0.01 day 
16,21; for group PBII.B: ρ < 0.025 day 13, ρ < 0.01 day 21). 
healthy controls of the same age shows that hypcrcholesterolaemia was 
present in the acute stage of the disease; hypcrcholesterolaemia was no 
longer present after several months. Neither during the acute stage nor 
subsequently was there any evident increase in plasma creatinine concen­
tration, conspicuous hypoproteinaemia or decreased creatinine clearance. 
We collected a number of data on serum protein levels in indomethacin-
treated animals at disease day 20. The values were found not to differ from 
those listed in table 5.2 for untreated animals. Apart from these protein 
levels, table 7.1 presents data which show that the groups of 10 animals each 
did not differ in body weight at day 3, and in severity of disease (protein 
excretion at day 20. maximum protein excretion, body weight fluctuation, 
endogenous creatinine clearance per kg body weight), and that there was no 
statistically significant difference in selectivity of proteinuria between the 
indomethacin-treated and the untreated animals. 
Morphological findings 
The indomethacin-treated animals with puromycin aminonucleoside 
nephropathy showed no light-microscopic renal changes different from those 
in the untreated nephrotic animals. Again, immunohistochemical examina­
tion failed to reveal deposits of IgG or complement. This is why the discus­
sion of morphological findings will be confined to the electron-microscopic 
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Table 7.1. Data on serum protein concentrations and selectivity of proteinuria on day 20 of puromycin aminonucleoside 
nephropathy in indomethacin-treated (B,C) vs untreated (A; cfr. table 5.2) animals from experiments PE and PF; В = 2 
d.d. 0.15 mg indomethacin p.o. from day 0; С = 2 d.d. 0.15 mg indomethacin p.o. from day 6. The compared groups A, B, 
С do not show difference in parameters of disease : protein excretion on day 20; maximum protein excretion; body weight 
at day 3 and fluctuation of body weight; endogenous creatinine clearance per kg body weight. 
Experi­
mental 
group 
η Total serum 
protein 
(g/1) 
Healthy 
controls: 5 
mean ± SE 
Nephropathy 
Group A: 10 
mean ± SE 
range 
Group B: 10 
mean ± SE 
range 
Group C: 10 
mean ± SE 
range 
Serum albumin Serum IgG Selectivity 
(% standard) (% standard) index 
Actual Maximum Body weight (g) Actual 
61.0±:1.0 
57.6: 
43.8-
:2.3 
-69.1 
56.9=b2.3 
47.2—69.0 
54.0+3.3 
40.7—66.3 
100 
72±5.7 
41—102 
73±8.3 
30—107 
81±10 
20—116 
Up
ro l.V U p r o l .V day 3 
(mg/day) (mg/day) 
fluctua- ECCN 
tion (ml/min/ 
kg) 
100 
23±2.4 0.33+0.076 238: 
12—37 0.10—0.95 97-
(250±11) 3.71 ±0.40 
:51 396±42 251: 
-525 179—587 231-
:4.5 20±5.3 4.14±0.42 
-270 0—51 3.19—7.14 
26±4.1 0.26±0.035 204±49 406±51 256±8.7 21±6.5 3.99±0.19 
10—52 0.09—0.41 38—491 174—702 228—308 5—60 3.02—4.80 
25±4.1 0.39±0.085 229±63 464±39 255±6.9 23±3.6 3.92±0.27 
14—50 0.07—0.86 53—675 299—725 236—297 16—48 2.92—5.46 
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Fig. 7.8 Collection of data concerning individual indomethacin-treated animals with 
puromycin aminonucleoside nephropathy. Values in this figure do not show differences 
from values in figure 5.9. 
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findings. All animals examined had been treated with a daily oral dose of 
2 X 0.15 mg indomethacin. Renal tissue was examined at days 16, 23 and 
110 for the animals treated with indomethacin from prior to the induction of 
disease, at days 8, 16, 23 and 110 for those treated from day 6; at days 23 
and 110 for the animals treated from day 16. Electron-microscopic examina-
tion was also carried out in animals which had had the acute disease 7 
months earlier and had been treated with indomethacin during the 7 days 
preceding the examination. 
In the animals treated with indomethacin from day - 2 on, the features 
a t d a y 16 did not differ from those in the natural history of the disease. 
A t d a y 2 3 (fig. 7.9; photo 54), the GBM was not thickened. Intact 
epithelial foot processes were much more frequently seen in the treated than 
in the untreated animal, and there was hardly an increase in the electron 
density of the epithelial cytoplasm. The sections examined a t d a y 1 1 0 
were identical with those of the natural history at that time. Subendothelial 
electron-dense deposits were not observed at any time. 
In an animal treated from day 6 and examined a t d a y 8 (photo 55), 
subendothelial electron-dense deposits were regularly found at high magnifi-
cation. Otherwise the features in this animal were not different from those 
in the natural history of the disease. Subendothelial electron-dense deposits 
were likewise observed a t d a y 16 (fig. 7.10; photo 56) in animals treated 
with indomethacin from day 6 on. In these animals the fusion of epithelial 
foot processes was not quite complete; this contrasted with the extensive 
fusion in untreated animals. A t d a y 2 3 (fig. 7.11; photo 57), the fusion 
of epithelial foot processes was complete, while at this time the natural 
history of the disease (photo 50) already showed some intact epithelial foot 
processes. There were no subendothelial electron-dense deposits. A t d a y 
1 1 0 the features in the treated animals did not differ from those in natural 
history. 
In an animal treated with indomethacin from day 16 (fig. 7.11; photo 58), 
examination a t d a y 2 3 revealed subendothelial electron-dense deposits 
at several sites. Intact epithelial foot processes were slightly more frequent 
than in the natural history at that time. The features a t d a y 1 1 0 in 
the animals treated from day 16 corresponded with those in the natural 
history of the disease. 
In animals who had had the acute disease 7 months earlier and were 
treated with indomethacin from day 232 to day 240, subendothelial electron-
dense deposits were regularly observed (photo 59). These deposits were not 
found at this time in untreated animals which had had acute puromycin 
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aminonucleoside nephropathy as much earlier (photo 52). Apart from this, 
no difference was found between the treated and the untreated animals which 
had had the disease 7 months earlier. 
Discussion 
The abovementioned observations are not indicative of an influence of 
indomethacin on the course of puromycin aminonucleoside nephropathy. A 
decreased protein excretion was observed only in a group of animals 
continuously kept in metabolic cages, in which the disease had been induced 
with a large dose of puromycin aminonucleoside; in view of the deaths of 
nearly all animals in this experiment, it is difficult to draw conclusions from 
this finding. In an experiment in which some difference was found between 
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untreated animals and animals given indomethacin from day 6 on, the 
difference should possibly be ascribed to pre-existent differences between 
the groups examined. In all other experiments in which the disease was 
induced by means of a single daily subcutaneous injection of 15 mg/kg 
during 5 days, indomethacin in daily oral doses of 2 X 0.15, 2 X 0.60 and 
2 X 0.30 mg, respectively, failed to exert an influence on protein excretion 
and on the further course of the disease. 
The higher protein excretion in the animals treated with a large dose of 
indomethacin after re-induction of the disease, could conceivably have been 
caused by an inhibitory effect of indomethacin on the elimination of puro-
mycin aminonucleoside in older animals. 
The most striking phenomenon at electron-microscopic examination of the 
indomethacin-treated animals was the presence of subendothelial electron-
dense deposits. Such deposits were found only after short-term indomethacin 
medication started after induction of the disease. When medication was 
started on day 6, these deposits were observed at day 8 and at day 16, but 
not at day 23. When medication was started on day 16, these deposits were 
observed at day 23. They were also found when indomethacin was given long 
after the acute stage of the disease, the animals being sacrificed after one 
final week of medication. Even apart from the finding of such subendothelial 
deposits in healthy indomethacin-treated animals, reported in chapter VI, the 
absence of these deposits in untreated animals with puromycin amino-
nucleoside nephropathy confirmed the relation to the medication and the 
non-immunological nature of these electron-dense deposits. 
The reason of the absence of these deposits at day 16 in an animal given 
indomethacin from day 0 on, remains obscure. The material available does 
not warrant the definite conclusion that these deposits are a transient 
phenomenon; however, in view of the absence of the deposits at day 23 in 
animals given indomethacin from day 6 on, it is conceivable (the drug has at 
that time been given for 17 days) that such deposits occur only during a 
short period in the course of indomethacin medication in puromycin amino-
nucleoside nephropathy, so that a first examination at day 16 of animals 
given indomethacin from day 0 on might be too late to detect subendothelial 
deposits previously present. 
The four animals examined at disease day 23 (photos 50, 54, 57 and 58) 
differed in the frequency of intact epithelial foot processes. These processes 
were most evidently intact in the animal treated with indomethacin from day 
0 on. This animal was not in any way clinically different from the other 3 
animals. 
The indomethacin-treated animals showed no changes of the epithelial 
cells in the glomeruli as reported by Sessa et al. (1975) in the treatment of 
puromycin aminonucleoside nephropathy with 4 mg indomethacin per kg 
per day: increased number of cellular organellae and the presence of pecu-
liar cytoplasmic inclusions, which they interpreted as GBM material. 
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Conclusion 
The observations on the possible influence of indomethacin on puromycin 
aminonucleoside nephropathy, have failed to demonstrate an effect of indo-
methacin on this disease. Further investigation during salt restriction in the 
course of the disease would seem to be indicated. Both during the acute 
stage of the disease and long after, short-term indomethacin medication 
proved to be associated with the presence of subendothelial electron-dense 
deposits in the GBM. The presence of these deposits in this non-immune 
disease supports the conclusion that such deposits are of a non-
immunological nature. Finally, the findings discussed in this chapter 
demonstrate that indomethacin administration started before or during the 
acute stage of the disease and continued for many months, did not influence 
the morphological features of the GBM in the subsequent course. It there-
fore seems unlikely that, upon re-induction of the disease after these months, 
these animals would show a response other than that of the previously 
described untreated animals after re-induction of the disease. 
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CHAPTER Vili 
SUMMARY 
1) The non-steroid anti-inflammatory agent indomethacin has been used 
in the treatment of human glomerulonephritis since ten years. It is some-
times applied because it has been demonstrated that indomethacin reduces 
protein excretion in glomerulonephritis associated with a nephrotic syn-
drome. The effect is often sufficient for successful control of the hypalbu-
minaemia resulting from the protein loss and the consequent tendency to 
form oedema. The mechanism of action of this antiproteinuric effect is un-
known. Apart from this, the question has arisen whether indomethacin 
could favourably influence the course of chronic glomerulonephritis. The 
literature comprises data indicative of such a favourable influence as well 
as findings which render it unlikely. The difference in views in this context 
concerns both the clinical course and the evolution of the morphological 
changes in the kidneys. 
2) These two effects, which we would call short-term and long-term 
effect, respectively, seem to deserve further study. For this purpose we chose 
animal-experimental models. Should it be possible to reproduce the short-
term effect in animal experiments, then a model would be available for 
further analysis of the mechanism of action of indomethacin and possibly of 
that of structurally related compounds. With regard to the long-term effect 
an animal-experimental model might also afford new possibilities. In human 
pathology there are several types of glomerulonephritis, the aetiology of 
which is not exactly known; it is always difficult to evaluate the stage which 
the disease has reached. It is therefore virtually impossible to establish in 
long-term clinical experiments whether, and to which extent, indomethacin 
exerts a favourable influence on the course of a chronic glomerulonephritis. 
In an animal experiment, the pathogenic mechanism and the time of induc-
tion of an experimental glomerulonephritis are controlled, and consequently 
larger series of comparable syndromes can be produced. 
The problem statement of our study was therefore a dual one: 
a) Does indomethacin have an effect on the proteinuria in rats and, if so, 
under which conditions does it have this effect (short-term effect)? 
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b) Does indomethacin have an effect on the natural history of an experi-
mental glomerular disease (long-term effect)? 
3) The two experimental models used in this study can be briefly describ-
ed as follows: 
a) A homologous, and probably autologous, immune complex glomerulo-
pathy, induced by repeated intraperitoneal immunization of male inbred 
PVG/C rats with a diazotized antigen prepared from the supernatant of 
Wistar rat kidney homogenate, with complete Freund's adjuvant (Heymann-
type nephritis). 
b) A toxic glomerulopathy induced by repeated injection of the amino-
nucleoside of puromycin (puromycin aminonucleoside nephropathy). 
Both syndromes were associated with severe proteinuria. In short-term 
experiments to study the effect of indomethacin the dose of the drug varied 
from 2 X 0.15 mg daily to 2 X 0.60 mg daily per rat. In the long-term 
experiments the daily doses were 2 X 0.15 mg and 2 X 0.30 mg per rat, 
because larger doses were found to be too toxic. 
4) The first part of the study is devoted to the natural course of both 
experimental diseases, as investigated on the basis of the protein excretion, 
renal function, serum protein concentrations, body weights, serum choleste-
rol concentrations and histological findings. The period of observation in 
long-term experiments was about 500 days - a period in rat life which 
corresponds to about half a human lifespan. 
5) The Heymann-type nephritis was associated with a protein excretion, 
which depended on the number of immunizations and - to lesser degree - on 
the antigen dose; after 12 immunizations during 6 weeks, continuation of 
the immunization no longer caused a further increase in protein excretion. 
With this scheme of immunization (12 injections of 2 mg diazotized antigen 
and 0.17 ml complete Freund's adjuvant in 6 weeks), mean protein excre-
tions between 430 and 900 mg per day were obtained. When undiazotized 
antigen was used, or after injection of complete Freund's adjuvant only, no 
pathological proteinuria occurred. The proteinuria was accompanied by a 
hypoproteinaemia of about 88%, a hypalbuminaemia of about 26% of 
control values, and a hypercholesterolaemia of 2 - 7 times the control values. 
The selectivity index averaged 0.41, and the proteinuria must therefore be 
interpreted as aselective. Proteinuria was less selective with increasing 
protein excretion. According to plasma creatinine concentration and endo-
genous creatinine clearance, no renal failure occurred during the period of 
observation. 
A surprising finding was that in spite of an unrestricted diet with a 
sodium uptake of about 2000 /¿mole/rat/day no oedema occurred. Animals 
on a sodium-restricted diet were found capable of producing virtually 
sodium-less urine. Under these conditions administration of 1 mg furosemide 
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per day did not lead to extra sodium excretion. During dietary salt restric­
tion the body weight decreased by about 5% and the endogenous creatinine 
clearance by about 50%. The decreases in weight and clearance proved to 
be reversible upon resumption of the unrestricted diet. It must be assumed 
that, at a given level of hypalbuminaemia, the PVG/C rat tends less to 
develop oedema than do humans. 
6) Light-microscopic examination of the kidneys of the animals with 
Heymann-type nephritis showed, from week 18 on, crest-like argyrophilic 
appositions on the epithelial side of the GBM, the so-called spikes of 
epimembranous glomerulonephritis. There were no signs of exudation, 
cellular proliferation or intraglomerular coagulation. Immunohistochemical 
examination revealed, from week 4 on, a fine granular deposition of IgG 
along the GBM; from week б і on there was also some fluorescence of 
complement, and at this time also IgG was seen on the brush borders of the 
proximal tubules. In the subsequent course, the granular depositions 
coarsened, and remained present throughout the observation period. 
Electron-microscopic examination revealed in week 4 sporadic electron-
dense deposits in the lamina rara externa of the GBM, localized in the slit 
pores, between the epithelial foot processes. In week 6V2 there were more 
of these deposits, and some fusion of epithelial foot processes was observed. 
From week 11 on more subepithelial deposits were observed, which became 
larger and more irregular. The GBM thickened due to formation of GBM 
substance between and around the subepithelial deposits. From week 33 on, 
translucent areas developed around the deposits. The structure of the 
epithelial foot processes was locally restored. From week 59 on, there were 
far more translucent areas around the electron-dense deposits, and even 
holes (translucent areas without immune complex aggregates) in the GBM. 
In week 75 the entire GBM was diffusely thickened, apparently due to 
deposition of a large amount of newly formed GBM substance. 
7) The data from the literature, the deposition of IgG on the tubular 
brush border observed, and the persistence of changes after the relatively 
short period of immunization, do suggest that the immunization with homo­
logous antigen is followed by a phase in which autologous antigen plays a 
role in the development of the immune complex glomerulopathy. 
8) The nephropathy in response to puromycin aminonucleoside (15 mg/ 
kg rat subcutaneously during 5 days) led to about 7 weeks of pathological 
proteinuria which increased to a maximum of 240 - 520 mg per day, and 
subsequently disappeared. This period of pathological proteinuria was initi­
ally associated with a weight gain of about 2 - 10%, and subsequently with 
a weight loss of about 4 - 14% of the control values. At the peak of the 
protein excretion, moreover, a period of polyuria was observed. Finally 
there was a transient decrease in creatinine excretion which suggests a brief 
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decrease in glomerular filtration rate. All symptoms were positively correlat-
ed with the body weight during the days of the induction of the disease, and 
this warrants the conclusion that the dose per unit of renal weight is the 
determinant factor: the weight of the kidneys shows a relative decrease with 
increasing body weight. The pathological proteinuria was associated with a 
slight decrease in total serum protein and a decrease in serum albumin and 
serum IgG levels to 72% and 23% of control values, respectively. An 
additional finding was a hypercholesterolaemia to 2 - 5 times the control 
values. The selectivity index of the proteinuria averaged 0.33, so that this 
proteinuria, too, proved to be aselective. In these experiments no correlation 
was found between selectivity index and protein excretion. No manifest 
oedema or ascites was observed. During observation periods of up to 480 
days after the acute phase, no new spontaneous pathological proteinuria or 
decrease in renal function occurred. A second subcutaneous injection of 
puromycin aminonucleoside (2 X 15 mg/kg rat) again led to marked 
transient proteinuria; the subsequent protein excretion level remained at 
twice the previous value. 
9) Light-microscopic and immunohistochemical examination of the kid-
neys revealed normal features. Electron-microscopic examination showed 
local fusion of epithelial foot processes as early as day 8; this fusion was 
complete on day 16. On day 8 a densification of the cytoplasm of the 
epithelial cells, especially adjacent to the GBM was observed as well as 
numerous vacuoles in the epithelium, particularly in the foot processes. 
After the proteinuric phase, again normal features were observed, apart 
from the fact that between day 110 and day 490 the GBM was about 25% 
thicker than that in healthy controls, in an animal given a larger dose of 
puromycin aminonucleoside, even about 50% thicker. 
10) This part of the study provided us with the background knowledge 
for a study of the effects of indomethacin. The Heymann-type nephritis can 
be accepted as analogue of epimembranous immune complex glomerulo-
nephritis in humans. The puromycin aminonucleoside nephropathy has been 
regarded as an analogue of the so-called genuine or lipoid nephrosis of man, 
although the aselectivity of the proteinuria in our model represented a 
difference from the latter. 
11) The short-term effects of indomethacin on proteinuria were found 
to be dependent on the sodium content of the diet of the nephrotic animals. 
At different times in the course of the disease, indomethacin was given in 
daily doses of 2 X 0.15 mg to 2 X 0.60 mg during periods of 7 - 26 days. 
As long as the animals were on an unrestricted diet as far as salt intake was 
concerned, no decrease in protein excretion in comparison to the control 
groups was observed during any of the periods of medication; indomethacin 
had no effect on the selectivity index of proteinuria. An exception must be 
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made for one experiment in which, for animals which had received 2 X 0.15 
mg indomethacin daily throughout the course of the disease, the dose was 
increased to 2 X 0.60 mg daily during weeks 31 and 32. During the second 
week of medication at the increased dosage the protein excretion fell to a 
level about 75% of that in the controls. This decrease was accompanied by 
an equally marked decrease in creatinine excretion, and must therefore 
probably be explained by a decrease in glomerular filtration rate. 
However, when animals on a salt-restricted diet were given indomethacin, 
an immediate decrease in protein excretion to about 60% of the control 
values occurred. This effect of indomethacin was also observed in animals 
given furosemide in addition to a salt-restricted diet. The effect proved to 
be reversible within a few days of discontinuation of indomethacin treat-
ment. This phenomenon shows a striking similarity to the short-term effects 
of indomethacin in humans with a nephrotic syndrome. 
12) The reproducibility of the short-term effect in an animal-experimental 
model seems to afford new possibilities for further analysis of this effect. 
Our study did not focus on an explanation of the antiproteinuric effect; the 
data available in the literature indicate the possibility of an effect via inhibi-
tion of synthesis of prostaglandins. Apparently a degree of hypovolaemia, 
achieved in the rat only by superimposing salt restriction on the hypalbu-
minaemia of the nephrotic syndrome, is required to produce the effect in the 
rat. The relatively unimportant haemodynamic consequences of the hypalbu-
minaemia as such in the rat are apparent from the absence of oedema in 
our rats, despite the use of a diet rich in salt and the presence of an excel-
lent capacity for renal sodium retention. One may be tempted to speculate 
on a disturbance of the equilibrium between prostaglandin and angiotensin 
in favour of angiotensin, in response to indomethacin. 
13) To ensure an optimally close approximation to the situation in 
human medicine for a study of the long-term effect of indomethacin, the 
agent was administered during several weeks to several months in different 
stages of Heymann-type nephritis. The daily dosage was 2 X 0.15 mg or 
2 X 0.30 mg. The proteinuria was found to be favourably influenced only 
if indomethacin was given at least during the phase of immunization, i.e. 
during induction of the disease. The effect on the protein excretion was 
found to be dose-dependent. A daily dose of 2 X 0.15 mg led to a reduc-
tion of the proteinuria by about 26% ; a daily dose of 2 X 0.30 mg reduced 
the proteinuria by about 45%. A comparison of groups of animals given 
2 X 0.15 mg indomethacin daily only during immunization with groups in 
which the medication was continued thereafter, showed that continuation of 
treatment produced no extra effect on the level of protein excretion. 
A striking finding was that, in several experiments, there was a period 
(between week 16 and week 21) during which the protein excretion in 
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treated animals was not different from that in untreated animals. After this 
period the effect of treatment became apparent again. It is uncertain whether 
this period is of particular significance in the pathogenesis of Heymann-type 
nephritis. 
Indomethacin started after the phase of immunization never had a long-
term effect on the proteinuria. Indomethacin had no effect on the course of 
parameters of renal function, serum protein levels and serum cholesterol 
level. Nor did it have a significant effect on the selectivity of the proteinuria; 
the selectivity index in animals, which were given 2 X 0.15 mg indometha-
cin daily during the weeks of antigen injections, in weeks 3 1 - 3 2 averaged 
0.46, to be compared with S = 0.41 in controls (no significant difference). 
14) Light-microscopic and immunohistochemical findings of the kidneys 
of indomethacin-treated animals with Heymann-type nephritis did not differ 
from those of the untreated controls with this disease, but there were some 
differences in electron-microscopic features. 
First of all, indomethacin (continuously given from week 0; weeks of 
antigen injections only; or started after immunization) seems to accelerate 
initially the morphological course of the immune complex glomerulopathy. 
In week 11 there were more subepithelial electron-dense deposits in the 
GBM. As early as weeks 18 - 22 there were translucent areas around the 
deposits, while in the untreated nephrotic rats they were not seen until week 
33. On the other hand, in treated (weeks 0 - 5 0 ; weeks 0 - 3 3 ; or weeks 
19 - 33) animals in week 59 there were far fewer holes in the GBM than in 
the late stage of the natural history of disease. 
Secondly, subendothelial electron-dense deposits were found in the initial 
phase of the disease after treatment from week 0 on at week 4. These 
deposits were no longer observed after a longer period of indomethacin 
treatment; nor were subendothelial deposits found in animals treated from 
the end of immunization, at weeks 11 and 18. The subendothelial deposits 
moreover were present after one single week of indomethacin medication 
(2 X 0.15 mg daily) and after four weeks of indomethacin (2 X 0.15 mg 
daily) preceding week 22; after two weeks of indomethacin (2 X 0.60 mg 
daily) in weeks 26 and 27; and after two weeks of indomethacin (2 X 0.60 
mg daily) in weeks 31 and 32 in animals treated with indomethacin from 
week 19 on. Such deposits repeatedly could not be found after an increase 
of dose following other long-term indomethacin medications. Administra-
tion of indomethacin (2 X 0.15 mg and 2 X 0.60 mg daily) to normal rats 
likewise led to the formation of subendothelial deposits. These deposits, 
therefore, are not a component of an autologous immune complex glomeru-
lopathy, and consequently represent no modification of the course of this 
disease. 
15) Assuming that a diminished protein excretion with unchanged glome-
rular filtration rate is a favourable effect, these data show that indomethacin 
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favourably influences the course of this autologous immune complex 
glomerulopathy only if given during the phase of immunization. Medication 
started later does not seem to have a favourable effect. The mechanism of 
action of this alleged favourable effect remains a matter of speculation. It 
is difficult to answer the question whether the morphological findings should 
be interpreted as favourable or as unfavourable. It is clear, however, that 
the effect of indomethacin on the morphology occurs also in cases in which 
the agent does not influence proteinuria. The presence of subendothelial 
electron-dense deposits, observed in particular after short-term indomethacin 
medications, is apparently unrelated to the experimental syndrome but repre­
sents a side effect of indomethacin which can also be produced in animals 
without nephritis. Considering the clinical implications of these findings -
with all the reservations demanded in the medical application of the results 
of animal experiments - we find that these results lend no support to the 
view that long-term indomethacin medication should favourably influence 
the natural course of chronic glomerulonephritis, unless the analogue of the 
immunization phase would be known still to be in progress at the time of 
medication. Moreover in this context, the effect in nephrotic rats of long-
term indomethacin medication combined with a salt-restricted diet merits 
further investigation. 
16) Indomethacin (2 X 0.15 to 2 X 0.60 mg per day per rat) had no 
effect on the protein excretion caused by puromycin aminonucleoside, either 
during the first period of administration or during induction of a relapse. 
Nor did it change the endogenous creatinine clearance, serum protein values, 
serum cholesterol level and selectivity of proteinuria. The morphological 
features did not differ from those in animals not given indomethacin. How­
ever, in animals with puromycin aminonucleoside nephropathy, also sub­
endothelial electron-dense deposits were observed following indomethacin 
medication not exceeding Ι'Λ week. 
17) Reverting to the problem statement of this study, the following con­
clusions can be presented: 
a) Indomethacin has a short-term effect on the protein excretion in rats with 
autologous immune complex glomerulopathy (animals without oedema at a 
hypalbuminaemia of about 30% of normal albumin concentration) only if 
a salt-restricted diet is given. 
b) Indomethacin has a long-term effect on the course of autologous im­
mune complex glomerulopathy. It reduces protein excretion if it is given at 
least during the phase of immunization. It seems to influence the morpho­
logical course in subsequent disease phases also. 
c) Indomethacin has no effect on either proteinuria or the morphological 
features of a toxic nephropathy caused by the aminonucleoside of puromy­
cin. 
132 
d) The study has led to an animal-experimental model for the study of the 
short-term antiproteinuric effect of indomethacin in human individuals. It 
does not support the view that the course of human glomerulonephritis can 
be favourably influenced by indomethacin, excepting situations in which 
medication can be started at the time of the analogue of the phase of im-
munization in our animal experiments. 
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Block diagram 1 
Survey of morphological studies in animals with Heymann-type nephritis. 
Capital letters and numbers to the left: 
allocation numbers of the animals in the specific experiment. 
Numbers to the right: nr of electron micrograph in photo section. 
Bottom: duration of illness. 
148 
PO 2 0 
PC Э9 PD 2 8 [ 
PC 45 [ 
PC 73 74 
PB 4Θ ба 73 
PD 7 29 5 2 
PA 7S 
PC 5 0 
PC 4 8 
PC 4 9 5 6 
P D S 
PC 6 0 PD 17 
РС 4 
PC 6 3 Θ5 
Р С З 
PC 7 0 71 
PB 3 28 3 0 
dz 
Ρ puromycm omino nucleoside 
no indomethacin 
indomethocin 
--=/^ 
=tez 
с ^/t: 
I I ISB 
I I , lü / 
ι ι . I 1 
^ 3 = 1 5 9 
=7^ 
^ÜÜ 
•2 5 8 16 23 490 day 
Block diagram 2 
Survey of morphological studies in animals with puromycin aminonucleoside nephro-
pathy. 
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Photo I. Electron micrograph of mitochondrial fraction of rat kidney homogenate; 
this fraction is used in the production of the antigenic material for induction of 
Heymann-type nephritis. Apart from the mitochondria dense bodies are present 
(asterisks) 10.000 χ (courtesy Dr J. H. Schuurmans Stekhoven, Institute of Pathology, 
Medical Faculty, Nijmegen). 
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Photo 2. Glomerulus from a rat with Heymann-type nephritis; week 33 (animal С 40; 
fig. 4. 15). No obvious structural changes are observed in the glomeruli of the animals 
with this disease. Capillaries are open; no hypercellularity is present. Only some 
thickening of the capillary walls can be observed. H and E. 600 χ. 
Photo 3. Glomerulus from the same rat as in photomicrograph 2. Basement membrane 
thickening is clearly demonstrated with characteristic epimembranous 'spike' projections. 
Silver methenamine. 500 x. 
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Piloto 4. Immunofluorescence of Heymann-type nephritis at week 4, using rabbit 
anti-rat IgG (RaR). Immune complexes containing rat IgG are detectable along the 
GBM in a finely granular pattern in this early stage of the disease (animal G 18). 350 χ. 
Photo 5 and 6. Immunofluorescence of Heymann-typc nephritis at week в і (RaR). 
A diffuse granular deposition of the rat IgG can be observed along the GBM. 250 x. 
5. animal I 4 (photo 21 and fig. 4.14; no pathological proteinuria) 
6. animal I 15 (fig. 4.14; considerable proteinuria in this animal) 
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Photo 7 and 8. Immunofluorescence of Heymann-type nephritis at week 6V2 
(RaR) in animals treated with indomethacin from week 0. A diffuse granular deposition 
of the rat IgG can be observed along the GBM; note the fluorescence of the brush 
border (arrows). 250 x. 
7. animal I 26 (no pathological proteinuria) 
8. animal I 37 (photo 29; considerable proteinuria in this animal) 
Photo 9. Immunofluorescence of Heymann-type nephritis at week 22 (RaR). The 
deposition of rat IgG is more dense than in weeks 4 and б'/г (preceding photographs). 
Animal D 14. 500 x. 
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Photo 10. Immunofluorescence of Heymann-typc nephritis at week 33 (RaR). 
Heavy deposition of rat IgG is observed along the GBM. Animal С 40 (photo 25 and 
fig. 4.15). 250 x. 
Photo 11. Immunofluorescence of Heymann-typc nephritis at week 75 (RaR). Animal 
С 48 (photo 27). 500 x. 
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Photo 12. Immunofluorescence of Heymann-type nephritis at week 6V2, using 
rabbit anti-rat complement (RaC). A weak, but distinct granular deposition of rat com-
plement is observed along the GBM. Animal I 4 (see also photo 5). 250 x. 
Photo 13. Immunofluorescence of Heymann-type nephritis at week 22 (RaC). In 
comparison to photo 12 the deposition of rat complement at this stage of disease is 
heavier. Animal D 14 (see also photo 9). 250 x. 
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Photo 14. Immunofluorescence of Heymann-type nephritis at week 59 (RaC). 
Immune complexes containing complement are clearly demonstrated on the outside of 
the GBM. Animal С 17 (fig. 4.16). 1.000 x. 
Photo 15. Immunofluorescence of Heymann-type nephritis at week 75 (RaC). 
Deposition of rat complement is still present. Animal С 48 (see also photo 11). 500 x. 
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Рйоіо І6. Healthy male PVG/C rat; age 21 weeks. Electronmicrograph of a portion 
of a normal glomerulus. The three layers of the GBM arc clearly seen. Animal PC 34 
(fig. 7.9). 6.500 x. 
Photo 17. Healthy male PVG/C rat; age 50 weeks. Electronmicrograph of a portion 
of a glomerulus. Some thickening of the GBM can be observed in this animal (full-
transversely cut parts to be compared with photo 16). 7.000 x. 
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Photo 18. Healthy male PVG/C rat; age 75 weeks. Thickening of the GBM in com­
parison to young animals is more marked. 19.000 x. 
Photo 19. Healthy male PVG/C rat; age 26 weeks; treated with 2 d.d. 0.15 mg indo-
methacin; day 9. A small subendothclial electron-dense deposit may be observed; there 
are no further abnormalities in the GBM. 42.000 x. 
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Photo 20.1. Natural history of Heymann-type nephritis; week 4. In comparison to 
healthy animals no changes can be observed in the GBM, with special reference to 
electron-dense deposits. Animal G 18 (see also photo 4). 6.000 x. 
Photo 20.2. Natural history; week 4. Portion of the same glomerulus as shown in 
photo 20.1. In the lamina rara externa a small electron-dense deposit can be seen 
lying in the slit-pore (arrows). Animal G 18 30.700 χ. 
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Photo 21.1. Natural history; week Ь г. Portion of a glomerulus showing numerous 
electron-dense deposits at the epithelial side of the GBM (arrows). Animal 1 4. 6.000 x. 
Photo 21.2. Natural history; week б'/г. Portion of the same glomerulus as shown in 
photo 21.1. The cytoplasm of the epithelial cells lying over the deposits shows 
increased density (asterisks). Animal I 4. 31.000 x. 
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f/io;« 22./. Natural history; week 11. Some thickening of the GBM may be observed. 
In some areas (arrows) there is fusion of epithelial foot processes. In this micrograph 
no electron-dense deposits are observed in the GBM. Animal G 23. 6.000 χ. 
Photo 22.2. Natural history; week 11. Different part of the same glomerulus as shown 
in photo 22.1. In this area some electron-dense deposits are observed lying in the 
lamina rara externa of the GBM. There is fusion of the epithelial foot processes. 
Animal G 23. 20.500 χ. 
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Photo 23.1. Natural history; week 18. The GBM is irregular and contains many large 
immune complex aggregates. There is fusion of the epithelial foot processes and 
especially over the deposits a cytoplasmic density of the epithelial cells may be 
observed. Animal D 2. 15.000 x. 
Photo 23.2. Natural history; week 18. Different portion of the same glomerulus as 
shown in photo 23.1. Newly formed GBM material can be seen in-between deposits 
and epithelial cell» (asterisk). Animal D 2. 50.000 x. 
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Photo 23.3. Natural history; week 18. Different area of the glomerulus shown in photo 
23.1 and 23.2. Irregularity of the GBM and fusion of the epithelial foot processes can 
be seen. Animal D 2. 38.000 x. 
Photo 24.1. Natural history; week 22. Very large and irregular immune complex 
aggregates are deposited in the GBM. There is complete fusion of the epithelial foot 
processes. In many places newly formed GBM material is deposited in-between and 
over the aggregates. Animal D 14. 6.000 x. 
Photo 24.2. Natural history; week 22. Different part of the same glomerulus as shown 
in photo 24.1. The immune complex aggregates are completely embedded in newly 
formed GBM material. Animal D 14. 22.000 x. 
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Photo 25.1. Natural history; week 33. Immune complex aggregates and surrounding 
GBM substance are projecting from the original GBM (asterisk). Some epithelial fool 
processes are completely surrounded by GBM material (arrows). In the epithelial cells 
a cytoplasmic density may be observed over 
С 40. 7.000 χ. 
immune complex aggregates. Animal 
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Photo 25.2. Natural history: week 33. Different part of the glomerulus shown in 
photo 25.1. Immune complex aggregates and surrounding GBM material are projecting 
from the GBM (asterisk). In several areas normal foot processes may be observed 
(arrows). Animal С 40. 22.000 χ. 
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Photo 26.1. Natural history; week 59. Less irregularly thickened GBM, which contains 
many immune complex aggregates surrounded by translucent areas. These translucent 
areas suggest a disappearance of aggregates. In some areas intact epithelial foot pro­
cesses arc seen. Animal С 17. 12.000 χ. 
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Photo 26.2. Natural history; week 59. Same glomerulus as shown in photo 26.1. Dense 
immune complex aggregates are seen lying within the translucent areas. Some epithelial 
foot processes are embedded in newly formed GBM material (arrow). Animal С 17. 
48.000 χ. 
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Photo 27.1. Natural history; week 75. Strongly thickened GBM, containing immune 
complex aggregates surrounded by translucent areas. The projections at the outside of 
the GBM, seen at week 33, seem to be taken into the GBM by formation of new 
basement membrane material. An extensive fusion of epithelial foot processes exists. 
Animal С 48. 7.000 χ. 
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Photo 27.2. Natural history; week 75. Same glomerulus as shown in photo 27.1. 
Irregular projections from the GBM at the epithelial side as seen at week 33 seem to 
be embedded entirely in newly formed GBM material in such a way that the impression 
of a strongly thickened GBM containing immune complex aggregates exists. At the 
endothelial side remnants of the original GBM may be observed, and even one 
epithelial foot process bordering it (arrows). Animal С 48. 29.000 χ. 
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P/ÍOÍO 2S./. Indomethacin from week 0; week 4. No abnormalities are seen at electron 
microscopy of the glomeruli. Animal G 44. 9.000 χ. 
Photo 28.2. Indomethacin from week 0; week 4. GBM and epithelial foot processes 
do not show abnormalities. A very small electron-dense deposit may be observed in 
the lamina rara externa (single arrow). At a few sites a subendothelial deposit is seen 
(double arrow). Animal G 44. 48.000 χ. 
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Photo 29.1. Indomethacin from week 0; week в і. Portion of a glomerulus showing 
various electron-dense deposits at the epithelial side of the GBM (arrows). Animal 
Г 37. 7.000 x. 
Photo 29.2. Indomethacin from week 0; week 6!/2. Same glomerulus as shown in 
photo 29.1. Large electron-dense aggregates are seen lying in the lamina rara externa 
of the GBM. Animal I 37. 24.000 x. 
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Pitólo 30.1. Indomethacin from week 0; week 11. Many subepithelial electron-dense 
deposits, lying underneath fused epithelial foot processes, are seen. Animal G 41. 
7.000 χ. 
Photo 30.2. Indomethacin from week 0; week 11. Same glomerulus as shown in photo 
30.1. Large immune complex aggregates are seen at the epithelial side, underneath 
fused epithelial foot processes, which show an increased cytoplasmic density. Animal 
G 41. 26.000 χ. 
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Photo 31. Indomethacin from weck 0; week 18. Pathological changes in the GBM arc 
comparable to those seen in the natural history at week 18. An epithelial foot process 
is entirely embedded in newly formed GBM material (asterisk). Animal D 17. 7.000 x. 
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Photo 33. Indomethacin from week 0; week 33. In comparison to week 33 of natural 
history (photo 25) the GBM shows much less irregularities and contains a smaller 
amount of electron-dense aggregates. Animal С 57. 7.000 χ 
Photo 32.1. Indomethacin from week 0; week 22. Large immune complex aggregates 
are seen lying in the GBM underneath fused epithelial foot processes. Already trans­
lucent areas are seen around the immune complex aggregates. Animal D 13. 6.500 x. 
Photo 32.2. Indomethacin from week 0; week 22. Same glomerulus as shown in photo 
32.1. Loose structure of the immune complex aggregates is clearly visible; translucent 
areas are seen lying around the immune complex aggregates. The epithelial foot pro­
cesses are fused. Animal D 13. 30.000 x. 
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Photo 34.1. Indomethacin from week 0; week 59. Strongly thickened GBM, compa­
rable with the same phase in the natural history. However, translucent areas are ob­
served in lesser degree in comparison to natural history (photo 26). Animal С 5. 7.000 χ. 
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Photo 34.2. Indomethacin from week 0; week 59. Same glomerulus as shown in photo 
34.1. Immune complex aggregates are seen entirely embedded in newly formed GBM 
material. Some translucency can be observed around the immune complex aggregates. 
Many intact epithelial foot processes are present. Animal С 5. 48.000 χ. 
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P/ÍOÍO 55. / . Indomethacin from week 7; week 11. Slightly thickened GBM in which 
many subepithelial immune complex agregates are observed. There is extensive 
fusion of foot processes with increased density in the epithelial cytoplasm. No 
subendothelial electron-dense deposits are seen. Animal G 34. 6.500 χ. 
Photo 35.2. Indomethacin from week 7; week 11. Same glomerulus as shown in photo 
35.1. Electron-dense immune complex aggregates underneath fused epithelial foot 
processes are seen. Animal G 34. 28.000 χ. 
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Photo 36.1. Indomethacin from week 7; week 18. Pathological changes seen in the 
GBM are comparable to those seen in the natural history at the same stage of disease 
(photo 23). Animal E 29. 8.000 χ. 
Photo 36.2. Indomethacin from week 7; week 18. Same glomerulus as shown in photo 
36.1. Large immune complex aggregates together with newly formed GBM material 
project from the epithelial side of the GBM. Some translucent areas are seen around 
the deposits. There is extensive fusion of foot processes. Animal E 29. 38.000 χ. 
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Photo 37.1. Indomethacin until week 7; week 11. Many electron-dense immune com­
plex aggregates can be observed lying beneath fused epithelial foot processes. No 
subendothelial deposits are present. Animal G 7. 7.000 χ. 
Photo 37.2. Indomethacin until week 7; week 11. Same glomerulus as shown in photo 
37.1. Immune complex aggregates are seen beneath fused epithelial foot processes. 
Animal G 7. 20.000 χ. 
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Photo 38.1. Indomethacin until week 7; week 18. The GBM is strongly thickened and 
contains electron-dense deposits surrounded by newly formed GBM material. In many 
places translucent areas are observed around these immune complex aggregates. Animal 
D 25. 6.000 x. 
Photo 38.2. Indomethacin until week 7; week 18. Same glomerulus as shown in photo 
38.1. Electron-dense immune complex aggregates are seen embedded in newly formed 
GBM material. Also in many places the aggregates are surrounded by translucent areas. 
Animal D 25. 19.000 x. 
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Photo 39.1. Indomethacin until week 7; week 22. Large deposits together with newly 
formed GBM material project from the GBM towards the epithelium. There is 
extensive fusion of epithelial foot processes. Animal D 9. 7.000 x. 
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Photo 39.2. Indomethacin until week 7; week 22. Same glomerulus as shown in photo 
39.1. Large immune complex aggregates are surrounded by newly formed GBM ma­
terial, and are lying between fused epithelial foot processes. There is a beginning 
translucency in the GBM. Animal D 9. 31.000 x. 
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Photo 40.1. Indomcthacin during week 22; week 22. The changes in the GBM do not 
differ from those observed in the natural history. Some epithelial foot processes are 
entirely embedded in the GBM (arrows). Animal D 10. 6.000 x. 
Photo 40.2. Indomethacin during week 22; week 22. Same glomerulus as shown in 
photo 40.1. Apart from electron-dense deposits lying underneath fused epithelial foot 
processes, a large subendothelial electron-dense deposit may be observed (asterisk). 
Animal D 10. 43.000 x. 
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P/ioío 41.1. Indomcthacin week 19 through 22; week 22. The changes of the GBM 
are comparable to those seen in the natural history. Animal D 12. 6.500 x. 
Photo 41.2. Indomethacin week 19 through 22; week 22. Same glomerulus as shown 
in photo 41.1. High magnification shows a small subendothelial deposit (arrow). Animal 
D 12. 43.000 x. 
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Photo 42. Indomethacin in large doses during weeks 26 and 27; week 27. Arrows 
indicate small subendothelial electron-dense deposits. Animal E 28. 45.000 >,. 
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Photo 43. Indomethacin from week 7; large doses during weeks 26 and 27; week 27. 
More than in other short treatments with indomethacin in this case translucent areas 
are seen around immune complex aggregates in the GBM. which are comparable to 
those seen in animals treated with indomethacin from week 0 (photo 32). Animal E 20. 
27 000 χ. 
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Photo 44.1. Indomethacin from week 19 with different doses; week 33. In comparison 
to the changes seen in natural history the GBM shows less irregularities; also trans­
lucent areas are less frequent. Animal С 30. 7.000 χ. 
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/"/¡oio 44.2. Indomethacin from week 19 with different doses; week 33. A high magni-
fication reveals various subendothelial deposits (asterisks). Animal С 16. 27.000 χ. 
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Photo 45.1. Indomethacin from week 19 with different doses; week 59. The GBM is 
strongly thickened like in week 59 of the natural history. Many large subendothelial 
electron-dense deposits are present (asterisks). Animal С 33. 29.000 χ. 
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Photo 45.2. Indomethacin from week 19 with different doses; week 59. Higher magni­
fication shows remnants of immune complex aggregates surrounded by translucent areas. 
In some areas (arrow) the epithelial foot processes seem to project into these areas. 
Animal С 33. 48.000 χ. 
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Photo 46. Indomethacin from week 0 with different doses until week 34; week 59. 
The irregular and thickened GBM contains some translucent areas around the immune 
complex aggregates. No subendothelial deposits are observed. Animal С 50. 24.000 χ. 
Photo 47.1. Indomethacin weeks 19 through 33 with different doses; week 59. The 
GBM is strongly thickened, and contains immune complex aggregates completely 
embedded in newly formed GBM material. There is an extensive fusion of epithelial 
foot processes in contrast to normal epithelial foot processes seen at this stage of 
disease in natural history and in animals treated with indomethacin from week 0. 
Translucent areas are hardly present. Animal С 42. 7.000 χ. 
Photo 47.2. Indomethacin weeks 19 through 33 with different doses; week 59. Same 
glomerulus as shown in photo 47.1. In some areas, in which translucency may be 
observed, the fusion of epithelial foot processes is less extensive. No subendothelial 
deposits are seen. Animal С 42. 24.000 χ. 
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f/íoío 4S./. Natural history of puromycin aminonucleoside nephropathy; day 8. The 
GBM does not show thickening. In some areas fusion of epithelial foot processes be-
comes obvious. Animal PD 26. 6.500 x. 
Photo 48.2. Natural history; day 8. Same glomerulus as shown in photo 48.1. In this 
area there is extensive fusion of epithelial foot processes. Animal PD 26. 14.000 x. 
Photo 48.3. Natural history; day 8. Same glomerulus as shown in photos 48.1 and 
48.2. Vacuoles are seen in the cytoplasm of the epithelial cell. There is a density in 
the foot processes where they are adjacent to the GBM. Animal PD 26. 29.000 x. 
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Photo 49.1. Natural history; day 16. The GBM is still normal, but there is extensive 
fusion of the epithelial foot processes. Animal PC 39. 6.000 x. 
Photo 49.2. Natural history; day 16. Same glomerulus as shown in photo 49.1. The 
GBM shows slight thickening: there is increased cytoplasmic density adjacent to the 
GBM in the epithelial cell. Animal PC 39. 56.000 x. 
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Photo 50.1. Natural history; day 23. The GBM is not thickened. The fusion of the 
epithelial foot processes is less extensive in comparison to day 16, and in some areas 
apparently normal foot processes can be seen. Mesangial cell cytoplasm is seen pro-
truding into the capillary lumen (asterisk). Animal PC 45. 6.000 x. 
Photo 50.2. Natural history; day 23. Same glomerulus as shown in photo 50.1. Epi-
thelial foot processes are seen (arrows). Animal PC 45. 22.000 x. 
2Ü1 
Photo 51, Natural history; day 110. The fusion of the epithelial foot processes has 
almost disappeared. The GBM is thickened in comparison to healthy animals. Animal 
PC 73. 6.000 x. 
Photo 52. Natural history; day 240. The changes in the GBM and in the epithelial 
foot processes are comparable to those seen at day 110. Animal PB 48. 14.000 χ. 
Photo 53. Natural history; day 490. In comparison to photo 51 and 52 marked 
thickening of the GBM is seen in this animal (cfr. fig. 5.1 and 5.3). This thickening 
exceeds the width of the GBM of healthy animals of age 75 weeks (photo 18). Animal 
PA 18. 6.500 x. 
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Photo 54. Indomethacin from day —2; day 23. The GBM is not thickened. In many 
areas intact epithelial foot processes are observed. Animal PC 48. 17.500 x. 
Photo 55. Indomethacin from day 6; day 8. High magnification shows a small 
subendothelial deposit (asterisk). Animal PD 6. 72.000 x. 
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Pìwto 56.1. Inciomethacin from day 6; day 16. There is no thickening of the GBM, 
but almost complete fusion of epithelial foot processes exists. The cytoplasmic density 
observed in photo 49 is less obvious. Animal PC 60. 14.000 x. 
Photo 56.2. Indomethacin from day 6; day 16. Same glomerulus as shown in photo 
56.1. The asterisks indicate possible subendothelial electron-dense deposits. Animal 
PC 60. 56.000 x. 
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Photo 57.1. Indomethacin from day 6; day 23. The GBM is not thickened. Fusion of 
epithelial foot processes is complete. Mesangial cell cytoplasm is seen protruding into 
the capillary lumen (cf. photo 50.1). Animal PC 64. 9.000 x. 
Photo 57.2. Indomethacin from day 6; day 23. Same glomerulus as shown in photo 
57.1. The increased density of the epithelial cytoplasm is clearly seen. Animal PC 64. 
60.000 x. 
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Photo 58. Indomethacin from day 16; day 23. In many areas of this glomerulus intact 
epithelial foot processes are seen. Arrows indicate subendothelial electron-dense 
deposits. Animal PC 38. 35.000 x. 
Photo 59. Indomethacin day 232 through 240; day 240. There is some thickening of 
the GBM. The epithelial foot processes are normal. Subendothelial electron-dense 
deposits are seen (asterisks). Animal PB 30. 45.000 χ. 
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Appendix I 
Details of experiments shown in chapters IV and VI 
p e n 8
, , Fieure Number of animals in weeks of experiment 
groups week 1 ч » " ^ 
(weeks) 
CA 18 
CB, CBi 18 
, CBa 18 
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DA 18 
DB2 18 
FA 12 
FB2 12 
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Appendix II 
Details of experiments shown in chapters V and VII 
Experimental Age at
 X T , , . . . , 
j - Figure Number of animals on days of experiment 
groups аУ days: (weeks) 
PA.A 
PA.B 
PA.C 
PC.A 
PC.Ci 
PD.A 
PD.C 
PE.A 
PE.B 
PE.Ci 
PE.C2 
PF.A 
PF.B 
PF.C 
PBII.A 
PBII.B 
PBII.B* 
PBII.C 
18 
18 
18 
18 
18 
14 
14 
17 
17 
17 
17 
12 
12 
12 
81 
81 
81 
81 
01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 60 
7.1 8 4 2 2 
6 3 0 
6 4 0 
7.2 10 9 8 8 
10 9 - 8 8 
7.4 10 , 10 
10^. 10 
7.5 8 
7.6 8 8 
8 8 
8^ 8 
7.7 5 . 
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STELLINGEN 
I 
Voor het ontstaan van het de eiwituitscheiding verlagend effect van indo-
methacin bij een nephrotisch syndroom is een bepaalde graad van hypo-
volaemie nodig. 
II 
Het is waarschijnlijk, dat indomethacin alleen in bijzondere situaties een 
gunstig effect heeft op de voortschrijdsnelheid van een chronische glomerulo-
nephritis. 
Ill 
Bij de opzet van dierexperimenten dient men "psychosomatische" invloeden 
in het oog te houden. De op dit gebied genomen voorzorgen verdienen ver-
melding in het methodisch gedeelte van publikaties. 
IV 
Dosering van geneesmiddelen per kilogram lichaamsgewicht is onbruikbaar 
wanneer het gaat om orgaanspecifieke geneesmiddelen. 
V 
De controle van medicatie m.b.v. "plasmaspiegels" van geneesmiddelen ver-
eist kennis van de farmacokinetiek bij degene die de meting aanvraagt. Is 
deze kennis onvoldoende, dan bestaat het gevaar van overbodig en over-
dadig gebruik van deze soms zeer kostbare bepalingsmethoden, en evenzeer 
van een misplaatst gevoel van veiligheid. 
VI 
Lijsten met wegens kans op teratogenese voor een gravida te ontraden 
farmaca kunnen leiden tot een misplaatst vertrouwen in de onschadelijkheid 
van de niet vermelde farmaca. 
Forfar JO (1973) Drugs to be avoided during the first three months of 
pregnancy 
Prescribers' J 13, 130 
Schou M, Goldfield MD, Weinstein MR, Villeneuve A (1973) Lithium 
and pregnancy — 1; Report from the register of lithium babies 
Br Med J 2, 135 
Weinstein MR, Goldfield MD (1975) Cardiovascular malformations with 
lithium use during pregnancy 
Am J Psychiatry 132, 529 
VII 
De stelling van Linus Pauling als zou vitamine С, massaal gebruikt in hoge 
dosis (1 gram per dag of meer) gedurende lange tijd, betekenis hebben als 
prophylacticum tegen verkoudheid mag als afdoende weerlegd worden be­
schouwd. 
Pauling L (1970) Vitamin С and the common cold 
San Francisco, Freeman 
Chalmers TC (1975) Effects of ascorbic acid on the common cold 
Am J Med 58, 532 
VIII 
Bij het beoordelen van de ernst van de situatie, waarin een aan anorexia 
nervosa lijdende patiënt verkeert, is de mate van hypothermie een waardevol 
gegeven. 
IX 
De aanwezigheid van een nagenoeg normaal hemoglobinegehalte is geen 
conditio sine qua non voor een goede wondgenezing; het geven van bloed-
transfusies "om de wondgenezing te bevorderen" is, in zijn algemeenheid, 
geen zinvolle maatregel binnen de postoperatieve behandeling van een 
patiënt. 
χ 
Op theoretische gronden verdient bij de behandeling van hypertensie-
patiënten met zgn ß-blockers gebruik van een cardioselectieve blocker de 
voorkeur. 
Johnsson G (1975) Influence of metoprolol and propranolol on hemo-
dynamic effects induced by adrenaline and physical work 
Acta Pharmacol et Toxicol 36, suppl. V, 59 
XI 
Bij geneesmiddeltrials bij patiënten lijdende aan M. Bechterew verdient oog-
heelkundig onderzoek een plaats in het onderzoeksprotocol. Het optreden 
van een subklinische iridocyclitis (aanwezigheid van cellen in de voorste 
oogkamer) zou men kunnen beschouwen als uiting van toegenomen ziekte-
activiteit, en in voorkomend geval dient staken van verdere deelname door 
de betreffende patiënt aan de trial te worden overwogen. 
XII 
De mening, dat de confessionele signatuur van ziekenhuizen snel dient te 
worden losgelaten berust niet op feitelijke informatie over de gevoelens van 
grote bevolkingsgroepen op dit punt. 
XIII 
Het door het Nationaal Ziekenhuis Instituut voorgestelde gebruik van volg-
nummers bij de patiënten-identificatie levert practische bezwaren op bij 
regionaal en landelijk gebruik van een identificatiesysteem. 
NZI-publicatie (1974) Identificatie van patiënten; p. 53 
XIV 
Voorzichtigheid is geboden bij het maken van gevolgtrekkingen uit "plasma-
spiegels van geneesmiddelen". Dit geldt met name in omstandigheden van 
wijziging van meer farmacokinetische variabelen. Zo is het denkbaar, dat bij 
bejaarden, ingeval van bestudering van een oraal toegediend geneesmiddel, 
een minder volledige resorptie enerzijds en een afgenomen eliminatie-
mogelijkheid anderzijds de vergelijking met de "gezonde jong-volwassene" in 
tegengestelde zin beïnvloeden. De gedane bevindingen kunnen dan ten on-
rechte als overeenkomstig worden geduid. 
XV 
De vertaling van de acclamatie "Dignum et justum est" door "Hij is onze 
dankbaarheid waardig" miskent de bedoeling van de tekst. Deze beoogt te 
bevestigen, dat wij verplicht zijn God te danken, en niet dat God het waard 
is door ons bedankt te worden. De opeenvolging van de woorden dignus 
en Justus, en de herhaling daarvan met de toevoeging van de woorden 
aequus en salutaris in de eerste zin van de erop volgende prefatie, moeten 
de bedoeling hebben deze plicht van verschillende gezichtspunten uit te 
benadrukken. Een parafrase, die dit weergeeft is "Daar hebben we alle reden 
toe". 


